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Neuropathic pain, a debilitating condition, occurs as a consequence of nerve 
injury with symptoms such as spontaneous pain, hyperalgesia, and allodynia 
commonly reported. In animal models of peripheral nerve injury, there is 
accumulation and proliferation of microglial cells in the injured spinal cord and 
macrophages within the injured nerve and dorsal root ganglion (DRG), 
contributing to the development of pain-like behaviours. The pro-inflammatory 
cytokine interleukin-1β (IL-1β) plays a key role in acute and chronic 
inflammation. It causes potent mechanical and thermal hyperalgesia when 
injected into peripheral tissues, and increased expression of IL-1β in the spinal 
cord, DRG, and injured nerve is seen in several animal models of inflammatory 
and neuropathic pain. A key step in the release of active IL-1β is the cleavage 
of pro-IL-1β by active caspase-1, generating mature IL-1β. Activation of this 
enzyme requires assembly of the inflammasome, a multi-protein complex. The 
active complex contains a central scaffold protein (eg nod-like receptor-1 
(NLRP1), NLRP3), the adaptor protein apoptosis-associated speck-like protein 
containing a CARD (ASC), and pro-caspase-1. It is known to assemble in 
response to a variety of exogenous and endogenous danger signals (eg 
adenosine-5’-triphosphate (ATP), monosodium urate (MSU)  crystals).  
 
Data presented in this thesis demonstrates that, following L5 Spinal Nerve 
Transection (SNT), an animal model of neuropathic pain, inflammasome 
components NLRP3, ASC, and caspase-1 are upregulated in the injured DRG 
and the ipsilateral lumbar dorsal horn. Immunohistochemical analysis reveals 
that ASC and caspase-1 are both highly co-localised with macrophage and 
microglial marker ionised calcium-binding adaptor molecule-1 (IBA1), but not 
with astrocytic marker glial fibrillary acid protein (GFAP) or neuronal marker 
NeuN. While daily intrathecal administration of Ac-YVAD-CMK, a cell-permeant 
caspase-1 inhibitor, significantly attenuated established behavioural 
hypersensitivity following L5 SNT, ASC-/- and NLRP3-/- mice developed 
behavioural hypersensitivity normally in the Partial Sciatic Nerve Ligation 
(PSNL) model of neuropathic pain, indicating an inflammasome-independent 




pharmacological inhibition of caspase-1 prevented the development of 
hindpaw mechanical hypersensitivity following intrathecal administration of 
lipopolysaccharide (LPS). ASC-/- mice had a significantly reduced mechanical 
hindpaw hypersensitivity following intrathecal administration of LPS. However 
NLRP3-/- mice developed hindpaw hypersensitivity normally following 
intrathecal administration of LPS, indicating a NLRP3-independent role for 
ASC and caspase-1 activation in this animal model of central inflammatory 
pain. Finally, although ASC appears to contribute to the development of 
hypersensitivity in a model of central inflammatory pain, ASC-/- mice 
developed behavioural hypersensitivity normally following intraplantar 
administration of complete Freund’s adjuvant (CFA) in an animal model of 
persistent peripheral inflammatory pain.  
 
Thus data presented in this thesis reveal a complex role for the inflammasome 
in animal models of pain, with differential contribution of inflammasome 
components to behavioural hypersensitivity in animal models of neuropathic 
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1.    Chronic pain 
Pain is an unpleasant and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage (IASP Pain 
Terminology). Thus pain is a protective mechanism, serving to warn the 
individual of tissue damage and any associated danger. Because it is an 
unpleasant experience, pain should elicit a behavioural response such as 
withdrawal from the harmful stimulus and some form of learning response to 
prevent further damage from such stimuli. The fundamental importance and 
adaptive function of such a warning system is highlighted in the unique cases 
of individuals with the rare phenotype of a complete inability to sense pain, 
resulting in inadvertent self-mutilation and repeated injuries from a young age 
(Cox et al., 2006).  
 
Nociceptive, or acute pain, occurs following stimulation of the high-threshold 
nociceptors in the periphery. This pain is short-lasting and should cease upon 
withdrawal from the noxious stimulus and tissue healing. Chronic pain may be 
defined as pain which persists for longer than three months. This duration is 
relatively arbitrary, and perhaps a better definition would be pain that continues 
after resolution of the initial insult and the normal time of tissue healing. 
Treatment of chronic pain is difficult, with existing treatments only partially 
efficacious, seldom providing complete relief (Dworkin et al., 2010). Generally 
chronic pain is considered in three broad categories; inflammatory, 
neuropathic, and idiopathic, although these classifications are simple and 
imply distinct and separate mechanisms, when in reality the lines of distinction 
are more blurred with some overlapping mechanisms. Inflammatory pain is 
caused by the action of inflammatory mediators on nociceptive afferents. 
Inflammatory pain may occur acutely, but may also become chronic such as in 
osteoarthritis. However inflammatory pain generally resolves with resolution of 
the initiating inflammation. Neuropathic pain occurs as a consequence of 
lesion or disease of the somatosensory nervous system (Treede et al., 2008). 
There are four broad aetiologies of neuropathic pain; peripheral focal and 
multifocal nerve lesions (traumatic, ischaemic, or inflammatory), peripheral 
generalised polyneuropathies (toxic, metabolic, hereditary, or inflammatory), 




neuropathic disorders (complex regional pain syndromes (CRPS)) (Baron, 
2006). Finally some chronic pain disorders must be described as idiopathic 
when no obvious pathological cause can be identified, such as in the case of 
fibromyalgia.  
 
1.1.   Neuropathic pain 
Patients with neuropathic pain exhibit abnormal responses of the sensory 
nervous system and may present with positive or negative symptoms, or a 
combination of both. A decrease in stimulus intensity threshold to signal pain 
can result in positive symptoms such as hyperalgesia (an increased sensitivity 
to a noxious stimulus), allodynia (pain due to a normally non-noxious stimulus), 
as well as dysethesia (an unpleasant abnormal sensation, which may be 
spontaneous or evoked), or spontaneous (not stimulus-induced) pain. Patients 
may also experience negative symptoms such as a loss of sensation to 
mechanical and thermal stimuli, which may be accompanied by spontaneous 
pain in the region (anaesthesia dolorosa)  (Baron, 2006). Although there are 
several different aetiologies of neuropathic pain, there is no simple link 
between the initial aetiology and the resultant symptoms experienced by the 
patient, and often there is overlap of symptoms. Additionally a lesion of the 
nervous system will not necessarily, and in many cases does not, result in 
neuropathic pain.  
 
Treatment of neuropathic pain is difficult. Many patients have pain that is 
refractory to treatment, and for those that do report pharmacological relief it is 
often incomplete. Current pharmacotherapies for the management of 
neuropathic pain include tricyclic antidepressants (eg nortiptyline), selective 
serotonin and noradrenaline reuptake inhibitors (eg duloxetine, venlafaxine), 
gabapentinoids (gabapentin, pregablin), topical lidocaine or capsaicin 
application, and opioids (eg tramadol) (Dworkin et al., 2010). This list of drugs 
represents a wide number of drug classes and actions, demonstrating the fact 
that there are a number of pathophysiological mechanisms contributing to the 
different pain symptoms reported. A recent and ongoing strategy for the 
treatment of neuropathic pain has been to group patients not by the aetiology 




in response to different modalities of stimuli in order to better target treatment 
therapies (Baron et al., 2009). 
 
1.2.    Inflammatory pain 
Inflammatory pain may be acute, for instance in the case of, for example, 
burns or penetration wounds. Common examples of chronic inflammatory pain 
include arthropathies such as gout, osteoarthritis and rheumatoid arthritis. In 
these conditions, the underlying initiating cause of pain is clear and lies in the 
pathology of the joint. However it is reported that there is often poor correlation 
between the clinical progression of the pathology and the occurrence of pain in 
these conditions (Schaible et al., 2009). Several treatments are available for 
chronic inflammatory pain, principally aimed at reducing or antagonising the 
action of inflammatory mediators such as IL-1β or TNF-α (Schaible et al., 
2010, Miller and Ranatunga, 2012).  
 
1.3.   Animal models of pain 
Much of the difficulty in treating chronic pain lies in a lack of understanding of 
the underlying mechanisms. For many years now animal models have been 
developed and used to investigate the underlying mechanisms in neuropathic 
pain. The earliest models utilised involved traumatic lesions of a peripheral 
nerve; the chronic constriction injury model (CCI) (Bennett and Xie, 1988), the 
partial sciatic nerve ligation (PSNL), or Seltzer model (Seltzer et al., 1990), the 
L5 or L5/6 spinal nerve transection model (SNT) (Kim and Chung, 1992), and 
the spared nerve injury model (SNI) (Decosterd and Woolf, 2000). These 
models are detailed in Figure i.1, and Table i.1. The development of these 
models has been of great value in studying the development of underlying 
pathophysiological changes along multiple levels of the somatosensory 
signalling system following peripheral nerve lesion, as detailed in the next 
section, and their use continues to be widespread for this purpose. However, 
more recently concerns about the clinical relevance of such models has been 
raised, leading to the development of models based on metabolic, toxic, or 
infection-induced neuropathic pain models. These include streptozotcin-
induced diabetic neuropathy (Malcangio and Tomlinson, 1998), varicella zoster 




envelope protein glycoprotein 120-induced neuropathy (Wallace et al., 2007), 
bone cancer model of neuropathic pain (Schwei et al., 1999), and 
chemotherapy-induced models of neuropathic pain (Jaggi and Singh, 2012). 
Typically outcome measures in animal models of pain look at changes in 
sensitivity to evoked stimuli such as in the von Frey test for mechanical 
sensitivity, the Hargreaves and hot plate tests for heat sensitivity, and the 
acetone and cold plate tests for cold sensitivity. These tests aim to determine 
the presence or not of hyperalgesia and allodynia. However it must be 
remembered that they cannot account for spontaneous pain, and indeed may 
be confounded by the development of negative (loss of sensation) symptoms 
both commonly reported in neuropathic patients. Other behavioural tests such 
as the open field paradigm have been employed in an attempt to model 



























Figure i.1: Commonly used models of peripheral nerve injury 
Schematic representing the methods of four commonly used animal models of 
peripheral nerve injury, as models of neuropathic pain. a: In the Chronic Constriction 
Injury model four loose chromic-gut ligatures are tied around the sciatic nerve at mid-
thigh level. b: In the Partial Sciatic Nerve Ligation (PSNL), or Seltzer, model ½ - ⅓ of 
the sciatic nerve is tightly ligated at the high-thigh level. c: In the Spinal Nerve Ligation 
(SNL) / Spinal Nerve Transection (SNT), or Chung model the L5 or the L5 and L6 
spinal nerves are exposed distal to the DRG by removal of the covering transverse 
process(es). The nerve(s) are then tightly ligated and may then be transected as in 
SNT. d: In the Spared Nerve Injury (SNI) model the common peroneal, and tibial 
nerves are sectioned, sparing the sural nerve. Figure adapted from (Campbell and 








Table i.1: Commonly used models of peripheral nerve injury 
 




(Bennett and Xie, 
1988) 
Four loose chromic-gut ligatures 
are tied around the sciatic nerve 
at mid-thigh level 
This model has both an inflammatory and neuropathic 
component. An inflammatory reaction to the ligatures causes 
swelling, granuloma, and nerve swelling, which may ultimately 
damage fibres located at the surface of the nerve. 
Partial Sciatic 
Nerve Ligation 
(PSL) / Seltzer 
Model 
(Seltzer et al., 1990) ½ - ⅓ of the sciatic nerve is 
tightly ligated at the high-thigh 
level 
This model is more clinically relevant since not all of the axon is 
damaged. However there may be issues of reproducibility in 
relation to the extent of damage, particularly between surgeons. 
Spinal Nerve 
Transection (SNT) 
/ Spinal Nerve 
Ligation (SNL) / 
Chung Model 
(Kim and Chung, 
1992) 
The L5 or the L5 and L6 spinal 
nerves are exposed distal to the 
DRG by removal of the covering 
transverse process(es). The 
nerve(s) are then tightly ligated 
and may then be transected as 
in SNT 
The main advantage of this model over others is the ability to 
identify and study differences in axotomised primary sensory 
neurons (all those found in the L5 or L5/6 DRG), and 
neighbouring intact primary sensory neurons (all those found in 
the L4 DRG). 
Spared Nerve 
Injury Model (SNI) 
(Decosterd and 
Woolf, 2000) 
The common peroneal, and tibial 
nerves are sectioned, sparing 
the sural nerve. 
This model has an advantage over the Seltzer model in that the 




There are several, commonly used, animal models of inflammatory pain. Acute 
and medium-term models often involve the administration of an inflammatory 
substance such as carrageenan or Complete Freund’s Adjuvant (CFA). Longer 
term, or chronic, models of inflammatory pain include the intra-articular 
injection monosodium iodoacetate (MIA) or CFA into the knee joint to induce 
joint destruction as a model of osteoarthritis, or inflammatory mono-arthritis 
respectively. Animal models of rheumatoid arthritis are also commonly 
employed in which an immune response is induced by the administration of 
immunogens such as CFA or cartilage antigens (Williams, 2004, Alzabin and 
Williams, 2011, Barrot, 2012).  
 
In animal models of both neuropathic and inflammatory pain there are several 
neurochemical changes occurring throughout the sensory neuraxis. In some 
cases there is overlap of these changes, and in others there are clear 
differences. Neurochemical changes following peripheral nerve injury in animal 
models of neuropathic pain are particularly well-characterised. The remainder 
of this section will discuss nociceptive signalling in the normal state, and the 
changes which occur in the injured or inflamed state. Subsequently the 








2.    Pain signalling and mechanisms of pain 
The experience of pain is a complex one involving multiple levels of the 
nervous system, each capable of modulating the perceived sensation. Under 
normal non-pathological conditions the process of sensation begins in the 
periphery following stimulation. Sensation from the periphery is conveyed via 
the excitation of peripheral terminals of primary afferent fibres, whose cell 
bodies reside in the dorsal root and trigeminal ganglia and bifurcate to give rise 
to both the peripheral branch and a central branch terminating in the dorsal 
horn of the spinal cord. Based on their functional and structural properties, 
these are broadly classified into three main types; Aβ, Aδ, and C fibres (Millan, 
1999, D'Mello and Dickenson, 2008). Aβ fibres are the largest in diameter (>1 
0μm) and are thickly myelinated, resulting in a fast conduction velocity (30-
100ms-1). These fibres have a low threshold for activation and respond to 
mechanical stimuli making them ideal for the purpose of conveying light touch 
and tactile information. Aδ fibres are smaller in diameter (2- 6 μm), and are 
more thinly myelinated than Aβ fibres, thus have a slower conduction velocity 
(12-20 ms-1). They respond to thermal and mechanical stimuli, and can 
respond to both innocuous and noxious inputs. C fibres have the smallest 
diameter (0.1-1.2 μm) and are unmyelinated, thus have a relatively slow 
conduction velocity (0.5-2.0 ms-1). Generally they are able to respond to 
thermal, mechanical, and chemical stimulation. C fibres have a high threshold 
for activation meaning they predominantly encode for stimuli capable of 
causing tissue damage. It is generally thought that Aδ fibres elicit the sharp 
first phase of pain felt upon noxious stimulation, whereas C fibres are 
responsible for the second dull-ache aspect of pain. Electrophysiological 
studies have enabled further subclassification of these primary afferent fibres 
based on responsiveness to different modalities of input, eg mechano-heat-
responsive C fibres, C fibres responsive only to mechanical stimuli, C fibres 
responsive only to heat, and normally “silent” C fibres (Schmidt et al., 1995, 
Lawson, 2002).  
 
Sensory modality of nociceptors, as well as their activation thresholds, is 
determined by their individual expressions of a repertoire of different receptors 




eventual fate of a primary afferent fibre is determined by which growth factor 
receptor it expresses during development. Neurotrophic tyrosine kinase (Trk)-
C-bearing fibres are responsive to the neurotrophin NT-3, and are 
predominantly large fibres giving rise to mainly large myelinated Aβ fibres in 
the mature animal. Trk-B-bearing fibres are responsive to the neurotrophin 
brain-derived neurotrophic factor (BDNF), and are predominantly small and 
medium-sized fibres. Trk-A-bearing fibres are responsive to the neurotrophin 
nerve growth factor (NGF), and are predominantly of a small diameter giving 
rise to C-fibres in the mature animal. In the rat and mouse neonate, 
approximately 80% of L4/5 dorsal root ganglion (DRG) neurons express TrkA. 
This proportion decreases to approximately 40% by the second postnatal week 
in mice, and the third postnatal week in rats. This decrease is the result of a 
switch in neurotrophin receptor expression from TrkA to Ret, the 
transmembrane signalling component of the receptor responsive to glial cell-
derived growth factor (GDNF), resulting in two classes of C-fibre defined by 
their differing immunohistochemistry. The TrkA-expressing population develop 
into the peptidergic nociceptors, expressing calcitonin gene related peptide 
(CGRP) and Substance P (SP) and terminating in lamina I and IIouter. The Ret-
expressing population develop into the non-peptidergic, isolectin B4 (IB4)-
binding nociceptors, expressing also fluoride-resistant acid phosphatase 
(FRAP), thiamine monophosphatase (TMP) and purinergic ionotropic receptors 
P2X3 and terminating in lamina IIinner (Mu et al., 1993, McMahon et al., 1994, 
Molliver and Snider, 1997, Bradbury et al., 1998, Snider and McMahon, 1998, 
Stucky and Lewin, 1999, Hunt and Mantyh, 2001, Chen et al., 2006, 
Ernsberger, 2009).  Intense mechanical, thermal or chemical stimuli are able to 
be transduced into electrical activity by the diverse array of ion channels 
expressed by nociceptors. Several ion channels and receptors are 
preferentially expressed in one of these two broad populations of nociceptors, 
their expression driven by specific neurotrophins. 
 
2.1.   Peripheral sensitisation 
Although there is still much to learn, it is clear from the structured 




synaptic termination that the process of sensation is a highly complex and 
ordered one. An important finding from the use of animal models of pain, such 
as those previously described, is that, following peripheral nerve injury or 
inflammation, this ordered system shows several plastic changes. Following 
tissue or peripheral nerve damage there is a change in the local chemical 
environment which can result in peripheral sensitisation of the primary 
afferents resulting in a reduction in threshold for activation and increase in 
responsiveness to stimulation. The change in the chemical milieu occurs as a 
result of the release of a multitude of mediators including neurotransmitters (eg 
5-hydroxytryptamine (5-HT), histamine), peptides (eg SP, CGRP, bradykinin), 
cytokines and chemokines (eg interleukin (IL)-1β, tumour necrosis factor 
(TNF)-α, chemokine (C-C motif) ligand 3 (CCL3)), protons, proteases, and 
neurotrophins (eg NGF), collectively referred to as an “inflammatory soup”, 
released from nociceptors as well as non-neuronal cells recruited to, or 
residing in, the local environment such as Schwann cells and macrophages. 
These inflammatory mediators act on their receptors expressed on nociceptor 
terminals, and exert their sensitising effects via second messenger action (eg 
protein kinase C (PKC), protein kinase A (PKA), phosphoinositol-3-kinase 
(PI3K), jun N-terminal kinase (JNK), extracellular signal-related kinase (ERK) 
and p38 mitogen-activated protein kinase (p38 MAPK)) on receptors and ion 
channels present in the nociceptor, most notably transient receptor potential 
(TRP) and voltage-gated sodium channels. Post-translational modification of 
these channels results in an alteration of their kinetics and thresholds of 
activation, resulting in an increase in sensitivity and excitability of the 
nociceptor terminal (Chuang et al., 2001, Wood et al., 2004, Pezet and 
McMahon, 2006, Hucho and Levine, 2007, Woolf and Ma, 2007, Basbaum et 
al., 2009, Uceyler et al., 2009). It had previously been thought that peripheral 
sensitisation of the nociceptors was of relevance only in inflammatory pain 
states, but it is now increasingly recognised to contribute to the initiation of 
neuropathic pain states also (Campbell and Meyer, 2006, Moalem and Tracey, 
2006). 
 
In addition to these short-term effects of “inflammatory soup” following damage 




messenger activation in the activation of transcription factors such as cAMP 
responsive element binding protein (CREB), signal transducer and activator of 
transcription (STAT), and activating transcription factor (ATF)-3. Changes in 
transcription factor activity in turn lead to characteristic changes in the 
expression of neurotransmitters, peptides, and ion channel proteins (Navarro 
et al., 2007). After peripheral nerve injury, mRNA and translated protein levels 
of SP, CGRP, and somatostatin have been shown to decrease in small 
nociceptors, whereas galanin and vasoactive intestinal polypeptide (VIP) levels 
are increased (Noguchi et al., 1990, Noguchi et al., 1994, Navarro et al., 
2007). However in animal models of inflammatory pain SP and CGRP levels 
increase in the lumbar dorsal horn (Honor et al., 1999, Honore et al., 2000, 
Allen et al., 2003). Damage to peripheral nerves also induces upregulation of 
various receptor proteins. After peripheral nerve injury TRPV1 expression has 
been shown to decrease in damaged afferents, but increase in uninjured C- 
and A-fibres (Hudson et al., 2001, Ma et al., 2005). Larger DRG neurons 
undergo a phenotypic switch after peripheral nerve axotomy with the de novo 
expression of SP, BDNF, and TRPV1 usually expressed only in small 
nociceptive fibres (Noguchi et al., 1994, Zhou et al., 1999, Malcangio et al., 
2000). Similarly in animal models of inflammatory pain TRPV1 expression 
increases in C fibres and there is de novo expression of SP in Aβ fibres 
(Neumann et al., 1996, Ji et al., 2002, Amaya et al., 2004). The non-
inactivating tetrodotoxin (TTX) sensitive sodium channel Nav1.3, usually 
expressed only during development, is upregulated in sensory neurons 
following peripheral axotomy, whereas Nav1.1, Nav1.2, Nav1.6, Nav1.7, Nav1.8, 
and Nav1.9 are all downregulated (Dib-Hajj et al., 1999, Waxman et al., 2000, 
Leffler et al., 2002). In animal models of inflammatory pain the changes in 
expression of voltage gated sodium channels differ, with increases in Nav1.3, 
Nav1.7, Nav1.8, and Nav1.9 reported (Tanaka et al., 1998, Tate et al., 1998, 
Black et al., 2004). Hyperpolarisation-activated cyclic nucleotide-modulated 2 
(HCN2) ion channels, responsible for generating inward current to depolarise 
the membrane to threshold for subsequent action potential generation have 
been shown to be upregulated following peripheral nerve injury, and 
pharmacological blockade reduces primary afferent ectopic activity as well as 




2012).  A-type potassium channels Kv3.4 and Kv4.3, crucial in controlling 
neuronal excitability, are also downregulated in sensory neurons after 
peripheral nerve injury (Chien et al., 2007). Similarly, in animal models of 
inflammation a suppression of A-type potassium currents has been observed, 
resulting in an overall enhancement of neuronal excitability (Takeda et al., 
2006, Takeda et al., 2008). 
 
As well as these changes in expression pattern of ion channels axotomy leads 
to a clustering of synthesised channels, normally transported along the axon in 
vesicles to be inserted at the non-myelinated nodes of Ranvier, inserted at the 
unmyelinated neuroma stump in damaged afferents (Dugandzija-Novakovic et 
al., 1995, Novakovic et al., 1998, Kretschmer et al., 2002, Devor, 2006).  Such 
changes lead ultimately to an overall change in the excitability properties of 
sensory neurons, including reduced threshold for activation (Ma et al., 2003, 
Devor, 2006, Navarro et al., 2007). Indeed many studies have shown that 
there is development of spontaneous activity in injured afferents following 
peripheral nerve injury in animal models of pain, as well as in humans 
(Campbell et al., 1988, Boucher et al., 2000, Liu et al., 2000b). Interestingly 
these studies have emphasised the origin of spontaneous activity to be 
myelinated Aβ-fibres, with no spontaneous activity found in damaged C-fibres. 
Spontaneous activity has also been shown to develop in uninjured 
unmyelinated nociceptive afferents sharing the same innervation territory as 
the damaged fibres, and behavioural studies suggest that the development of 
spontaneous activity in these uninjured afferents contributes to the 
maintenance of neuropathic pain-like behaviours (Boucher et al., 2000, Wu et 
al., 2002, Ma et al., 2003, Djouhri et al., 2006). The L5 spinal nerve transection 
(SNT) model has been of great use in studying these changes as all the L4 
DRG neurons are left intact, whereas all L5 DRG neurons are damaged. Using 
this model other changes have been reported in the intact L4 DRG, including 
increased expression of TRPV1, TRPA1, and CGRP mRNA (Boucher and 
McMahon, 2001, Campbell and Meyer, 2006). It is postulated that the reasons 
for changes in uninjured afferents stems from a change in target-derived 
neurotrophic factors as a result of the lesion of the injured afferents innervating 




from denervated Schwann cells binds to Trk-A receptors on the uninjured 
afferents to bring about trophic changes. In addition to this increased presence 
of NGF, its availability is, too, increased since there is reduced competition for 
uptake from the injured afferents. Many of the changes following peripheral 
nerve axotomy are likely due to a change in neuronal drive to promote a state 
of survival and repair, and are largely brought about by changes in 
neurotrophin levels both at the target and synthesised by the damaged neuron. 
Interestingly intrathecal delivery of different neurotrophins is able to variously 
reverse or attenuate many of these changes (Bennett et al., 1996, Bennett et 
al., 1998, Boucher et al., 2000, Boucher and McMahon, 2001, Pezet and 
McMahon, 2006). The development of spontaneous activity in sensory 
neurons is a feature of animal models of inflammation also. Following 
intraplantar injection of CFA spontaneous activity develops in both A- and C-
fibres, and is correlated with the development of behavioural hypersensitivity 











Figure i.2: Mechanisms of peripheral sensitisation of sensory neurons 
Schematic representing mechanisms of peripheral sensitisation in animal models of 
pain. Peripheral nerve damage or inflammation causes resident and infiltrating 
immune cells, as well as the sensory nerve terminals themselves, to release 
inflammatory mediators including IL-1β, TNF-α, bradykinin, SP, CGRP, NGF, and 
prostaglandins, contributing to the “inflammatory soup”. Inflammatory mediators act on 
their receptors on primary afferents and sensitise sensory neurons via second 
messenger (eg PKA, PKC, ERK, JNK, p38 MAPK) actions. PKC action increases 
TRPV1 insertion into the plasma membrane, and phosphorylates TRPV1 receptors  
decreasing activation thresholds. PKA and p38 MAPK activation lead to increased 
insertion of voltage-gated sodium channels into the plasma membrane, and 
phosphorylation of ion channels, decreasing activation thresholds. In the long-term 
second messenger activation leads to the phosphorylation and upregulation of 






2.2.   Nociceptive processing in the dorsal horn 
The central terminal of primary afferent neurons synapse onto second order 
neurons in the dorsal horn of the spinal cord in a specific distribution pattern, 
determined by their functional class. Generally high-threshold nociceptive 
afferents terminate superficially in laminae I and II, whereas the low threshold 
myelinated mechanoresponsive afferents terminate predominantly in laminae 
III – V. C-fibres terminate differentially depending on their neurochemical class, 
whereby peptidergic C-fibres terminate in laminae I and IIouter, and non-
peptidergic C-fibres terminate in lamina IIinner. Broadly speaking, there are 
three types of second-order neuron within the dorsal horn responsive to 
primary afferent sensory information. These are non-nociceptive, nociceptive, 
and wide dynamic range (WDR) neurons. Non-nociceptive neurons, found 
primarily in laminae III and IV, respond only to innocuous tactile information 
coming from Aβ primary afferent input. Nociceptive-specific neurons are found 
more superficially in laminae I and II, receiving noxious input from nociceptive 
Aδ- and C-fibres. WDR neurons are located predominantly is lamina V and 
receive, indirectly, input from all three types of primary afferent fibre. Thus they 
are able to encode sensory information over the range of modalities and 
intensities, displaying stimulus intensity-dependent responses (Millan, 1999, 
D'Mello and Dickenson, 2008, Todd, 2010). Following peripheral nerve injury it 
has been postulated that, in addition to phenotype switching of myelinated 
fibres, there is a sprouting of the central terminals of Aβ fibres into superficial 
laminae allowing access to nociceptive pathways (Woolf et al., 1992, Kohama 
et al., 2000, Watanabe et al., 2007). This, along with the change in 
neurotransmitter expression of these fibres, may possibly explain why normally 
innocuous, low-threshold stimuli, can become painful in some patients. 
However, it remains controversial as to whether these changes do occur 
following reports that some of the labelling techniques employed in these 
studies lack specificity and the recent finding that, in the thoracic cord of the 
mouse, Aβ-fibres in fact projected throughout the dorsal horn laminae I-V 






Input from the periphery is signalled by the release of glutamate onto second 
order neurons within the dorsal horn. Under non-pathological conditions 
signalling is primarily through activation of alpha-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid (AMPA) or kainate receptor subtypes. N-methyl-D-
aspartate (NMDA) receptors are also present, but the presence of a Mg2+ block 
at the ion channel pore prevents flow of current. Sustained slow depolarisation 
of the membrane induced by the co-release of peptidergic transmitters such as 
SP and CGRP during continuous or repetitive input from the periphery is 
necessary for the release of this block. Subsequent NMDA receptor-mediated 
increases in calcium influx leads to downstream activation of signalling 
pathways and second messenger action which are able to modulate post-
synaptic receptor function, for instance via phosphorylation of NMDA receptors 
and increased trafficking of AMPA receptors to the surface. The de novo 
expression of SP by large myelinated Aβ afferent fibres following peripheral 
nerve injury or inflammation may be one mechanism by which low-threshold 
stimulation begins to generate painful sensations in patients with allodynia 
(Campbell and Meyer, 2006, D'Mello and Dickenson, 2008, Costigan et al., 
2009b). Vesicular release of neurotransmitters from the central terminals of 
primary afferent fibres is triggered by voltage-gated calcium channel activity. 
Following peripheral nerve injury it has been shown that the α2δ-1 calcium 
channel subunit is upregulated in both DRG and the dorsal horn of the spinal 
cord (Li et al., 2004, Bauer et al., 2009). This may lead to increased 
neurotransmitter release following peripheral input, and thus may represent 
another mechanism of central sensitisation following peripheral nerve injury.  
 
Input from the periphery is subject to substantial modulation within the dorsal 
horn from interneurons, both excitatory and inhibitory. One way in which 
sensitisation appears to occur following peripheral nerve injury is via the 
disinhibition of peripheral afferent signalling. Pre-synaptic release of glutamate 
from primary afferents can be inhibited by activation of pre-synaptic μ-opioid 
receptors. It has been shown that expression of μ-opioid receptors is 
decreased both pre- and post-synaptically following peripheral nerve injury, 
presumably leading to an increase in excitatory transmission from the 




gradients across the neuronal membrane. It has been shown that this 
transporter, normally expressed in lamina I projection neurons, is 
downregulated in an animal model of neuropathic pain and inflammatory pain. 
As a result there is a shift in the anion gradient across the neuronal membrane 
such that gamma-aminobutyric acid (GABA) action, which is normally 
hyperpolarising, causes neuronal depolarisation instead (Coull et al., 2003, 
Zhang et al., 2008b).There is evidence to suggest a microglial contribution to 
this phenomenon (Coull et al., 2005), which will be further discussed in Section 
4.1.2. In addition to this change in GABA action, it has also been reported that 
GABA transmission is reduced following peripheral nerve injury. A reduction in 
levels of glutamic acid decarboxylase (GAD)  in lamina II of the dorsal horn has 
been shown following peripheral nerve injury in several animal models of 
neuropathic pain (Moore et al., 2002, Scholz et al., 2005). This has been 
attributed to neuronal apoptosis within the dorsal horn, although there are 
conflicting reports (Polgar et al., 2005). The expression of the gamma isoform 
of protein kinase C (PKCγ) is restricted to lamina IIinner, and is likely to 
represent a population of excitatory interneurons (Polgar et al., 1999). 
Transgenic mice lacking PKCγ have been shown to display normal responses 
to acute noxious stimuli, but fail to develop thermal and mechanical 
hypersensitivity after peripheral nerve injury (Malmberg et al., 1997). It has 
more recently been shown that PKCγ expressing neurons receive input from 
large myelinated Aβ-fibres, and are normally subject to inhibitory glycinergic 
modulation (Miraucourt et al., 2007, Neumann et al., 2008). Peripheral nerve 
injury causes ectopic activity in Aβ-fibres, as well as a decrease in glycinergic 
inhibition (Miraucourt et al., 2007), both of which may contribute to the 
generation of painful sensation to normally innocuous low-threshold 
mechanical stimuli.  
 
In animal models of inflammatory pain there is also a disinhibition of glycinergic 
transmission, primarily in the superficial dorsal horn. Spinal cord increases in 
PGE2 following a peripheral inflammatory stimulus have been shown to inhibit 
glycinergic neurotransmission via PKA second messenger action (Beiche et 
al., 1996, Ahmadi et al., 2002). Interestingly PKA has been shown to have a 




to be of greater importance in the development of neuropathic pain (Yajima et 
al., 2003). This finding is in agreement with the finding that mice deficient in 
PKA showed reduced behavioural hypersensitivity in a model of inflammatory 
pain, but developed peripheral nerve injury-induced behavioural 







Figure i.3: Mechanisms of dorsal horn sensitisation  
Schematic representing mechanisms of dorsal horn sensitisation in animal models of 
pain. Enhanced pre-synaptic activity leads to prolonged post-synaptic depolarisation 
via glutamatergic action at AMPA receptors, and SP and CGRP action at 
metabotropic receptors. Prolonged depolarisation of the membrane relieves the 
physiological Mg2+ block of NMDA receptors, with subsequent activation further 
enhancing postsynaptic activity and leading to second messenger-mediated changes. 
ATP released from pre-synaptic terminals acts on post-synaptic P2X4 and P2X7 
receptors. In peripheral nerve injury models of neuropathic pain TrkB-mediated 
downregulation of K+Cl- transporter KCC2 results in an anion gradient shift, causing 
GABAA receptor activation to be depolarising. Evidence for a microglial contribution to 
this phenomenon is discussed in section 4.1.2. In animal models of inflammatory pain 
disinhibiton of the post-synaptic terminal is brought about by PGE2-mediated 




2.3.   Brainstem modulation 
The eventual output from signalling from the dorsal horn to higher centres in 
the brain is via ascending pathways signalled by spinal projection neurons. 
These neurons are found predominantly in lamina I, though there are also 
projection neurons to be found throughout lamina III-VI. Using antero- and 
reterograde tracing techniques it has been shown that the main targets of 
lamina I projection neurons are the caudal ventrolateral medulla, the nucleus 
of the solitary tract, the lateral parabrachial area, the periaqueductal grey 
matter (PAG), and certain nuclei within the thalamus and these areas may be 
subject to modulation from the limbic system (Todd, 2010). Around 80% of 
lamina I projection neurons have been shown to express the neurokinin-1 (NK-
1) receptor, which binds the peptide Substance P, and thus have been 
suggested to be nociceptive-specific. In line with this view, specific ablation of 
NK-1 expressing spinal neurons via the administration of a SP-conjugated 
toxin prevents the development of hyperalgesia in response to Intraplantar 
capsaicin treatment, without affecting baseline responses (Mantyh et al., 
1997). Projection neurons from deeper laminae III – VI project predominantly 
to the thalamus which has further connections to cortical regions such as 
somatosensory cortices, the insular, the anterior cingulate, and the prefrontal 
cortices, collectively often referred to as the “pain matrix” (Tracey and Mantyh, 
2007, Todd, 2010). The pain experience does not stop at these higher centres, 
however, and sensory processing within the spinal cord is subject to further 
modulation from higher centres via descending pathways from brainstem 
structures, principally the rostral ventromedial medulla (RVM) and 
periaqueductal grey (PAG), projecting heavily to the superficial dorsal horn 
(D'Mello and Dickenson, 2008, Heinricher et al., 2009). Early studies identified 
the PAG as a promising target for pain modulation when it was shown that 
electrical stimulation of the PAG resulted in analgesia, fuelling much research 
into the field of descending modulation of pain pathways. The PAG does not 
project directly to the spinal cord, however, instead projecting first to the RVM.   
 
It is now well-appreciated that descending control of sensory pathways is 
bidirectional, with both facilitatory and inhibitory drives. Characterisation of 




“ON-cells”, “OFF-cells”, and “NEUTRAL-cells” (Fields et al., 1983). The tails of 
lightly anaesthetised rats were exposed to heat, generating a tail-flick 
response. Neuronal discharges recorded from ON-cells were found to increase 
immediately prior to the tail-flick, whereas neuronal discharges recorded from 
OFF-cells were found to decrease at this time. The NEUTRAL-cells were so-
called since their activity remained unchanged. Since this time many other 
reports have confirmed this characterisation. As a result it is generally believed 
that ON-cells mediate descending facilitation, and OFF-cells mediate 
descending inhibition (Vanegas and Schaible, 2004). Further work has 
suggested that under normal conditions, as well as after nerve injury and 
inflammation, the net balance of output of descending pathways is facilitatory 
since injection of lignocaine into the RVM causes a reduction in deep dorsal 
horn neuronal responses to electrical and natural stimuli (Porreca et al., 2002). 
This effect was greater in animals that had received a peripheral nerve injury, 
and further included responses to non-noxious stimuli (Bee and Dickenson, 
2007). The facilitatory transmitter in this pathway is 5-HT, which acts on spinal 
5-HT3 receptors located on nerve terminals of small diameter afferents (Millan, 
2002, Suzuki et al., 2002, Zeitz et al., 2002). Under normal, non-pathological, 
conditions there is also a tonic inhibitory drive from higher centres, mediated 
by noradrenaline acting at α2-adrenoreceptors, and following peripheral nerve 
injury this drive is reduced (Millan, 2002, Rahman et al., 2008) further shifting 
the balance of descending modulation to that of facilitation of nociceptive 





3.    The immune response in pain 
Inflammation is the process by which an organism responds to tissue injury 
and is an attempt to remove the injurious stimuli and to initiate healing. This 
constitutes immune cell recruitment and mediator release in response to 
diverse forms of tissue injury of which pathogen infection is only one 
component. The inflammatory response consists of a pro-inflammatory phase 
in which any pathogens are removed, damaged cells and debris cleared, and 
the local homeostasis restored. Following this there is a phase of resolution in 
which there is local tissue repair and the potentially damaging effects of a 
continued inflammatory response are dissipated. Several cell types mediate 
the immune response with temporally distinct contributions. The immune 
response is recruited and mediated via the release of a range of chemical 
mediators, many of which have effects in common. Inflammation is a well-
established cause of nociceptive pain whether due to autoimmunity such as in 
rheumatoid arthritis or chemical mediators such as in gout. In addition many 
diverse aetiologies of neuropathic pain such as traumatic neuropathy or spinal 
cord injury are associated with excessive inflammation. The following section 
will discuss inflammatory mechanisms at differing levels of the sensory 
neuraxis which play a role in persistent pain states. Although the inflammatory 
response is likely to differ depending on the physiological situation, an 

















Figure i.4: Overview of the stages of the inflammatory response 
Schematic representing the stages of the inflammatory response. 1: Infection, tissue 
injury, or stress can trigger the immune response via activation of receptors 
responsive to pathogen-associated molecular patterns (PAMP), such as LPS, and 
danger-associated molecular patterns (DAMP), such as uric acid. 2: This leads to the 
activation, migration, and proliferation of resident immune cells, including mast cells 
and macrophages. 3: Activated immune cells release inflammatory mediators which 
mediate 4: recruitment of circulating immune cells, including neutrophils, 
macrophages, and T cells. Inflammatory mediator release from these, and resident, 
cells also induces 4: immune cell effector functions such as phagocytosis, and brings 
about further inflammatory mediator release. Pro-inflammatory mediators excite 
sensory afferents generating pain signals. 5: As the course of the inflammatory 
process progresses, there is a switch in mediator production to pro-resolution 
mediators such as resolvins. These promote resolution of the inflammatory response, 
limiting further immune cell infiltration and promoting phagocytosis of infiltrated 
immune cells. There is evidence that such resolution of inflammation can also reduce 






















3.1.   The inflammatory response within the peripheral nerve trunk to 
injury  
For many years research into pain signalling, and pathological pain states, 
focused on the role of neuronal changes and activity as discussed in the 
previous section. However it is now well-accepted that there is a key role for 
the immune system in the initiation and maintenance of pathological pain 
states. As previously mentioned damage to peripheral nerves generates an 
inflammatory response at the site of injury, mediated by immune cells recruited 
to the site of injury to remove cellular debris of degenerating axons (Wallerian 
degeneration) and facilitate regeneration. The first cells to react to damage of 
the nerve are resident immune cells; Schwann cells, mast cells, and 
macrophages. Myelinating Schwann cells dedifferentiate and begin the 
process of degrading the myelin sheath at the site of injury, a necessary 
prerequisite for regeneration, prior to macrophage recruitment (Allodi et al., 
2012). An as yet unspecified signal results in the activation of the ERK MAP 
kinase signalling pathway in these cells and this is one of the earliest events 
triggering the expression of inflammatory mediators and recruiting immune 
cells to the damaged nerve (Napoli et al., 2012). TNF-α secreted by Schwann 
cells, and also resident mast cells following nerve injury, induces the 
production of MMP-9 which degrades myelin basic protein and also promotes 
macrophage recruitment (Wagner and Myers, 1996, Kobayashi et al., 2008a). 
Additionally TNF-α secreted by Schwann cells induces the production of 
monocyte chemoattractant protein-1 (MCP-1) and leukotriene inhibitory factor 
(LIF) which also promote macrophage recruitment (Subang and Richardson, 
2001, Tofaris et al., 2002, Shubayev et al., 2006). After injury resident mast 
cells degranulate releasing inflammatory mediators including histamine, 5-HT, 
nerve growth factor (NGF), and leukotrienes, which can sensitise nociceptors 
and also contribute to the recruitment of neutrophils, the first cells to infiltrate 
damaged tissue (Perkins and Tracey, 2000, Zuo et al., 2003, Smith et al., 
2007, Kim and Moalem-Taylor, 2011). Mast cell stabilisation with sodium 
cromoglycate reduces the infiltration of neutrophils to the injured nerve and 
suppresses the development of peripheral nerve injury-induced thermal and 
mechanical hypersensitivity, highlighting the importance of the early immune 




using an anti-neutrophil antibody to deplete circulating neutrophils at the time 
of injury has been shown to significantly attenuate subsequent behavioural 
hypersensitivity (Perkins and Tracey, 2000). Neutrophil infiltration to the site of 
injury is acute, peaking within the first few hours after injury and declining after 
three days, though levels remain elevated. Neutrophils also release mediators 
capable of sensitising nociceptors, as well as recruiting macrophages and T 
cells to the injury site (Moalem et al., 2004, Kumar and Sharma, 2010). T cells 
are characterised by the expression of surface molecule CD4 (CD4+ T helper 
(Th) cells) or CD8 (CD8+ cytotoxic T cells), and are further subclassified as 
Type 1 or 2 based on their cytokine expression profile. Infiltrating T cells 
release pro-inflammatory cytokines such as IL-1β, TNF-α, in the case of Th1  
cells, and IL-17, in the case of Th17 cells. However Th2 cells release mainly 
anti-inflammatory cytokines such as IL-4 and IL-10 (Palmer and Weaver, 
2010). Recruited infiltrating macrophages join resident cells and, along with 
Schwann cells, take part in the phagocytosis of degenerating axons and 
myelin sheaths. In addition to this function, they are capable of secreting a 
myriad of substances including prostaglandins E2 and I2, cytokines including 
IL-1β, IL-6, IL-8, and TNF-α, and the leukotriene LTB4 (Nathan, 1987). 
Depletion of the circulating population of macrophages via the administration 
of liposomes containing clodronate reduces behavioural hypersensitivity 
following peripheral nerve injury (Liu et al., 2000a). Perhaps unsurprisingly, a 
role for neutrophils, mast cells, macrophages, and T cells has been shown in 
animal models of inflammatory pain also (Woolf et al., 1996, Kidd and Urban, 
2001, Tanaka et al., 2006, Ulmann et al., 2010, Alzabin and Williams, 2011, 
Boue et al., 2011, Li et al., 2012). 
 
In addition to the release of inflammatory mediators from infiltrating immune 
cells, the sensory terminals release neuropeptides such as Substance P and 
CGRP upon antidromic conduction of impulses. These vasoactive peptides 
may enhance the immune response by their actions increasing vascular 
permeability and may actually directly interact with immune cells such as 
Langerhan’s cells and macrophages. Additionally they act directly on primary 
afferent neurons, further stimulating and sensitising the sensory pathway (Torii 




brought about by the inflammatory response not only has actions on damaged, 
degenerating, neurons, but also on the neighbouring uninjured afferents 
sharing the same innervation territory. As a result these fibres exhibit 
spontaneous activity (Wu et al., 2002, Ma et al., 2003). Spontaneous activity 
also develops following peripheral administration of an inflammatory stimulus, 
such as CFA (Djouhri et al., 2006, Xiao and Bennett, 2007). The sensitising 
action of mediators of the inflammatory response can be due to a direct action 
on nociceptors, in the case of PGE2 and PGI2, or an indirect action. IL-1β 
indirectly sensitises nociceptors as its release leads to prostaglandin synthesis, 
and it is also able to directly sensitise nociceptors via actions on TRPV1 
receptors (Kiguchi et al., 2012).  
 
The injured DRG, and to a lesser extent adjacent DRG containing uninjured 
neurons innervating the injured territories, are also subject to an immune 
response following peripheral nerve injury or inflammation. Neutrophils have 
been shown to invade the ipsilateral L3-5 DRG following partial sciatic nerve 
ligation in the mouse at day 14, much later than that observed peripherally and 
at lower levels (Kim and Moalem-Taylor, 2011). Peripheral nerve injury also 
induces significant T cell infiltration, most of which are CD8+ as opposed to 
CD4+, to the ipsilateral DRGs from around 7 days after injury (Hu and 
McLachlan, 2002, Hu et al., 2007, Kim and Moalem-Taylor, 2011). 
Macrophages infiltrate ipsilateral DRGs, forming perineuronal rings around 
medium to large diameter neurons, from approximately 3 days post-injury, 
peaking at 7 days, and continuing for several weeks (Hu and McLachlan, 
2002, Kim and Moalem-Taylor, 2011). Similarly macrophage infiltration of the 
DRG is reported in animal models of arthritis (Inglis et al., 2005, Segond von 




3.2.    Central immune response 
Unlike the peripheral nerve and DRG, the spinal cord is protected by the 
blood-spinal cord barrier, which was thought to prevent the same influx of 
immune cells following nerve injury and inflammation. However emerging 
reports suggest that peripheral nerve injury can result in a disruption of the 
blood-spinal cord barrier allowing influx of peripheral immune cells, an effect 
shown to be mediated by the action of MCP-1 (Beggs et al., 2010, Echeverry 
et al., 2011). In several animal models of pain a central immune response is 
reported, generally being strongest in surgical models of traumatic nerve injury 
where there is a profound immune response, mainly involving cell types 
resident to the CNS; astrocytes and microglia. There is also a low level 
infiltration of T cells into the dorsal spinal cord following peripheral nerve injury 
by leukocyte extravasation. This is likely to contribute to the neuropathic pain 
phenotype since mice deficient in T cells show attenuated behavioural 
hypersensitivity in response to peripheral nerve injury (Cao and DeLeo, 2008, 
Costigan et al., 2009a).  
 
Glial cells constitute some 70% of the total cell population of the brain and 
spinal cord (Vallejo et al., 2010), with microglia comprising some 5% to 10% of 
the glial population, though for many years it was thought the role of CNS glia 
was simply one of neurotrophic support and immune protection. It is now well-
established, however, that glia play an important role in the generation of 
persistent pain syndromes. Much research in recent years has focused, in 
particular, on the contribution of microglia to such pain states. The response of 
spinal cord microglia in a variety of animal models of pain has been 
investigated, particularly in nerve-injury induced pain models (Colburn et al., 
1999, Hains and Waxman, 2006, Wen et al., 2007, Scholz et al., 2008, 
Hathway et al., 2009, Wodarski et al., 2009, Staniland et al., 2010, Clark et al., 
2012). The microglial response to several commonly used nerve injury models, 
SNI, CCI, and SNL, was recently compared by Scholz et al.. The group found 
consistently an increase in CD11b (OX42 / complement receptor 3) 
immunoreactivity, a commonly used marker of microglial activation, in the 
spinal cord 3 days after injury of all types tested. This was maximal after 7 




course was in agreement with several other studies (Jin et al., 2003, Wen et 
al., 2007, Tsuda et al., 2009b). Blockade of the microglial response with 
minocycline, a second-generation tetracycline, prevents the development of 
injury-induced behavioural hypersensitivity in rats (Raghavendra et al., 2003, 
Ledeboer et al., 2005), further implicating microglia in the development of 
hypersensitivity in animal models of pain. That minocycline is effective only in 
preventing the development of such behaviours, and is unable to reverse 
established hypersensitivity, suggests that microglia contribute only in the 
early, initiation, stages of pathological pain. In addition to animal models of 
traumatic peripheral nerve injury, microgliosis has also been observed in 
several other animal models of pain, including the formalin model, 
streptozotocin-induced diabetic neuropathy, collagen-induced arthritis, and 
bone cancer pain (Fu et al., 2009, Talbot et al., 2010, Clark et al., 2012, Hu et 
al., 2012). However the extent of this microglial response differs among 
models, generally being strongest in surgical models of traumatic nerve injury 
(Zheng et al., 2011, Blackbeard et al., 2012). And although a central glial 
response is observed in some animal models of pain, it is almost absent in 
others. For example there is little to no microgliosis observed in anti-retroviral 
2’, 3’-dideoxycitidine (ddC)-induced neuropathy or in the d4T-induced HIV-SIN 
model of neuropathic pain (Zheng et al., 2011, Huang, 2013). There are 
conflicting reports regarding the microglial response to chemotherapy-induced 
neuropathy, however (Sweitzer et al., 2006, Kiguchi et al., 2008, Zheng et al., 
2011). In the streptozotocin-induced diabetic neuropathy model of neuropathic 
pain a small, but significant, increase in IBA1 is observed (Wodarski et al., 
2009, Talbot et al., 2010). However in the db/db mouse model of diabetes–
induced neuropathy, astrocytic, but not microglial, activation is seen in the 







4.    Microglia 
Microglia are often considered the resident macrophages of the CNS due to 
their shared properties with the phagocytic macrophage. It is thought microglia 
are of myeloid origin, invading the developing CNS during embryogenesis, as 
they have been shown to express the myeloid-specific transcription factor PU.I 
and microglia in an activated state are found to have a common expression of 
cell surface markers as macrophages and myeloid-derived immature dendritic 
cells (Chan et al., 2007, Ransohoff and Perry, 2009). Additionally microglia are 
absent from the CNS of mice deficient in PU.1 (McKercher et al., 1996). Other 
studies which have sought to address the question of microglial origin have 
used the technique of irradiation chimerism to examine the way in which the 
CNS was repopulated. However data from these studies must be considered 
carefully as it has since become evident that this technique disrupts the normal 
functioning of the blood-brain barrier, and irradiation-induced cell death may 
lead to fluxes of cytokines which would alter the responses of repopulating 
haematopoietic cells (Ransohoff and Perry, 2009).  
 
For many years microglia were though to exist in either a resting quiescent or 
activated phenotype, with the implication of an “all-or-nothing” role. Although 
these terms remain in regular use, it is now accepted that this is an over-
simplistic view, specifically with regard to the “resting” state. Using two-photon 
microscopy, Nimmerjahn et al. and Davalos et al. examined the activity of 
microglia in the live adult mouse brain (Davalos et al., 2005, Nimmerjahn et al., 
2005). The groups used a thinned skull preparation which enabled imaging up 
to 200 μm below the cranial surface. A transgenic mouse with the EGFP 
reporter gene inserted into the CX3CR1 locus enabled specific visualisation of  
microglia. This technique was able to show, for the first time, that far from 
being “resting”, microglia in the healthy brain are highly motile, apparently 
continually surveying their microenvironment. Baseline time-lapse imaging 
experiments of the healthy adult brain, spanning up to 10 hours, showed that 
the somata of the microglial cells remained generally fixed while their 
processes were observed to be highly motile. Microglial processes showed 
rapid extension and retraction, reaching up to several micrometres in length. It 




monitored every few hours. Based on these reports, Hanisch and Kettenmann 
proposed a new terminology of “surveying” and “effector” microglia to better 
describe these dynamic microglial phenotypes (Hanisch and Kettenmann, 
2007).  
 
Under normal physiological conditions, microglia are thought to act to stabilise 
the CNS by surveying the local environment for stimuli and changes which 
may indicate a threat to the physiological homeostasis of the system such as 
trauma, ischaemia, and infection. The morphology of microglia under these 
conditions is ideally suited for this role, with a small soma and thin branching 
ramified processes. Whilst in this state there is low expression of surface 
antigens. Upon activation a number of changes take place. The ramified 
processes are retracted, and the small soma hypertrophies taking on an 
amoeboid shape. Activated microglia, in various experimental paradigms, have 
been shown to have the ability to secrete inflammatory molecules such as 
TNFα, interferons (IFN), inflammatory interleukins such as IL-1β, nitric oxide 
(NO), trophic factors such as BDNF and GDNF, and reactive oxygen species 
(ROS). Additionally there are changes in gene expression and upregulation of 
cell surface proteins such as complement 3 receptor (CD3, also known as 
CD11b or OX42), major histocompatibility complex (MHC) class I and II, and 
receptors for cytokines and chemokines. These phenotypic changes are 
accompanied by cell proliferation, phagocytosis of cellular debris, and 
migration to the site of injury or threat (Honda et al., 2001, Hanisch, 2002, 
Takahashi et al., 2005, Garden and Moller, 2006, Hanisch and Kettenmann, 
2007, Echeverry et al., 2008, Neumann et al., 2009).  
 
4.1.    Microglia in animal models of pain 
 
4.1.1.   Recruitment and activation: candidate signals 
Following peripheral nerve injury, microglia have been shown to proliferate and 
migrate to the injured level of the spinal cord, as early as 3 days post-injury 
(Echeverry et al., 2008). Using bromodeoxyuridine (BrdU) as a mitotic marker 




cord, as early as 3 days after peripheral nerve injury. Immunohistochemical 
analysis revealed that the majority of these cells were microglia. The cells have 
an activated amoeboid morphology, and microgliosis can be observed both in 
the superficial dorsal horn and surrounding injured motor neuron of the ventral 
horn. Increased immunoreactivity of OX42 in these areas demonstrates a more 
activated phenotype of the cells also (Scholz et al., 2008). Using real-time RT-
PCR methods it has been shown that microglia activation in the spinal cord in 
response to peripheral nerve injury occurs even earlier than this; mRNA of 
microglial surface markers CD11b, toll-like receptor 4 (TLR4), and cluster 
determinant 14 (CD14) were all shown to be upregulated as early as 4 hours 
after spinal nerve transection injury (Tanga et al., 2004). 
 
It is thought that several signals may be responsible for this microglial 
recruitment following peripheral nerve injury or inflammation. Glutamate and 
SP released in the dorsal horn following activation of nociceptive neurons are 
able to act on NMDA and mGluR, and NK1 receptors found to be expressed 
on “resting” microglia (McMahon and Malcangio, 2009, Ransohoff and Perry, 
2009). Additionally release of ATP, neuronal chemokines, BDNF, and other as 
yet unidentified mediators may be responsible for the microgliosis (McMahon 
and Malcangio, 2009). As previously discussed peripheral nerve injury or 
inflammation leads to electrical discharge at the time of the injury, and later 
spontaneous activity of the injured and neighbouring uninjured afferents. In 
several animal models of peripheral nerve injury it has been shown that nerve 
conduction blockade with local anaesthetic prior to the injury is able to prevent 
microglial activation (Wen et al., 2007, Hathway et al., 2009, Suter et al., 2009, 
Xie et al., 2009), although the relative contributions of A- and C-fibres to this 
phenomenon remain elusive and may well differ between animal models 
(Hathway et al., 2009, Suter et al., 2009). Precisely how this primary afferent 
barrage signals to recruit and activate microglia is still unclear, although there 
are now several candidate molecules thought to mediate this signal, including 
CCL2, IFN-γ, fractalkine, neuregulin 1 (NRG1), TLR4, CCL21, and ATP. 
 
The chemokine CCL2, also known as MCP-1, is undetectable in the DRG and 




injury (Flugel et al., 2001, Tanaka et al., 2004, Zhang and De Koninck, 2006, 
Thacker et al., 2009, Van Steenwinckel et al., 2011). Expression of MCP-1 was 
seen from 1 day post-injury in the ipsilateral DRG and from 3 days post-injury 
in the ipsilateral dorsal horn following chronic constriction injury, suggesting 
anterograde axonal transport to central nerve terminals (Zhang and De 
Koninck, 2006). This is supported by evidence that tight ligation of the L5 
spinal nerve as well as the L5 dorsal root leads to accumulation of CCL2 
immunoreactivity proximal to the spinal nerve ligature, and distal to the dorsal 
root ligature suggesting injury-induced transport of CCL2 anterogradely 
towards both the periphery and dorsal horn of the spinal cord (Thacker et al., 
2009). Closer investigation revealed that CCL2 is mainly upregulated in small, 
non-peptidergic neurons of the DRG co-expressing marker of neuronal 
damage ATF-3 following peripheral nerve injury (Tanaka et al., 2004, Zhang 
and De Koninck, 2006, Thacker et al., 2009). Evoked release of CCL2 from ex 
vivo isolated dorsal horn slices with dorsal roots attached has been shown to 
be significantly increased following peripheral nerve injury (Thacker et al., 
2009). Following chronic constriction injury, the upregulation of CCL2 
expression has been shown to be  temporally related to both the microgliosis 
observed following peripheral nerve injury, and the consequent mechanical 
hypersensitivity (Zhang and De Koninck, 2006), and mice deficient in CCL2 
receptor, CCR2, fail to develop either mechanical hypersensitivity or spinal 
microgliosis in response to partial sciatic nerve ligation (Seltzer) injury 
(Abbadie et al., 2003, Zhang et al., 2007). Additionally intrathecal 
administration of CCL2 leads to a long-lasting mechanical, but not thermal, 
hypersensitivity in rats accompanied by an increase in OX-42 
immunoreactivity, whereas spinal pre-treatment with a CCL2 neutralising 
antibody prior to CCI injury in rats attenuated the subsequent mechanical 
hypersensitivity and microgliosis compared to control IgG-treated rats (Thacker 
et al., 2009). 
 
More recently IFN-γ has been suggested to play an important role in microglial 
recruitment and activation. IFN-γ has been shown to activate primary cultured 
microglial cells (Hanisch and Kettenmann, 2007), and IFN-γ levels have been 




2005). Using in situ hybridisation techniques Tsuda et al. showed that IFN-γR 
mRNA is present in the dorsal horn of the uninjured lumbar spinal cord, and 
this signal co-localises with microglial marker ionised calcium-binding adapter 
molecule-1 (IBA1). Intrathecal injection of IFN-γ in wild-type, but not IFN-γ 
receptor deficient, mice led to a long-lasting mechanical hypersensitivity and 
spinal microgliosis, an effect inhibited by minocycline pre-treatment. The 
response of IFN-γ receptor deficient mice to peripheral nerve injury was also 
investigated. Development of mechanical hypersensitivity and spinal 
microgliosis was significantly impaired in IFN-γ receptor deficient mice 
compared to wild-type mice, further suggesting a role for IFN-γ in nerve injury-
induced microglial recruitment and activation. Finally both intrathecal 
administration of IFN-γ and peripheral nerve injury were shown to upregulate 
P2X4 receptor expression, a marker of microglial activation (discussed later, 
see section 4.1.2), in wild-type mice, but not in mice lacking the IFN-γ receptor 
(Tsuda et al., 2009b). 
 
Fractalkine, or CX3CL1, is a neuronal transmembrane glycoprotein with a 
chemokine domain expressed constitutively by neurons in the brain, spinal 
cord, and DRG. Its only receptor, CX3CR1 is expressed by microglia (Verge et 
al., 2004). Fractalkine has been shown to be chemotactic in cultured microglia 
(Harrison et al., 1998). This chemokine is active when membrane-bound, but 
may also act as a soluble chemokine following proteolytic cleavage by 
Cathepsin S, released by activated microglia (Clark et al., 2007, Clark et al., 
2009). Intrathecal administration of fractalkine has been shown to cause 
mechanical hypersensitivity as well as a marked microgliosis and activation of 
p38 MAPK in spinal microglia, a marker of microglial activation (discussed 
later, see section 4.1.3). Conversely intrathecal administration of a CX3CR1-
neutralising antibody prior to nerve injury attenuated the development of 
mechanical hypersensitivity and p38 MAPK activation in microglia (Zhuang et 
al., 2007). Additionally CX3CR1 knockout mice have been shown to have 
deficits in the development of both inflammatory and neuropathic pain 
(Staniland et al., 2010). More recently it has been suggested that injury-
induced upregulation of CX3CR1 expression, and subsequent p38 MAPK 




neutralising antibody prior to CCI injury in rats, and on intermittent subsequent 
days, attenuated the development of both mechanical and thermal 
hyperalgesia as well as the injury-induced upregulation of both CX3CR1 and 
activated p38 MAPK in microglia. Intrathecal administration of IL-6 in naïve rats 
caused behavioural hypersensitivity, as well as upregulation of CX3CR1 and 
p38 MAPK activation in the spinal cord (Lee et al., 2010a). Following 
peripheral nerve injury Cathepsin S expression has been shown to be 
upregulated in the ipsilateral dorsal horn in a temporal profile similar to that of 
the observed microgliosis, significantly increasing 3 days post-injury, peaking 7 
days post-injury, and beginning to decline 14 days post-injury (Clark et al., 
2007). Pharmacological inhibition of Cathepsin S, via continuous intrathecal 
infusion, reduced injury-induced mechanical hypersensitivity only 7 and 14 
days after injury when Cathepsin S expression was at its peak (Clark et al., 
2007). Thus although Cathepsin S expression is seen earlier, the fractalkine-
CX3CR1 signalling system may be of more importance at later time-points. A 
role for fractalkine and Cathepsin S in microglial activation and subsequent 
behavioural hypersensitivity has also been shown in collagen-induced arthritis 
and intrathecally administered LPS-induced hindpaw hypersensitivity (Nanki et 
al., 2004, Staniland et al., 2010, Clark et al., 2012).  
 
Calvo et al. have recently shown that neuregulin 1 (NRG1) signalling through 
erbB2, 3, and 4 receptors in microglia promotes proliferation and chemotaxis. 
Intrathecal treatment with NRG1 in rats led to a microglial proliferation within 
the dorsal horn, as assessed by BrdU immunohistochemistry. Behaviourally 
the NRG1-treated animals developed a cold and mechanical hypersensitivity. 
Using in situ hybridisation techniques, the authors found clear expression of 
NRG1 in both small and large diameter DRG neurons. Only low levels were 
found to be expressed in dorsal horn neurons, thus it was concluded that the 
most likely source of NRG1 within the dorsal horn was from the primary 
afferent terminals of DRG cells. To determine the extent of the role of NRG1 in 
injury-induced gliosis of the spinal cord, erbB2 receptor inhibition and the 
sequestration of endogenous NRG1 were employed in rats with L5 SNT injury. 
Both strategies reduced injury-induced behavioural hypersensitivities and the 




the proliferative effect of NRG1 was mediated via the MEK/ERK/1/2 pathway, 
and the chemotactic effect was dependent on the PI3K/Akt signalling pathway. 
Interestingly the p38 MAPK pathway was shown not to play a role (Calvo et al., 
2011).  
 
TLR4 is a member of the family of toll-like receptors; a family of 12 
evolutionary conserved membrane proteins that are fundamental to the innate 
immune response (Trinchieri and Sher, 2007). It has been shown that an 
increase in spinal microglial TLR4 activation correlates with the onset of 
behavioural hypersensitivity in response to peripheral nerve injury (Tanga et 
al., 2004). Mice deficient in TLR4 showed reduced behavioural hypersensitivity 
in response to peripheral nerve injury compared with wild-type controls, as well 
as an attenuated spinal microgliosis. Additionally daily Intrathecal 
administration of TLR4 antisense oligodeoxynucleotide in rats following 
peripheral nerve injury resulted in an attenuated behavioural hypersensitivity 
and spinal microglial activation compared to those animals receiving control 
mismatch oligodeoxynucleotide (Tanga et al., 2005). CD14 is an accessory 
protein which amplifies the TLR4 response to pathogens. CD14 knockout mice 
also show a decreased behavioural sensitivity to peripheral nerve injury, and 
intrathecal injection of CD14 in mice can lead to mechanical hypersensitivity 
(Cao et al., 2009), further implicating TLR4 as having a role in nerve injury-
induced microgliosis. TLR4 is a pattern recognition receptor (PRR), meaning it 
recognises and binds to a range of patterns or motifs associated with 
pathogens or danger such as the release of nucleic acids and proteins 
released after cell damage. Peripheral nerve injury may lead to the release of 
such substances, leading to TLR4 activation, ultimately leading downstream to 
the release of pro-inflammatory cytokines such as IFN-γ, IL-1β, and TNF-α, 
expression of which was significantly reduced after injury in the TLR4 KO mice 
compared to wild-type control (Tanga et al., 2005). These cytokines may serve 
to further activate and recruit the microglial response.  
 
The chemokine CCL21, or secondary lymphoid–tissue chemokine (SLC), is 
rapidly upregulated in damaged neurons (Biber et al., 2001), and has been 




rats (Biber et al., 2011). CCL21 in neurons is sorted in vesicles and 
transported to nerve terminals via the Golgi and trans-Golgi network (de Jong 
et al., 2005). Indeed, after L5 SNT staining for the chemokine was initially 
detected only in the DRG, 12 hours after injury, but was later detected in the 
nerve terminals of the primary afferents of the dorsal horn 1 and 2 days after 
nerve injury indicating axonal transport to the terminals (Biber et al., 2011). 
CCL21 acts via CXCR3 receptors on microglia to induce chemotaxis in vitro 
(Rappert et al., 2002, de Jong et al., 2005). It is unlikely to be responsible for 
microglial recruitment following nerve injury, however, and instead appears to 
be more important in microglial activation. Mice deficient in CCL21 did not 
develop mechanical hypersensitivity following L5 SNT, though were shown to 
have a comparable microglial response to that of wild-type mice following L5 
SNT injury, with comparable morphology, levels of proliferation, and OX42 
immunoreactivity. However microglial P2X4 receptor upregulation (discussed 
later, see section 4.1.2), seen in wild-type mice, was absent in CCL21-deficient 
mice. Intrathecal injection of CCL21 2 days after nerve injury in these mice did 
result in P2X4 receptor upregulation, however, suggesting that the 
downstream effects of CCL21 are mediated via the P2X4 receptor pathway 
(Biber et al., 2011). Interestingly although CCL21 deficient mice failed to 
develop mechanical hypersensitivity in response to peripheral nerve injury, 
development of heat sensitivity, assayed by the hot plate test, was comparable 
to that observed in wild-type mice, suggesting different mechanisms and 
pathways are responsible for the changes observed in the different modalities 
of behaviour.  
 
4.1.2.   Purinergic systems 
A prominent signalling pathway in the development of neuropathic pain 
involves ATP acting on microglial purinergic receptors. ATP is known to 
stimulate microglial cells both in vitro and in vivo (Honda et al., 2001, Tsuda et 
al., 2003, Davalos et al., 2005). Using two-photon imaging techniques, 
Davalos et al. showed that focal application of ATP induced a rapid microglial 
response similar to that observed following laser ablation injury, a response 




express several metabotropic P2Y receptor subtypes: P2Y1, 4, 6, and 12, as 
well as the P2X4 and 7 ionotropic purinergic receptors (Trang et al., 2012). In 
broad terms P2Y receptors appear to regulate motility and chemotaxis in the 
surveillance phenotype, and phagocytosis following activation. P2X receptors, 
however, appear to be expressed only in activated microglia (Haynes et al., 
2006, Ulmann et al., 2008).  
 
P2X4 receptors 
A crucial role for microglial purinergic signalling in chronic pain was first 
demonstrated in 2003 by Tsuda et al. who showed a critical role for P2X4 in 
initiating injury-induced hypersensitive behaviours (Tsuda et al., 2003). 
Following peripheral nerve injury P2X4 was shown to be upregulated in 
microglia, and not neurons or astrocytes, as early as 1 day after injury, 
continuing for at least 14 days post-injury, a finding corroborated using eGFP 
labelled knock-in mice (Tsuda et al., 2003, Coull et al., 2005). Pharmacological 
inhibition of P2X4 receptors 7 days after injury transiently increased 
mechanical paw withdrawal threshold, while intrathecal injection of cultured 
ATP-stimulated microglia in naïve mice led to a marked decrease in paw 
withdrawal threshold 5 hours later (Tsuda et al., 2003). These findings are 
supported by recent work showing that mice lacking the P2X4 receptor exhibit 
reduced mechanical hypersensitivity subsequent to peripheral nerve injury 
(Ulmann et al., 2008, Tsuda et al., 2009a). As previously mentioned, several 
signals have been implicated in the upregulation of P2X4 expression in animal 
models of nerve injury, including IFN-γ and CCL21 (Tsuda et al., 2009b, Biber 
et al., 2011).  
 
P2X4 receptor activation leads to p38MAPK-mediated BDNF release 
The downstream effects of spinal microglial P2X4 receptor stimulation have 
been proposed to be mediated by a release in BDNF. In vivo intrathecal 
application of ATP-stimulated cultured microglia results in behavioural 
hypersensitivity (Tsuda et al., 2003, Coull et al., 2005). Recordings from lamina 
I neurons of lumbar spinal cord slices taken from rats which had received 
intrathecal injection of ATP-stimulated cultured microglia revealed a 




resulted in an inversion of polarity of GABA-induced currents (from outward to 
inward) (Coull et al., 2005). This hyperpolarising effect of GABA had been 
previously reported in lumbar spinal cord slice recordings obtained from 
animals which had received peripheral nerve injury, and had been attributed to 
a reduction in expression the potassium-chloride exporter KCC2 (Coull et al., 
2003). Peripheral nerve injury-induced decrease in KCC2 expression 
temporally coincides with a concomitant increase in spinal BDNF expression, 
and BDNF-sequestration with a TrkB/Fc chimera protein prior to injury 
prevented both the KCC2 decrease and injury-induced behavioural 
hypersensitivity (Miletic and Miletic, 2008). Application of BDNF to spinal cord 
slices caused a depolarising shift in the anion reversal potential of lamina I 
neurons, and a hyperpolarising effect of subsequently applied GABA. 
Administration of a TrkB inhibitor prior to intrathecal application of ATP-
stimulated cultured microglia in rats prevented the development of mechanical 
hypersensitivity. Finally by pre-treatment of the culture with siRNA directed 
against BDNF, which also prevented the onset of mechanical hypersensitivity, 
the group showed that the source of BDNF in this paradigm was from the 
microglial cells as opposed to neurons or other cell types within the spinal cord 
(Coull et al., 2005). This effect was demonstrated to be P2X4 receptor-
mediated by Ulmann et al. Mice lacking the P2X4 receptor demonstrated an 
accumulation of BDNF within spinal microglia following peripheral nerve injury. 
In primary cultured microglia from these mice ATP stimulation did not induce 
BDNF release, whereas ATP stimulation of cultured microglia from wild-type 
mice did induce BDNF release (Ulmann et al., 2008). Experiments using 
primary cultured microglia show that ATP-induced BDNF release occurs in two 
phases, with significant release occurring in the first 5 minutes and again 60 
minutes after ATP application. BDNF levels within the cells themselves 
showed only one phase of increase, peaking at 60 minutes post-application of 
ATP, suggesting the BDNF released in the first phase was from a pre-existing 
intracellular pool.  Pre-treatment with a p38 MAPK inhibitor prevented release 
of BDNF in both phases following ATP application. Levels of phosphorylated 
p38 MAPK, the activated form of this kinase, were increased significantly 60 
minutes after ATP application, but not 5 minutes post-application. The authors 




p38 MAPK activity, whereas the increased production of BDNF and late phase 
of release was mediated by an increase in p38 MAPK activity (Trang et al., 
2009). 
 
P2X7 receptor signalling 
Spinal microglial P2X7 receptor activation has also been implicated in the 
development of neuropathic pain-like behaviours in animal models of 
peripheral nerve injury. Mice lacking the P2X7 receptor show reduced 
behavioural hypersensitivity after partial sciatic nerve ligation (Chessell et al., 
2005). Systemic pre-treatment with selective P2X7 antagonists has been 
shown to be effective in alleviating the behavioural hypersensitivity induced by 
intraplantar injection of complete Freund’s adjuvant (CFA), an inflammatory 
model of pain (Honore et al., 2009). However P2X7 is widely expressed in 
several cell types (Burnstock, 2007), and this may not represent a microglial-
specific mechanism of pain signalling. However microglial P2X7 receptors are 
likely to at least contribute to the generation of pain-like behaviours since the 
release of Cathepsin S has been demonstrated to be P2X7-dependent. Similar 
to downstream effects of P2X4 receptor signalling in microglia, this effect has 
been shown to be mediated by p38 MAPK activation (Clark et al., 2010b).  
 
P2Y12 receptor signalling 
P2Y12 expression levels in microglia have been shown to increase in the 
ipsilateral dorsal horn of peripheral nerve-injured rats (Kobayashi et al., 2008b, 
Tozaki-Saitoh et al., 2008). Intrathecal administration of a P2Y12 antagonist or 
P2Y12 antisense oligonucleotides prior to peripheral nerve injury prevented 
the development of behavioural hypersensitivity as well as suppressed the 
phosphorylation of p38 MAPK in spinal microglia, a marker of microglial 
activation (see section 4.1.3) (Kobayashi et al., 2008b). While P2Y12 
antagonism did prevent behavioural hypersensitivity induced by peripheral 
nerve injury, it did not affect the associated spinal increase in OX42 
immunoreactivity, indicating that P2Y12 receptors do not play a role in 
recruitment of microglia, rather the subsequent pathways which affect sensory 





4.1.3.   Microglial intracellular signalling  
The MAPK family are evolutionally conserved, and play a critical role in cell 
signalling and gene expression. The family consists of three major members: 
ERK, p38, and JNK kinases. Following L5 SNT in rats, it has been shown that 
ERK is sequentially activated in neurons, microglia, and astrocytes. In the first 
few hours after injury phosphorylated ERK was seen in neurons in the 
ipsilateral superficial dorsal horn. Microglial expression of active ERK peaked 
between 1 and 3 days after surgery, but was still present 10 days after 
surgery. 10 days after surgery ERK expression was also observed in 
astrocytes. Active ERK expression was predominantly seen in astrocytes only 
in the spinal cord by 21 days after surgery (Zhuang et al., 2005). Intrathecal 
administration of a MEK inhibitor 2, 10, and 21 days after surgery attenuated 
injury-induced behavioural hypersensitivity (Zhuang et al., 2007). ERK 
activation in microglia has also been demonstrated in the streptozotocin-
induced diabetes model of neuropathic pain. Inhibition of the pathway was 
shown to reduce behavioural hypersensitivity in this model also (Tsuda et al., 
2008).  
 
Another major signalling pathway implicated in peripheral injury-induced 
microgliosis is the p38 MAPK pathway, and the active form of the kinase 
phosphorylated p38 (hereafter referred to as p-p38) is often used as a marker 
of microglial activation in animal models of pain. Following peripheral nerve 
injury, it has been shown that p-p38 levels increase in the ipsilateral dorsal 
horn from 1 day post-injury, peak around 3 days, and continue to be elevated 
up to 3 weeks post-injury. Immunohistochemical analysis has shown that this 
increase occurs in microglia, and not astrocytes or neurons, at these time 
points (Jin et al., 2003, Tsuda et al., 2004). Pharmacological inhibition of p38 
MAPK is able to prevent, but not reverse, pain-like behaviours and spinal 
microgliosis. Similarly pre-treatment with bupivacaine microspheres prevented, 
but did not reverse, dorsal horn increases in p-p38. Presumably this was due 
to the prevention of the microgliosis observed (Jin et al., 2003, Svensson et al., 





Activated p38 is translocated to the nucleus, where it phosphorylates 
transcription factors such as ATF-2. IL-β, IL-6, TNF-α, cyclooxygenase-2 
(COX-2), inducible nitric oxide synthase (iNOS), and  several other inducible 
cytokines are upregulated in response to p38 activation, many of which have 
been shown to be pro-nociceptive (Kumar et al., 2003, Svensson et al., 2003, 
Sung et al., 2005, Ji and Suter, 2007, Matsui et al., 2010). p38 activation has 
also been demonstrated to have post-translational effects since application of 
lipopolysaccharide (LPS) to ex vivo spinal cord slices has been shown to 
induce rapid release of IL-1β via  p38 activation, an effect abolished by pre-
treatment with a p38 MAPK inhibitor (Clark et al., 2006). Several mediators 
have been shown to activate p38 MAPK in microglia, including TNF-α, IL-1β, 
fractalkine, MCP-1, and iNOS (Sung et al., 2005, Clark et al., 2007, Zhuang et 
al., 2007, Clark et al., 2010b). Activation of purinergic receptors P2X4, P2X7, 
and P2Y12 has also been shown to activate p38 (Kobayashi et al., 2008b, 
Trang et al., 2009). It is of interest to note that several p38 activators are also 
upregulated by p-p38, generating a positive feedback loop. 
 
4.1.4.   Microglial mediators  
Several of the mediators shown to be released by activated microglia are the 
same as those that are known to bring about further microglial activation, in a 
positive feedback loop that no doubt amplifies the microglial response to 
peripheral nerve damage. These include TNF-α, IL-1β, and IL-6 (Sweitzer et 
al., 2001, Hanisch and Kettenmann, 2007, Lee et al., 2010a, Zhang et al., 
2011). TNF-α and IL-1β both upregulate iNOS expression in microglia and 
neurons (Schomberg and Olson, 2012). The resultant production of diffusible 
NO is thought to modulate synaptic plasticity by post-translational 
modifications to the NMDA receptor (Meller and Gebhart, 1993). 
Pharmacological inhibition of NO production has been shown to reduce 
thermal hypersensitivity in rats after CCI injury although this would have 
blocked all forms of NOS, including microglial iNOS (Meller et al., 1992). A 
recent study showed that TNF-α and IL-1β applied to isolated lumbar spinal 
cord slices led to an enhancement of excitatory AMPA and NMDA-induced 




glycine-induced currents (Kawasaki et al., 2008b). Similar data have been 
obtained in the examination of dorsal root ganglion neurons (Ozaktay et al., 
2006). In addition to these pro-inflammatory cytokines, other pro-inflammatory 
cytokines and algesic mediators released from activated microglia include IL-
15, IL-17, IL-18, PGE2, leukotrienes, NO, and BDNF. Evidence for a role of IL-
1β in pain signalling will be discussed in detail in a later section. 
 
It is now well accepted that injury-induced microglial activation contributes to 
the initiation of pain states, evidenced by the effectiveness of pre-treatment 
with inhibitors such as minocycline. However it is also now emerging that there 
are mechanisms in place which may limit the extent of microglial activation. 
Anti-inflammatory cytokines such as IL-10, IL-4, and TGF-β have all been 
shown to have the potential to inhibit activated microglial responses (Austin 
and Moalem-Taylor, 2010). This is perhaps not so surprising given that the role 
of microglial activation should ultimately be to recruit and effect an immune 
response, via secretion of inflammatory cytokines and upregulation of cell 
surface receptors such as complement receptor C5a, which should remove the 
perceived threat. However once the job of the immune response is complete, 
there should be some mechanism to “call off” the immune response and allow 








Figure i.5: Overview of the microglial activation in animal models of pain 
A: TLR4 activation by unknown agonists leads to NFκB activation which leads to the 
upregulation and release of various known algesic mediators. p38 MAPK activation 
has also been shown to upregulate production of algesic mediators. These mediators 
are able to sensitise neurons, and activate astrocytes leading to their proliferation and 
secretion of inflammatory mediators. B: IFN-γ and also CXCR3 receptor activation 
lead to increased P2X4 receptor expression. P2X4 receptor activation leads to the 
upregulation of p38 MAPK which in turn leads to an increase in BDNF production and 
release. BDNF action at neuronal TrkB receptors causes a downregulation of KCC2, 
resulting in an anion gradient shift. C: Reactive microglia increase expression and 
release of the protease Cathepsin S which cleaves, and liberates, neuronal 
membrane-bound fractalkine. Release of Cathepsin S is P2X7-dependent. IL-6 
receptor activation leads to increased CX3CR1 expression, the receptor at which 
fractalkine acts. CX3CR1 receptor activation leads to p38 MAPK activation. D: CCL2, 
upregulated in sensory neurons following peripheral nerve damage, binds to microglial 
receptor CCR2. E: NRG1 binds to erbB2/3/4 receptors leading to activation of 
intracellular signalling PI3K and MEK/ERK pathways, leading to chemotaxis and 




5.    Astrocytes 
That minocycline and other treatments targeted at inhibiting microglial 
activation are able to prevent, but not reverse, established pain-like behaviours 
is indicative of their transient role in initiating a cascade of events downstream 
of their own activation. One such series of events appears to be the activation 
of astrocytes. Unlike microglial activation, astrocytic activation in animal 
models of pain occurs several days after the insult, and is much longer lasting 
(Colburn et al., 1999, Tanga et al., 2004, Romero-Sandoval et al., 2008).  
 
Under normal physiological conditions astrocytes act to “mop up” molecules 
that are toxic or are in excessively high concentration, keeping the extracellular 
homeostasis. Removal of excess extracellular potassium during neuronal 
signalling is mediated by its uptake into adjacent astrocytes. This potassium is 
later released back into the extracellular space in a regulated fashion (Kofuji 
and Newman, 2004). Additionally astrocytes are thought to be able to regulate 
neurotransmitter release via release of calcium from internal stores (De Leo et 
al., 2006). Following peripheral nerve injury astrocytes enlarge, and upregulate 
intermediate filament protein GFAP, vimentin, and the calcium-binding peptide 
S100β (Ridet et al., 1997, Pekny and Nilsson, 2005, Tanga et al., 2006). Mice 
deficient in GFAP do develop pain-like behaviours normally after peripheral 
nerve injury, although this is shorter-lasting than that observed in wild-type 
mice. Additionally the administration of GFAP antisense treatment in rats 6 
weeks after peripheral nerve injury reversed established behavioural 
hypersensitivity. Both these findings point towards a role in maintenance of 
neuropathic pain for astrocytes (Kim et al., 2009). Like microglia, activated 
astrocytes secrete a number of pro-inflammatory mediators which either 
directly excite neurons or modulate activation thresholds, including excitatory 
amino acids, ATP, IL-1β, TNF-α, IL-6, CCL2, NGF, and glutamate (Sweitzer et 
al., 1999, Gao et al., 2009, Austin and Moalem-Taylor, 2010). 
 
As discussed earlier, ERK activation in astrocytes following peripheral nerve 
injury has been observed 10 and 21 days after surgery, and injection of a MEK 
(ERK kinase) inhibitor at both these time points reduced associated 




has been described in activated astrocytes following peripheral nerve injury. 
Expression of this MAP kinase is more restricted than that of the other two in 
the family, p38 and ERK. Following L5 SNT JNK was briefly upregulated in the 
injured DRG 12 hours after injury and was later upregulated exclusively in 
astrocytes in the spinal cord 3 days after injury, persisting to the end of the 
study (21 days after injury). Infusion with an inhibitor of JNK was able to 
reverse established mechanical hypersensitivity 10 days after injury. However 
the injury-induced upregulation of GFAP was unaffected by this treatment 
suggesting that JNK is not responsible for the proliferation of astrocytes 
following peripheral nerve injury (Zhuang et al., 2006). Basic fibroblast growth 
factor (bFGF) is an astrocyte activator that has been implicated in activation of 
the JNK pathway. After peripheral nerve injury bFGF is upregulated in injured 
DRG neurons (Ji et al., 1995), and intrathecal infusion of bFGF is sufficient to 
produce mechanical hypersensitivity in rats (Ji et al., 2006).  
 
The precise mechanisms behind the proliferation and activation of astrocytes 
following peripheral nerve injury are unclear. One possible mechanism may be 
related to injury-induced upregulation of bFGF. Another algesic mediator which 
has recently gained attention as a possible mediator of astrocytic activation is 
IL-18. Recently Miyoshi and colleagues showed that following peripheral nerve 
injury there is a marked upregulation of both IL-18 and IL-18 receptor in the 
spinal cord, and in microglia and astrocytes respectively. Administration of an 
IL-18 and IL-18 receptor neutralising antibody reduced nerve injury-induced 
mechanical hypersensitivity, as well as astrocytic activation as assessed by 
NFκB activation and GFAP immunoreactivity. Conversely, intrathecal injection 
of IL-18 in naive rats caused mechanical hypersensitivity and upregulation of 
both GFAP and IBA1 in the dorsal horn of the spinal cord. Thus it was 
concluded that IL-18 released from activated microglia in the spinal cord 
following peripheral nerve injury subsequently activates astrocytes through an 
NFκB-dependent signalling pathway (Miyoshi et al., 2008). Interestingly IL-18 
was initially known as IFN-γ-inducing factor, owing to its ability to cause 
release of the cytokine from immune cells, and indeed has been shown to 
cause upregulation of IFN-γ mRNA and protein in cultured microglia and 




which the response of activated microglia, following peripheral nerve injury, 
may be amplified as IFN-γ receptor activation in microglia has been shown to 




6.    Endogenous anti-inflammatory mediators 
As previously mentioned, as well as a pro-inflammatory phase, an 
inflammatory response should also consist of a resolution phase. It is now 
accepted that this is an active phase of the inflammatory response, mediated 
by pro-resolution molecules (Serhan and Savill, 2005, Serhan et al., 2008). 
Lipoxins, derived from arachidonic acid, and resolvins and protectin, derived 
from omega-3 essential polyunsaturated fatty acids, have recently been 
identified as pro-resolution molecules.  Anti-inflammatory actions of these 
molecules include the promotion of phagocytosis of dead cells by 
macrophages, the cessation of production of chemoattractants, and the 
departure of inflammatory cells from the site of inflammation via the lymphatics 
(Levy et al., 2001). The role of pro-inflammatory molecules in pain has begun 
to generate interest. Intrathecal pre-treatment with Resolvin E1 has been 
shown to attenuate the development of peripheral nerve injury-induced 
hypersensitivity by preventing the microglial inflammatory response (Xu et al., 
2012). Additionally intrathecal application of LipoxinA4 prevented development 
of behavioural hypersensitivity following chronic compression of DRG, and 
prevented the spinal upregulation of pro-inflammatory cytokines TNF-α, IL-1β, 
and IL-6. Thus a pharmacological approach aimed at enhancing the pro-
resolution phase of inflammation may prove beneficial in the treatment of 






7.    Interleukin-1β and Interleukin-18 
 
7.1.   Interleukin-1β 
IL-1 was first described in the 1940s as the pyrogenic mediator released from 
the leukocytes of rabbits (Dinarello, 2010), and is the founding member of the 
IL-1 family of cytokines, which at present consists of 11 members including IL-
1α, IL-1β, IL-1Ra, IL-18, and IL-33 (Dinarello, 2009). A primary function of the 
IL-1 family is to elicit, but also control, a pro-inflammatory reaction in response 
to danger signals in the form of pathogen-associated molecular patterns 
(PAMPs) and danger-associated molecular patterns (DAMPs) as part of the 
innate immune response. Molecules and molecular patterns which are 
expressed by microbes, but which are not normally associated with 
mammalian cells, are called PAMPs. Examples of PAMPs include LPS, a 
component of cell wall of gram negative bacteria, peptidoglycan, a component 
of cell wall of gram positive bacteria, bacterial flagellin, and unmethylated CpG 
DNA of bacteria and viruses. DAMPs are typically molecules released from 
damaged or dying cells such as uric acid crystals or ATP which indicate 
danger, possibly related to infection or tissue injury (Martinon et al., 2009).  
 
The inflammatory mediator first described as IL-1 was subsequently 
determined to be two proteins; IL-1α and IL-1β. Although the products of two 
different genes, IL-1α and IL-1β have high sequence homology. Both are 
initially synthesized as larger pre-cursor proteins, which are cleaved to 
generate the smaller mature proteins. However pro-IL-1α is biologically active, 
whereas pro-IL-1β does not have biological activity and must be cleaved to 
exert its effects. Both cytokines bind to the same receptor, IL-1R1, and thus 
exert similar biological effects. Pro-IL-1α is expressed constitutively in all 
epithelial cells, and can be found expressed on the surface of several cell 
types including monocytes and B lymphocytes. Like pro-IL-1β, pro-IL-1α lacks 
a leader sequence, meaning it cannot be secreted by classical ER / golgi 
secretion pathways. However, unlike IL-1β, the vast majority of IL-1α, in both 
its larger pro-form and cleaved mature form, remains either in the cell or 




thought that in addition to its ability to exert inflammatory effects, pro-IL-1α acts 
as an autocrine growth factor in fibroblasts and endothelial cells (Dinarello, 
2009). In fact both IL-1α and IL-1β are capable of rapidly inducing the mRNA 
expression of hundreds of genes, including the expression of their own genes 
(Jura et al., 2008, Weber et al., 2010).  
 
In addition to IL-1α and IL-1β there is a third IL-1 protein, IL-1 receptor 
antagonist (IL-1Ra). This molecule is structurally related to both IL-1α and IL-
1β, and binds the same receptors with similar specificity and affinity. However 
it lacks biological activity owing to its inability to interact with IL-1RAcP 
(interleukin-1 receptor accessory protein), a necessary step in IL-1 signalling. 
Thus IL-1Ra represents the first of several controls within the IL-1 family 
limiting the IL-1 inflammatory response. (Arend et al., 2008, Weber et al., 
2010). In addition to IL-1R1, the IL-1 ligands may also bind IL-1R2. Structurally 
similar to IL-1R1, IL-1R2 lacks a signalling-competent cytosolic domain and 
thus acts as a decoy receptor. The inflammatory effects of extracellularly 
released IL-1 ligands can be further controlled by the shedding of the 
extracellular IL-1-binding domains of the receptors leading to soluble IL-1R1 
(sIL-1R1), soluble IL-1R2 (sIL-1R2), and soluble IL-1RAcP (sIL-RAcP) 
(Subramaniam et al., 2004, Dinarello, 2005, Weber et al., 2010).  
 
Following binding of IL-1α or IL-1β to functional IL-1R1, the intracellular 
signalling pathway is long and complex with multiple levels for regulation of 
signalling, allowing further opportunity to regulate the effects of IL-1. A 
simplified schematic of IL-1 signalling is shown in Figure i.6, and described 
below. Functional ligand binding to IL-1R1 results in a conformational change 
which allows recruitment and binding of IL-1R1AcP. Following this step 
adaptor molecule myeloid differentiation primary response gene 88 (MyD88) is 
recruited to the complex via homotypic protein-protein interactions at the 
toll/IL—1R (TIR) domain, characteristic of proteins of the TLR superfamily. 
Subsequently MyD88 recruits serine/threonine kinases IL-1R-associated 
kinase (IRAK)-1, IRAK-2, and IRAK-4 to the complex via interactions of death 
domains in the kinases with a death domain at the N-terminal portion of 




of tumour necrosis factor-associated factor (TRAF)-6. The IRAK-1, IRAK-2, 
and TRAF-6 complex dissociates from the initial receptor complex and forms a 
new complex with transforming growth factor β-activated kinase-1 (TAK-1), 
TAK-1-binding protein (TAB)-1, and TAB-2 at the plasma membrane. IRAK-1 
phosphorylates TAK-1 and TAB-1 before ubiquitination marks it for 
degradation at the plasma membrane causing it to dissociate from the 
complex. The remaining complex translocates to the cytosol where 
ubiquitination of TRAF-6 leads to TRAF-6-induced activation of TAK-1. TAK-1 
is then able to phosphorylate cytosolic MAP kinases, as well as the IKK 
complex (inhibitor of NFκB kinase). The IKK complex consists of IKK-α, IKK-β, 
and IKK-γ (also sometimes referred to as NFκB essential modulator (NEMO)). 
The activated IKK complex phosphorylates IκB, which leads to its 
ubiquitination and subsequent degradation. IκB associates with, and inhibits, 
NFκB. Its degradation allows NFκB to translocate to the nucleus and induce 
expression of target genes. NFκB binds to a conserved DNA motif found in 
numerous IL-1-responsive genes, including IL-1, IL-6, IL-8, MCP-1, and COX-
2. Activation of TAK-1 can also lead to the activation of JNK and p38 MAPK 
(Korherr et al., 1997, Holtmann et al., 2001, Akira and Takeda, 2004, 









Figure i.6: Overview of IL-1R activation 
Activation of IL-1R1 leads to conformational change allowing recruitment of IL-1RAcP. 
MyD88 is recruited to the complex via TIR-TIR interaction. Subsequently IRAK-1/2/4 are 
recruited by Death Domain (DD) interaction. Phosphorylation of IRAK-1/2 by IRAK-4 leads 
to recruitment of TRAF-6 and subsequent dissociation of the complex, and association 
with the TAK1/TAB1/TAB2 complex. IRAK-1 phosphorylates TAK1 and TAB1. The TRAF-
6, TAK1/TAB1/TAB2 complex translocates to the cytosol where TRAF-6 activates TAK1. 
TAK1 phosphorylates cytosolic MAP kinases as well as the IKK complex. Phosphorylation 
and activation of the IKK complex leads to phosphorylation of the inhibitory IκB. IκB is 




7.1.1.   Interleukin-1β and pain 
IL-1β has been shown experimentally to have the ability to cause pain-like 
behaviours in rodents at multiple levels of the pain pathway. Following 
peripheral nerve injury, expression of both IL-1α and IL-1β are quickly 
upregulated at the site of injury (Okamoto et al., 2001). Intraplantar injection of 
IL-1β has been showed to elicit rapid behavioural hypersensitivity, an effect 
accompanied by a decrease in activation thresholds of DRG neurons to touch 
stimuli and a significant increase in firing response to touch, cold, and heat 
stimulations of the periphery (Fukuoka et al., 1994, Cunha et al., 2000). 
Additionally, intraplantar injection of inflammatory stimuli such as LPS and 
complete Freund’s adjuvant (CFA) leads to an upregulation of inflammatory 
cytokines, including IL-1β, at the site of injection as well as in the DRG and 
spinal cord (Cunha et al., 2000, Samad et al., 2001). Application of IL-1β in the 
spinal cord and brain have been shown to cause thermal hypersensitivity, and 
potentiation of responses of WDR neurons (Oka et al., 1993, 1994, Sung et al., 
2004, Kawasaki et al., 2008b). IL-1β expression has been shown to be 
increased at several levels of the pain pathway in several animal models of 
neuropathic pain (Milligan et al., 2001, Lee et al., 2004, Clark et al., 2006, 
Uceyler and Sommer, 2008). Inhibition of IL-1β signalling by IL-1RA or 
neutralising antibodies against the IL-1β or IL-1R have been shown to 
attenuate pain-like behaviours (Sommer et al., 1999, Sweitzer et al., 2001, 
Zhang et al., 2008a). IL-1β is thought to exert its hyperalgesic effects both 
indirectly, via its ability to induce expression of a variety of proteins associated 
with pain signalling including PGE2, COX2, NO, IL-6, and MCP-1 (Jura et al., 
2008, Weber et al., 2010), and also directly by enhancing calcium and non-
selective cation currents, and inhibiting potassium efflux (Kawasaki et al., 
2008b, Zhang et al., 2008a, Austin and Moalem-Taylor, 2010). In the spinal 
cord, application of IL-1β leads to an increase in excitatory AMPA and NMDA-
induced currents, through PKC mediated phosphorylation of NR1 and NR2B 
subunits, and decreases spontaneous GABA and glycine inhibitory currents 






7.2.   Interleukin-18 
IL-18, a member of the IL-1 family, is structurally related to IL-1β and was 
originally identified as an IFN-γ-inducing factor. Similar to IL-1β, IL-18 is 
synthesised as a 24kDa pre-cursor lacking a leader sequence, pro-IL-18, 
which must be enzymatically cleaved by caspase-1 to generate the mature 
18kDa active cytokine. However, unlike pro-IL-1β, pro-IL-18 mRNA is 
constitutively expressed (Gracie et al., 2003, Dinarello, 2009). Alone, IL-18 is 
able to induce low levels of IFN-γ, though this effect is greatly enhanced in the 
presence of IL-12 (Munder et al., 1998). Caspase-1-deficient mice injected with 
endotoxin have significantly lower levels of circulating IFN-γ compared to wild-
type littermates (Fantuzzi et al., 1999). As well as a role in IFN-γ induction, IL-
18 has a variety of other effects on the immune system, including a role in T 
and NK cell maturation and cytokine production (Gracie et al., 2003). 
Additionally IL-18 is thought to play a role in homeostasis, and dysfunction of 
IL-18 signalling has been implicated in a variety of diseases including 
metabolic syndromes, inflammatory arthritis, and multiple sclerosis (Gracie et 
al., 2003, Arend et al., 2008). 
 
IL-18 signals via the IL-18R complex in a similar manner to IL-1, and TLR, 
signalling. Briefly IL-18 binds to IL-18Rα, which then binds to IL-18Rβ. The 
complex then recruits and binds MyD88, which recruits the IRAK kinases in a 
similar fashion to IL-1R, and TLR, signalling. MyD88 binds IRAK1-4, which in 
turn recruit TRAF6. IRAK phosphorylation of the IKK complex leads to the 
degradation of IκB. The dissociation of IκB from NFκB allows NFκB to 
translocate to the nucleus and induce expression of target genes. TRAF-6 
activation is also able to induce p38 MAPK activation (Gracie et al., 2003). 
Also analogous to IL-1, there are endogenous mechanisms to restrict IL-18 
signalling. Like pro-IL-18, IL-18-binding protein (IL-18BP) is constitutively 
expressed. IL-18BP inhibits IL-18-induced IFN-γ production in vitro, and LPS-
induced IFN-γ production in vivo (Aizawa et al., 1999, Faggioni et al., 2001). 
IL-18BP production is inducible by IFN-γ, negatively regulating the effects of 






7.2.1.   Interleukin-18 and pain 
As previously discussed (see section 5), IL-18 has been implicated in playing a 
role in mediating pain. Intrathecal administration of IL-18 in rats leads to 
behavioural hypersensitivity, while inhibition of IL-18 in the spinal cord 
suppresses nerve injury-induced mechanical hypersensitivity (Miyoshi et al., 
2008). Additionally IL-18 is increased in the synovium of patients with 
rheumatoid arthritis (Arend et al., 2008). 
 
 
8.    The Inflammasome – A molecular platform for the activation of 
inflammatory caspases 
As previously mentioned, IL-1β is synthesised as a 33kDa inactive precursor, 
pro-IL-1β, that must be enzymatically cleaved to generate mature active 17kDa 
IL-1β. Although it had been known for several years that caspase-1 (initially 
called interleukin-1 converting enzyme (ICE)) is necessary for IL-1β maturation 
in a variety of experimental paradigms, it is only more recently that the 
mechanisms behind this association are being elucidated. In 2002, Martinon et 
al. showed that a novel protein, Nod-like receptor protein-1 (NLRP1), along 
with an adaptor protein, apoptosis-associated speck-like protein containing a 
CARD (ASC), provide a platform for the activation of caspase-1. Analogous to 
a similar protein complex involved in the activation of caspase-9 and 
apoptosis, the apoptosome, this NLRP1-containing caspase-1 activating 
complex was termed the inflammasome (Martinon et al., 2002). Since then the 
inflammasome has been extensively researched, and several types are now 
recognised; NLRP1, NLRP3, NLRC4 (NLR family CARD domain-containing 
protein 4, previously known as IPAF), and AIM2, all named for the central 
scaffold protein involved (Schroder and Tschopp, 2010). 
 
The inflammasome is a multi-protein complex which acts as a regulating 
platform for the eventual cleavage and secretion of mature IL-1β via activation 
of the enzyme caspase-1. The inflammasome consists of a central scaffold 
protein, for which it is named, an adaptor protein (ASC, cardinal), and 




immune system. It is important for an organism to be able to discriminate self 
from non-self invading microorganisms. Pattern recognition receptors (PRRs) 
are able to recognise a range of conserved microbial motifs and are expressed 
in cells of the immune system such as macrophages, monocytes, and dendritic 
cells. They may be membrane-associated, as in the case of toll-like receptors 
(TLRs), or cytosolic as in the case of Nod-like receptors (NLRs). The NLRs are 
cytosolic sensors, recognising a wide range of both pathogen-associated 
molecular patterns (PAMPs) and danger-associated molecular patterns 
(DAMPs) (Martinon and Tschopp, 2005). The NLR family of proteins is 
characterised by a central nucleotide-binding and oligomerisation (NACHT) 
domain, a region of leucine-rich repeats (LRR) in the C-terminus region, and 
an N-terminal caspase recruitment (CARD) or pyrin (PYD) domain. Earlier 
nomenclature convention named NLRP1 and NLRP3 as NALP1 and NALP3, 
being NACHT, LRR, and PYD containing proteins. NLRP1, NLRP3, and 
NLRC4 are all members of the NLR family, AIM2 is a HIN-200 family member 
(Schroder and Tschopp, 2010).  
 
The central scaffold proteins of the inflammasome are able to recognise a 
large number of both exogenous and endogenous activators, including 
muramyl dipeptide (NLRP1, NLRP3), sendai virus, influenza virus, adenovirus, 
nigericin, silica, asbestos, ATP, monosodium urate crystals, β-amyloid 
(NLRP3), flagellin (NLRC4), and dsDNA (AIM2) (Bryant and Fitzgerald, 2009, 
Martinon et al., 2009, Latz, 2010). It is thought that agonist binding occurs at 
the LRR, as is the case for TLR3 and TLR5 (Martinon and Tschopp, 2005, 
Petrilli et al., 2005), though this has yet to be conclusively demonstrated. 
dsDNA binds to the C-terminal HIN domain in the case of the AIM2 
inflammasome. Upon agonist activation the central scaffold protein 
oligomerises at the NACHT domain (Duncan et al., 2007). In the case of 
NLRP3 and human NLRP1 (containing a PYRIN domain; this domain is absent 
in mouse), adaptor proteins ASC, and possibly also cardinal, are recruited to 
the complex via homotypic PYRIN-PYRIN domain protein interactions. In turn, 
inactive caspase-1 is recruited to the complex via CARD-CARD domain 
interactions with the adaptor proteins. NLRP1 additionally has an N-terminus 




as well as another inflammatory caspase, caspase-5 (Martinon et al., 2002). 
NLRC4 also contains a CARD domain and appears to be able to interact 
directly with caspase-1. However ASC is still required for maximal NLRC4 
activation, though the exact mechanisms involved are unclear since NLRC4 
lacks a PYRIN domain. A diagram demonstrating structural similarities of 









Figure i.7: Inflammasome scaffold proteins 
Schematic representation of the protein domains of the inflammasome scaffold 
proteins NLRP1, NLRP3, NLRC4, and AIM2. Where LRR = Leucine Rich Region, 
NACHT = the central nucleotide binding and oligomerisation domain, PYD = Pyrin 










8.1.   Caspase-1 
Caspases are a family of cysteine proteases which cleaves proteins following 
an aspartate residue, the founding member of which is caspase-1. Caspase-1, 
then known as ICE, was originally described following attempts to purify the 
enzyme responsible for the cleavage of pro-IL-1β (Thornberry et al., 1992). All 
caspases are synthesised as inactive pre-cursors, consisting of an N-terminal 
pro-domain of variable length, followed by two subunits which form the 
protease domain. Caspases with a large pro-domain contain homotypic 
protein-protein interaction motifs which function to recruit them to large 
multiprotein complexes; caspase-1 contains a caspase activation and 
recruitment domain (CARD) through which it is recruited to the inflammasome 
(Lamkanfi and Dixit, 2009). Pro-caspase-1 is an autolytic enzyme meaning that 
it is able to enzymatically cleave, and subsequently activate, other pro-
caspase-1 molecules. In order for this process of activation to occur, pro-
caspase-1 molecules must be recruited to the inflammasome complex where 
the induced proximity and dimerisation of the zymogen molecules allows this 
cleavage to take place. Cleavage of the pro-caspase-1 molecules results in 
dissociation of active caspase-1, a heterodimer complex of two p10 and two 
p20 subunits. Active caspase-1 is then able to cleave any pro-IL-1β and pro-IL-
18 present in the cytosol, resulting in their activation (Boatright et al., 2003, 
Boatright and Salvesen, 2003, Martinon and Tschopp, 2004).  
 
As with many other steps in the interleukin-1 family inflammatory pathway, the 
actions of caspase-1 are tightly regulated, preventing excessive and 
uncontrolled release of the pro-inflammatory cytokines. In humans three 
endogenous inhibitors of the enzyme have been described; ICEBERG, 
pseudo-ICE, and INCA. All are short proteins, comprising of essentially just a 
CARD domain, and are encoded by caspase-like genes that have acquired a 
premature nonsense mutation. Thus they are able to sequester pro-caspase-1 
by binding at the CARD domain, preventing its recruitment to the 
inflammasome complex. ICEBERG, pseudo-ICE, and INCA, are all found in 
the same locus as caspase-1 in humans, though are absent from the murine 
genome (Druilhe et al., 2001, Lamkanfi et al., 2004). Caspase-12 is thought to 




domain-containing caspase which appears to lack any enzymatic activity. It 
has been shown to interact with caspase-1 and inhibit its activity. Moreover 
administration of various TLR ligands to splenocytes from mice deficient in 
caspase-12 resulted in an increased production of IL-1β and IL-18 compared 
to that observed in cells from wild-type litter mates (Saleh et al., 2006). Like 
ICEBERG, pseudo-ICE, and INCA, caspase-12 can also be mapped to the 
same chromosome as caspase-1 in humans, although is also to be found in 
the murine genome. Following activation of caspase-1, and subsequent 
cleavage of pro-IL-1β, mature IL-1β is rapidly ejected from the cell, via non-
classical secretion pathways (Brough et al., 2003, Andrei et al., 2004, Keller et 
al., 2008, Lopez-Castejon and Brough, 2011). The secretion of mature IL-1β is 
accompanied by the secretion of active caspase-1, seen in several 
experimental paradigms both in vitro and ex vivo (Sanz and Di Virgilio, 2000, 
Clark et al., 2006, Pelegrin and Surprenant, 2006, Qu et al., 2007, May, 2008, 
Pelegrin et al., 2008, Qu et al., 2009). This likely reflects a further regulatory 
step of the inflammatory pathway, the ejection of the active caspase-1 enzyme 
from the cell limiting the amount of pro-IL-1β cleavage that can take place.  
 
8.2.   ASC 
Apoptosis-associated speck-like protein containing a CARD (ASC) was initially 
identified as a molecule which formed speck-like aggregates in HL-60 cells 
when apoptosis was induced by retinoic acid and other anti-tumour drugs 
(Masumoto et al., 1999). The protein was subsequently shown to be a short 
one, 195 amino acids in length, encoded by three exons; exon 1 encodes a 
PYRIN domain, exon 3 encodes a CARD domain, while exon 2 encodes a 
proline and glycine-rich domain (Matsushita et al., 2009). It is thought that this 
proline and glycine-rich domain imparts a bending, hinge-like, property to ASC, 
aiding its aggregation into the characteristic specks. A splice variant of the 
ASC protein, lacking the proline and glycine-rich domain, has been shown to 
differently regulate IL-1β release, despite no discernible differences in 
caspase-1 activation, with a higher level of IL-1β excreted from transfected 
Cos7 cells. Additionally ASC aggregates formed differently, with the splice 




length ASC-transfected cells which exhibited more circular aggregates 
(Matsushita et al., 2009). 
 
The PYRIN domain of ASC was first shown to associate as part of a larger 
complex, the inflammasome, in 2002 where it was shown to be essential for 
pro-caspase-1 activation (Martinon et al., 2002). In support of this, several 
studies have shown ASC to be essential for pro-caspase-1 activation 
(Srinivasula et al., 2002, Mariathasan et al., 2004, Sutterwala et al., 2006, Yu 
et al., 2006, Yamamoto et al., 2008, Bryan et al., 2009). Unlike NLRP3, which 
appears to have a cytosolic localisation (O'Connor et al., 2003, Kummer et al., 
2007), ASC has been shown to have a nuclear localisation in unstimulated 
cells (Bryan et al., 2009). Following stimulation, ASC rapidly redistributes from 
the nucleus to cytosol, while longer stimulation causes aggregation of ASC into 
speck-like structures which increase in size over time. Sequestration of ASC in 
the nucleus via fusion of proteins with nuclear localisation sequences greatly 
reduces the processing of IL-1β following cell stimulation, demonstrating the 
importance of redistribution of ASC in the activation of pro-caspase-1 (Bryan et 
al., 2009). 
 
In humans a small protein found at the same gene locus as ASC, POP1, with a 
64% sequence homology to the PYRIN domain of ASC, acts to sequester ASC 
and prevent its binding to the inflammasome. POP2 has less sequence 
homology to ASC, but is able to bind weakly with ASC. Instead it is able to 
bind to several NLRPs, particularly NLRP2 and NLRP7. Again, binding of 
POP2 will prevent recruitment of ASC to the complex. POP1 and POP2 do not 
appear to be present in the murine genome (Stehlik and Dorfleutner, 2007). 
However a third protein, PYNOD (also known as NLRP10) is found in both the 
human and murine genome. PYNOD is a member of the NLR family, but lacks 
the LRR region. PYNOD has been shown to interact with and inhibit both ASC 
and caspase-1 (Wang et al., 2004a).  
 
Although the role of ASC as an inflammasome adaptor protein is well 
characterised emerging evidence suggests that ASC serves a variety of roles, 




initially characterised in a search for proteins associated with the process of 
apoptosis (Masumoto et al., 1999). Pyroptosis is a newly-described form of 
programmed cell death, which is distinct from that of apoptosis. Importantly 
pyroptosis involves the release of inflammatory mediators, a process which is 
inhibited in apoptosis (Fink and Cookson, 2005). Pyroptosis was initially 
described in response to the intracellular infection of macrophages with S. 
typhimurium, but has subsequently been shown to occur in response to other 
bacterial and viral pathogens, as well as non-infectious stimulators such as 
LPS, MSU, R837, and nigericin (Perregaux and Gabel, 1994, Aliprantis et al., 
2000, Le Feuvre et al., 2002, Fink and Cookson, 2006, Fernandes-Alnemri et 
al., 2007). During pyroptosis small pores form in the cell membrane leading to 
swelling and osmotic lysis of the cell. Prior to lysis and release of lactate 
dehydrogenase, a marker of cell death, processed IL-1β is released (Brough 
and Rothwell, 2007). The process of pyroptosis has been shown to be 
dependent on caspase-1 (Fink and Cookson, 2006, Brough and Rothwell, 
2007). At least in the case of ATP-stimulated pyroptosis, P2X7 receptors have 
been shown to be activated (Brough and Rothwell, 2007). In this paradigm, at 
least, the recruitment of pannexin channels by P2X7 may be responsible for 
the osmotic lysis occurring in pyroptosis. Similar to inflammasome formation, 
pyroptosome formation forms downstream of a reduction in intracellular 
potassium, as demonstrated by increasing extracellular potassium 
concentrations, or blocking potassium channels (Perregaux and Gabel, 1994, 
Fernandes-Alnemri et al., 2007). It is not clear what role, if any, NLRP3, or 
other inflammasome scaffold proteins, plays in the process of pyroptosis. It has 
been postulated that NLRP3 may function as an initial catalyst or enhancer of 
ASC oligomerisation (Fernandes-Alnemri et al., 2007). It is possible that 
sustained activation of inflammasome pathways eventually leads to pyroptosis, 
as IL-1β is secreted from the cell prior to cell death (Brough and Rothwell, 
2007). ASC specks have been observed to grow in size over time, in the 
absence of cell death, following primary macrophage cell stimulation which 
supports this idea (Bryan et al., 2009).  
 
In addition to its role in inflammasome and pyroptosome formation, ASC has 




regulation of MAPK phosphorylation in response to pathogens and Toll-like 
receptor agonists via a suppressive action of DUSP10, a dual-specificity 
phosphatase. DUSP10 negatively regulates the MAPK superfamily via 
dephosphorylation of serine/threonine residues. In macrophages derived from 
ASC-deficient, but not NLRP3-, NLRC4-, or caspase-1-deficient, animals 
MAPK activation and chemokine induction was reduced, whereas DUSP10 
expression was increased in these cells. In wild-type cells, the application of 
DUSP10 abrogated MAPK activation and chemokine induction (Taxman et al., 
2011). Finally, ASC has been shown to have a role in T cell priming in the 
development of arthritis in the rodent model of collagen-induced arthritis, which 
was also shown to be independent of other inflammasome components (Kolly 
et al., 2009, Ippagunta et al., 2010). Mice deficient in ASC failed to develop 
arthritis in this model, whereas mice deficient in both caspase-1 and NLRP3 
developed arthritis normally. Collagen-specific antibodies were not detected in 
ASC-deficient mice as a result of a reduced antigen-specific activation of T 
lymphocytes by dendritic cells (Ippagunta et al., 2010). In these cases ASC is 
acting independently of the NLRP3 inflammasome. However it is not clear 
whether the protein is acting alone, or as an adaptor molecule for some other, 
as yet unidentified, PYRIN- or CARD domain-containing protein in these 
instances. 
 
8.3.    Inflammasome expression 
Of the inflammasomes, the NLRP3 inflammasome is currently the best 
characterised. Despite appearing to have the largest range of activators, 
NLRP3 appears to have the most limited pattern of expression. NLRP3 mRNA 
has been demonstrated to be predominantly expressed in lymphoid organs, 
and organs highly populated by immune cells, such as the liver (Anderson et 
al., 2004, Guarda et al., 2011). NLRP3 mRNA was found in neutrophils, 
peripheral blood mononuclear cells, monocytes, and mast cells (Anderson et 
al., 2004). This is confirmed at the protein level where expression of NLRP3 
has been shown in neutrophils, monocytes, and dendritic cells (Kummer et al., 
2007, Guarda et al., 2011). In terms of tissue distribution NLRP3 was mainly 




ectocervix, as well as in the urothelial layer of the bladder. This is in contrast to 
the far more widespread expression of NLRP1, found in glandular epithelia 
structures including the gut, lung, and testis. NLRP1 was also found to be 
expressed in granulocytes, monocytes, dendritic cells, B and T cells, as well as 
neurons  (Kummer et al., 2007). Owing to this more restricted cell and tissue 
expression and the range of endogenous danger signal activators, including 
ATP, it is of interest to investigate the potential contribution of the NLRP3 
inflammasome in microgliosis and neuropathic pain. 
 
It is known that in many cell types expression of NLRP3 is inducible following 
inflammatory stimuli such as TLR agonists and TNF-α. This is thought to 
reflect a further control on interleukin inflammatory signalling, preventing 
uncontrolled release of inflammatory cytokines. However less is known about 
the constitutive expression of this protein. Recently the development of a 
NLRP3-deficient mouse with an in-frame insertion of the enhanced GFP gene 
at the Nlrp3 locus has provided greater insight into this question. In these mice 
the transcription of enhanced GFP is controlled by endogenous Nlrp3 
regulatory elements, allowing the expression of the fluorescent protein to act 
as a reporter. This study largely confirmed previous findings, showing that 
NLRP3 is expressed mainly in myeloid cells, including dendritic cells and 
monocytes. Of particular interest was the finding that different cell types 
appear to express differing levels of NLRP3 under resting conditions such that 
conventional dendritic cells and monocytes showed the highest levels of 
expression, with neutrophils and macrophages showing lower constitutive 
levels of expression. Administration of pro-inflammatory stimuli in vivo lead to a 
marked increase in GFP expression in monocytes, neutrophils, and 
macrophages. However there was no change observed in GFP expression in 
conventional dendritic cells suggesting that these cells do not further 
upregulate NLRP3 expression in an inflammatory environment (Guarda et al., 
2011).  
 
The secretion of pro-inflammatory cytokines is a two-step process; cells must 
first be primed as the expression of both IL-1β and NLRP3 are inducible; 




reduces caspase-1 activation of LPS-primed macrophages following ATP 
stimulation, and LPS stimulation has been shown to lead to dose-dependent 
increases in Nlrp3 mRNA levels  (O'Connor et al., 2003, Kahlenberg et al., 
2005, Bauernfeind et al., 2009). Induction of NLRP3 expression, like pro-IL-1β 
expression, can be brought about by the action of a number of different 
stimulators whose signalling converges at the TLR/IL-1R signalling pathways 
such as LPS, TLR2, and TLR7 activators (Bauernfeind et al., 2009). It has 
been shown that macrophages from mice deficient in MyD88 or TRIF, two 
alternative adaptors in the TLR4 signalling pathway, were still able to respond 
normally to LPS followed by ATP stimulation. However macrophages from 
animals deficient in both proteins failed to respond, showing a level of 
compensation in the TLR4-signalling pathway. The group also showed that 
TNF-α was able to prime cells from wild-type animals, but not from mice 
doubly deficient in TNFR1 and TNFR2. TNFR signalling converges on the TLR 
signalling pathways in that activation leads ultimately to the degradation of the 
NFκB inhibitory protein IκB, allowing nuclear translocation of the transcription 
factor (O'Connor et al., 2003). Inhibition of NFκB with the inhibitor Bay11-7082 
dose-dependently reduced LPS-induced expression of Nlrp3 mRNA, 
suggesting that NLRP3 expression is under the control of the rapid-acting 
transcription factor (Bauernfeind et al., 2009). As would be expected therefore, 
pre-treatment of macrophages with Bay11-7082 leads to a reduction in 
caspase-1 activation (Kahlenberg et al., 2005). As with other levels of the 
pathways responsible ultimately for the release of IL-1β and IL-18, induction of 
NLRP3 expression is regulated in a negative feedback loop whereby the 
NLRP3 protein inhibits translocation of the p65 subunit of NFκB to the nucleus. 
The generation of a series of FLAG-tagged deletion constructs of NLRP3 
showed that the NACHT and LRR domains together were responsible for this 
inhibition (O'Connor et al., 2003). Interestingly co-expression of ASC and 
NLRP3 has been shown to activate NFκB, whereas expression of ASC alone 
inhibited NFκB activation by stabilising the IκB-NFκB complex in TNF-α- and 
LPS-stimulated transfected cells. Transfection of siRNA targeted at the ASC 
protein enhanced degradation of IκB (Stehlik et al., 2002). However another 




NLRP3 induced NFκB activation, suggesting that this story is complex and 
likely depends on cellular context (Yu et al., 2006).  
 
8.4.   Inflammasome activation 
Prior to activator binding, the NLRP3 protein exists in a repressed 
conformation in the cytosol. Analogous to structurally related plant R proteins, 
NLRP3, Nod2, and NLRC4 have been found to interact with chaperone 
proteins SGT1 and hsp90. Further analysis using flag-tagged NLRP3 domains 
showed that hsp90 binds the NACHT and LRR domains, while SGT1 binds to 
the LRR domain only. SGT1 binding was found to be reliant on active hsp90; 
geldanamycin (an inhibitor of hsp90 function) was found to inhibit SGT1-
NLRP3 interactions. At larger doses it was reported that geldanamycin 
substantially reduced endogenous levels of NLRP3, an effect that was 
prevented by pre-treatment with a proteasome inhibitor. Thus binding of hsp90 
appears to prevent proteasome degradation of NLRP3. In contrast, knockdown 
of SGT1 with siRNA reduced inflammasome activity as assessed by released 
mature IL-1β, but did not appear to affect protein stability. Upon binding of an 
inflammasome activator it is thus postulated that SGT1 and hsp90 dissociate, 
allowing oligomerisation of the NACHT domains to take place (Mayor et al., 
2007). This self-association has been shown to be depend on ATP binding and 
hydrolysis at the NACHT domain. Transfected cells containing mutated NLRP3 
proteins lacking a motif within the nucleotide binding domain of the NACHT 
domain were shown to produce decreased levels of mature IL-1β, and NLRP3 
was found to self-associate less efficiently that the wt protein. Additionally 
association of the mutant protein with adaptor protein ASC was drastically 
reduced, demonstrating that nucleotide binding and hydrolysis is also critically 
important in recruitment of the adaptor protein (Duncan et al., 2007). 
 
How such a diverse range of structurally distinct activators (particularly in the 
case of NLRP3) is able to activate the inflammasome is unclear. Each may 
directly bind to the scaffold protein, or alternatively each ligand may activate a 
common cellular signal which in turn activates the appropriate inflammasome. 




and all have been shown to decrease intracellular potassium (Di Virgilio, 
2007). It has been shown that addition of ATP to LPS-primed microglial cells 
causes release of IL-1β. Active p20 caspase-1 fragment was detected by 
immunoblot of these cells, and the caspase-1 inhibitor YVAD-CHO prevented 
this release, showing it to be a caspase-1-dependent mechanism (Sanz and Di 
Virgilio, 2000). It was postulated that the ATP was acting on P2X7 receptors, a 
non-selective cation channel, activation of which decreased intracellular 
potassium concentration. Increased extracellular potassium concentration 
inhibited release of IL-1β. Further to this data, Petrilli et al. and Dostert et al. 
showed that activation of the NLRP3 inflammasome by a variety of known 
ligands was inhibited by increasing extracellular potassium concentration, 
suggesting that potassium efflux is a specific and common trigger to  
inflammasome activation (Petrilli et al., 2007a, Dostert et al., 2008).  
 
Another common trigger to inflammasome activation appears to be reactive 
oxygen species (ROS). Increased levels of ROS are reported as a result of 
incomplete or “frustrated” phagocytosis (Hornung et al., 2008). In the case of 
asbestos, silica, and MSU activation of the NLRP3 inflammasome, endocytosis 
and ROS are required to elicit activation (Martinon et al., 2006, Petrilli et al., 
2007b, Dostert et al., 2008, Dostert et al., 2009, Gasse et al., 2009). Inhibition 
of phagocytosis with cytochalasin D prevents NLRP3 activation by crystalline 
activators as measured by subsequent cytokine release (Dostert et al., 2008, 
Hornung et al., 2008). Inhibition of ROS by N-acetyl-cysteine (NAC) or 
(2R,4R)-4-aminopyrolidine-2,4-dicarboxylate (APDC) pre-treatment has been 
shown to prevent IL-1β release in response to asbestos, MSU, and, 
surprisingly, ATP. Thus ROS may also be  a common and necessary trigger 
for inflammasome activation (Dostert et al., 2008). In a separate study looking 
at ATP-induced cytokine release in alveolar macrophages, it was shown that 
P2X7R activation led to a transient production of ROS; detectable within 30 
seconds, maximal after 5 minutes, and returned to basal levels 15 minutes 
after stimulation (Cruz et al., 2007). The P2X7R agonist BzATP was sufficient 
to cause this production, whereas P2X7R antagonism with oxATP blocked this 
response. In agreement with Dostert et al., NAC pre-treatment inhibited 




revealed that ATP-induced ROS production led to the activation of the Akt and 
ERK1/2 pathways due to an inhibitory effect on PTEN, the inactivation of which 
shifts the equilibrium in favour of PI3K activation (upstream of Akt and ERK1/2 
pathways).  Interestingly inhibition of the PI3K pathway with LY294002 
inhibited cytokine secretion in LPS-primed cells stimulated with ATP, and the 
authors suggest that this pathway is somehow responsible for the activation of 
caspase-1 (Cruz et al., 2007). 
 
More recently, a yeast two-hybrid screen using the LRR of NLRP3 as bait was 
employed in order to identify potential NLRP3 binding partners which led to the 
identification of thioredoxin-interacting protein (TXNIP) as one such protein. 
Thioredoxin (TRX) acts as an antioxidant which facilitates the reduction of 
other proteins. TXNIP regulates the antioxidant function of TRX and is thought 
to act as a negative regulator of the TRX reductase activity. At high 
concentrations of H2O2, TXNIP dissociates from TRX (Zhou et al., 2010). 
NLRP3 activators R-837 and MSU, which have also been shown to generate 
ROS, caused TXNIP to dissociate from TRX. This effect was blocked by pre-
treatment with the ROS inhibitor APDC. It was shown that MSU-induced 
dissociation of TXNIP from TRX was maximal one hour after stimulation, at 
which time association with NLRP3 became evident. siRNA-mediated 
downregulation of TXNIP suppressed MSU-, R-837-, and ATP-induced 
cytokine release. The authors proposed a model whereby TXNIP dissociates 
from TRX following its oxidation by ROS, allowing TXNIP to bind to, and 
participate in the activation of, NLRP3 (Zhou et al., 2010). 
 
It was initially posited that the source of the ROS might be the phagasomal 
respiratory-burst oxidase system, associated with the degradation of 
internalised bacterial particles. However, normal NLRP3 inflammasome 
activation in response to silica crystals, MSU, and ATP occurs in mice lacking 
gp91phox, a subunit of the phagasomal NADPH oxidase cytochrome b 
(Hornung et al., 2008). The main source of cellular ROS is the mitochondria, 
which has prompted investigation into the role of mitochondrial ROS in NLRP3 
inflammasome activation. Treatment of human THP-1 macrophages with 




secretion in a dose-dependent manner, which was prevented when cells were 
pre-treated with the ROS inhibitor APDC. This effect was not observed in 
macrophages obtained from mice deficient in NLRP3 (Zhou et al., 2011). 
Inhibition of mitophagy, which leads to an accumulation of damaged 
mitochondria and thus increased concentrations of mitochondrial ROS, led to 
the enhanced secretion of IL-1β (Nakahira et al., 2011, Zhou et al., 2011). 
Mice lacking LC3B, a protein contributing to the process of autophagy, were 
shown to produce more IL-1β and IL-18 in a model of septic shock than 
wildtype littermates (Nakahira et al., 2011). Finally inhibition of voltage-
dependent anion channels (VDAC) VDAC1 and VDAC2 (major channels for 
the exchange of metabolites and ions between the mitochondria and other 
cellular compartments) caused a significant reduction of IL-1β secretion in 
response to NLRP3 activators. However VDAC3 inhibition did not affect 
inflammasome activity (Zhou et al., 2011). Further investigation into the role of 
ROS in inflammasome activation has led one group to conclude that rather 
than directly activating NLRP3, ROS function to upregulate NLRP3 expression. 
This conclusion was made on the basis that ROS inhibition decreased the 
LPS-mediated induction of IL-β, TNFα, and NLRP3. Cells treated with ROS 
inhibitors after the LPS-priming step still showed NLRP3 activation and 
cytokine secretion in response to nigericin. In support of this hypothesis, ROS 
inhibition in cells stably overexpressing NLRP3 did not affect NLRP3 activation 
(Bauernfeind et al., 2011).  
 
In addition to K+ depletion and the action of ROS, the protease cathepsin B 
has been proposed to play a role in inflammasome activation in response to 
the crystalline and particulate activators. It was proposed that phagocytosis of 
crystals leads to destabilisation and rupture of lysosomes, leading to the 
release of, among others, the protease cathepsin B. In line with this 
hypothesis, pre-treatment of cells with the inhibitor CA-074-Me led to reduced 
secretion of IL-1β following stimulation with silica, or amyloid beta (Halle et al., 
2008, Hornung et al., 2008). However, macrophages from mice deficient in 
cathepsin B showed normal NLRP3 activation in response to hemazoin, MSU, 
and alum (Dostert et al., 2009). This suggests an off-target effect of CA-074-




from damaged lysosomes. A schematic representing the activation of the 







Figure i.8: Overview of NLRP3 inflammasome activation 
NLRP3 exists in a repressed state, held in an inactive conformation by chaperone 
proteins SGT1 and hsp90. NLRP3 is activated by a range of molecules; it is 
postulated that common, downstream, pathways activate NLRP3. Putative activators 
include K+ efflux, possibly via P2X7 receptor activation, Cathepsin B released from 
lysosomes, and mitochondrial ROS. Increased ROS levels result in the dissociation of 
TXNIP from binding partner THX, and binds the LRR of NLRP3. Once activated SGT1 
and hsp90 dissociate and are degraded, resulting in a change in NLRP3 
conformation. ATP binding and hydrolysis at the NACHT domain results in 
oligomerisation at the NACHT domain and recruitment of adaptor protein ASC, via 
PYD-PYD protein interactions. Pro-caspase-1 is recruited to the complex via CARD-
CARD interactions. Induced proximity results in the autocleavage of pro-caspase-1 
generating active caspase-1 tetramers, consisting of two p10 and two p20 subunits. 
Active caspase-1 dissociates from the complex and goes on to cleave pro-IL-1β and 




8.5.   Abnormal inflammasome signalling in disease 
IL-1β is a pro-inflammatory cytokine with a range of physiological effects, 
including generation of fever, rash, and the upregulation of the expression of 
other pro-inflammatory cytokines. IL-1β also appears to have homeostatic 
functions including the regulation of feeding, sleep, and temperature (Ren and 
Torres, 2009). Thus it is hardly surprising that there exist multiple levels of 
control in the expression, maturation, and release of this cytokine. The need 
for so many levels of regulation is exemplified in several autoimmune 
disorders, characterised by an excessive and uncontrolled release of IL-1β. 
Cryopyrin-associated periodic syndromes (CAPS) are hereditary diseases 
characterised by recurrent fever and inflammation often with a lack of 
detectable cause. Symptoms include rash, fever/chills, joint and muscle pain. 
There are three CAPS syndromes; familial cold autoinflammatory syndrome 
(FACS), Muckle-Wells syndrome, and chronic infantile cutaneous neurological 
articular syndrome (CINCA). Macrophages from patients with Muckle-Wells 
syndrome have been shown to spontaneously secrete IL-1β (Agostini et al., 
2004). CAPS patients respond well to treatment with IL-1RA. CAPS 
syndromes have been shown to be caused by mutations in the gene encoding 
the NLRP3 protein, specifically in exon 3 which encodes the NACHT domain 
(Hoffman et al., 2001, Feldmann et al., 2002).  
 
Gout is an autoinflammatory disease characterised by severe joint 
inflammation. Gout is caused by elevated levels of uric acid in the blood. The 
uric acid crystallises to form monosodium urate (MSU), and becomes 
deposited in joints, tendons, and muscles. MSU is a potent activator of the 
NLRP3 inflammasome (Martinon et al., 2006).  
 
Elevated IL-1β has also been identified as a risk factor in the development of 
type II diabetes as it has been shown to mediate the toxic effects of prolonged 
hyperglycaemia in pancreatic islets (Schroder and Tschopp, 2010). It has been 
shown that high glucose concentrations induce IL-1β secretion. This effect is 
considerably reduced in islets from mice deficient in TXNIP, and from mice 
deficient in NLRP3, suggesting that high glucose concentration activates the 




NLRP3 showed improved glucose tolerance and insulin sensitivity (Zhou et al., 
2010). 
 
8.6.   A role for the NLRP3 inflammasome in pain? 
There are several lines of evidence which might indicate a role of the 
inflammasome in both neuropathic and inflammatory pain states. IL-1β is 
algesic when administered to a variety of tissues, and its expression has been 
shown to be upregulated in several animal models of pain, including CCI and 
intraplantar injection of CFA (Fukuoka et al., 1994, Cunha et al., 2000, Samad 
et al., 2001, Sung et al., 2004, Kawasaki et al., 2008b, Gabay et al., 2011). As 
previously mentioned, microglia and macrophages, which express and release 
IL-1β, have been strongly implicated as having a role in the development of 
pain-like behaviours in several animal models of pain. To date there is little 
investigation of the inflammasome in microglia, though one publication has 
investigated the role of the inflammasome in the microglial response to 
amyloid-beta (Halle et al., 2008), demonstrating a presence of the 
inflammasome within microglia. IL-1β, as well as activated caspase-1 and 
ASC, have been shown to be released from LPS-stimulated ex-vivo dorsal 
horn slices. This effect is inhibited by treatment with a glial inhibitor (Clark et 
al., 2006). P2X7 receptor activation has been shown to cause inflammasome 
activation in primed cells, and, as discussed earlier, P2X7 receptor signalling 
plays a role in pain signalling (Chessell et al., 2005, Honore et al., 2009, Clark 
et al., 2010b). TLR4 signalling in microglia has been shown to play a role in the 
initiation of neuropathic pain-like behaviours in mice (Tanga et al., 2005), and, 
as discussed above, TLR signalling converges to activate transcription factor 
NFκB which, in some cellular contexts at least, upregulates pro-IL-1β and 
NLRP3 expression (Bauernfeind et al., 2009, Berger et al., 2011). Finally it has 
been shown that ROS production in animal models of neuropathic and 
inflammatory pain contribute to behavioural  hypersensitivity (van de Loo et al., 
2003, Gao et al., 2007, Ibi et al., 2008, Kim et al., 2010a, Berger et al., 2011). 
Pre-treatment with the antioxidant sulforaphane reduced pain-like behaviours, 
microglial activation, and expression of pro-inflammatory cytokines TNF-α and 




deficient in Nox2 were shown to have attenuated ROS activation following 
SNT injury compared to wildtype litter mates (Kim et al., 2010a).  
 
Thus the aim of the research presented in this thesis was to investigate a 
possible role for the NLRP3 inflammasome, upstream of IL-1β maturation and 





Chapter 1: Inflammasome Expression in Microglia and Macrophages, and 
its Dysregulation Following Peripheral Nerve Injury 
 
 
1.    Introduction 
 
Neuropathic pain, a debilitating condition, arises as a consequence of neural 
injury with symptoms such as spontaneous pain, hyperalgesia, and allodynia 
commonly reported. The underlying mechanisms involved in the generation of 
such pain syndromes are currently unclear. In several animal models of 
neuropathic pain it has been shown that there is accumulation and proliferation 
of microglial cells in the injured spinal cord and macrophages within injured 
nerve and dorsal root ganglion (DRG), contributing to the development of pain-
like behaviours (Hu and McLachlan, 2002, Tsuda et al., 2005, McMahon and 
Malcangio, 2009, Calvo et al., 2012). In studies in which microglial activation 
was prevented, for instance with minocycline, the development of pain-like 
behaviours in response to nerve injury was also prevented, demonstrating the 
importance of microglial contribution in generating pain states (Raghavendra et 
al., 2003, Ledeboer et al., 2005, Sun et al., 2012b). Microglia are the resident 
immune cells of the CNS, and share many properties with the phagocytic 
macrophage. Under normal physiological conditions microglia are thought to 
act to stabilise the CNS by surveying the local environment for stimuli and 
changes which might indicate a threat to the physiological homeostasis of the 
system such as trauma, ischaemia, and infection. Insult to the CNS causes 
microglia to undergo a series of phenotypic changes including changes in 
gene expression, cell proliferation, migration to the site of injury or threat, and 
secretion of pro-inflammatory molecules such as TNFα, NO, IL-18 and IL-1β 
(Ransohoff and Perry, 2009). The precise role of macrophages in the DRG 
following peripheral nerve injury is not fully understood, though it is likely that 
they release inflammatory mediators such as Cathepsin S, TNF-α, and IL-1β, 
which sensitise sensory neurons (Sommer and Kress, 2004, Ozaktay et al., 
2006, Barclay et al., 2007). Depletion of macrophages has been found to 




2000a), demonstrating the importance of macrophage contribution in 
generating pain states.  
 
The pro-inflammatory cytokine IL-1β plays a key role in acute and chronic 
inflammation. It has been shown to cause mechanical and thermal 
hyperalgesia when injected into peripheral tissues, and increased expression 
of IL-1β in the spinal cord, DRG, and injured nerve is seen in several animal 
models of neuropathic pain (Ren and Torres, 2009). IL-1β is synthesised as an 
inactive pre-cursor, pro-IL-1β, that must be enzymatically cleaved by active 
caspase-1 to generate mature active IL-1β. The inflammasome is a multi-
protein complex which acts as a regulating platform for the eventual cleavage 
and secretion of mature IL-1β via activation of caspase-1. Caspase-1 also 
cleaves pro-IL-18, to generate the mature cytokine IL-18 (Fantuzzi et al., 
1999). IL-18 has also, more recently, been shown to potentially play a role in 
animal models of pain (Miyoshi et al., 2008). The inflammasome complex 
consists of a central scaffold protein for which it is named (eg NLRP1, NLRP3, 
NLRC4), an adaptor protein, ASC, and pro-caspase-1. Inflammasome 
complexes assemble in response to a variety of exogenous and endogenous 
danger signals (eg MSU crystals, ATP, flagellin) (Schroder and Tschopp, 
2010). Of the inflammasome complexes described to date, the NLRP3 
inflammasome appears to have the most restricted tissue distribution pattern, 
found mainly in immune cells (Kummer et al., 2007). The NLRP3 protein 
consists of three domains; a leucine rich region (LRR), the putative agonist-
binding region, the NACHT domain, and a PYRIN domain. Upon activation the 
inflammasome assembles by oligomerisation of the scaffold at the NACHT 
domain. The adaptor protein ASC, which contains a PYRIN and CARD 
domain, is recruited to the complex via PYRIN-PRYIN domain protein 
interactions. In turn, inactive pro-caspase-1 is recruited to the complex via 
CARD-CARD protein interactions with the adaptor protein ASC. Autolysis of 
pro-caspase-1 to the p10/p20 active caspase-1 tetramer is then able to occur 
due to the clustering induced by recruitment to the complex. Active caspase-1 
processes pro-IL-1β and pro-IL-18 to generate the active cytokines which are 





 The inflammasome, part of the innate immune system, is best studied in the 
field of immunology. The NLRP3 inflammasome is expressed in murine 
macrophages, and these cell types are commonly employed to study 
inflammasome responses. It is only more recently that a potential role for the 
inflammasome in CNS pathologies, such as Alzheimer’s disease, Parkinson’s 
disease, and Multiple Sclerosis, has gained attention (Halle et al., 2008, 
Chakraborty et al., 2010). This study set out to determine if the NLRP3 
inflammasome, known to be expressed in macrophages, is also expressed in 
microglia. This study also sought to determine if the inflammasome is activated 
following L5 spinal nerve transection injury, a commonly used animal model of 
neuropathic pain in which microglia and macrophages are thought to 





2.    Methods 
 
2.1.   Primary microglia culture 
Primary microglial cultures were prepared using post-natal day (P)3-5 Wistar 
pups, killed by decapitation. The brains were removed and the meninges 
dissected away. The tissue was minced and digested with EDTA Trypsin 
(Invitrogen) for 30 minutes at 37°C, 5% CO2. Trypsination was stopped with 
addition of Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 
15% foetal bovine serum (FBS), 1% penicillin/streptomycin, and 100µl 
DNAase1 (Sigma, 150U/10ml). The tissue was thoroughly mixed. The tissue 
clumps were allowed to settle and the supernatant removed and filtered 
through a 80µm mesh. This process was repeated a further two times. The 
collected supernatant was then centrifuged at 2250 g for 5 minutes. The 
resulting supernatant was discarded and the cells re-suspended in DMEM + 
15% FBS, and plated in 75ml2, seeded at 4-5 million cells per flask.  
 
Cultures were maintained at 37°C, 5% CO2. Media was changed every 2-3 
days. After 5 days in vitro the flasks were confluent with astrocytes and 
microglia. Flasks were shaken by hand for 5 minutes in order to detach the 
microglia (formed in a monolayer above the astrocytes), and the media 
removed and centrifuged at 2250 gfor 5 minutes. The supernatant was 
discarded and the cells re-suspended, ready for experimental use. 
 
For Western blotting experiments, cells were plated in 6 well plates at a density 
of 1x106 cells per well. 15-20 minutes after plating the medium was changed to 
discard any non-adherent cells. Cells were then incubated overnight to allow 
them to become more “resting”. In the morning the media was removed, the 
cells washed in HBSS in order to ensure all traces of FBS were removed, and 
then incubated in serum-free media for 3 hours before stimulation protocols 
were carried out to ensure microglia were in a resting state before 
experimentation. For immunocytochemistry and ELISA experiments cells were 
plated in 24 well plates at a density of 5x104 cells per well, on sterile glass 




 2.2.   Peritoneal macrophage culture 
Adult female Wistar rats were killed with increasing CO2 concentrations. 
Immediately after they were injected intraperitoneally with 40ml of ice-cold 
sterile Hank’s Balanced Salt Solution (HBSS), and the area gently massaged. 
The elicited peritoneal exudate cells were harvested and re-suspended in 
DMEM supplemented with 15% FBS, 1% penicillin/streptomycin. Media was 
changed every 2-3 days. 
 
As for the microglia, cells used for Western blot experiments were plated at a 
density of 1x106 cells per well in a 6 well plate and incubated at 37°C, 5% CO2. 
Media was changed 15-20 minutes after plating to discard any non-adherent 
cells. Thereafter media was changed every 2-3 days. Cells were used for 
LPS/ATP stimulation experiments one week later, when the cells had taken on 
a completely resting morphology (ramified processes, not "bright" and round in 
appearance as at time of culture). On the day of experimental use, media was 
removed and the cells were washed in HBSS in order to ensure all traces of 
FBS were removed, and then incubated in serum-free media for 3 hours 
before stimulation protocols were carried out to ensure cells were in a resting 
state before experimentation. For immunocytochemistry experiments cells 
were plated in 24 well plates at a density of 5x104 cells per well, on sterile 
glass coverslips. Media were changed 15-20 minutes later to discard any non-
adherent cells. Media were thereafter changed every 2-3 days. Cells were 
typically ready for experimentation 3-4 days after culture. On the day of use 
the same protocol as above was used.  
 
2.3.   Immunocytochemistry 
Microglial and macrophage cells were plated at a density of 50,000 cells per 
well on a 24-well plate. Cells were fixed for 10 min with 100% ice-cold 
methanol, followed by 30 min with 4% ice-cold paraformaldehyde (PFA). 
Plates were stored at 4°C until required. Wells were washed 3 times with PBS. 
Antibody block was not performed. Primary antibodies were applied for 3 




then applied for 1.5 hours, followed by washing with PBS as above.  Microglia 
were labelled with biotin-conjugated isolectin B4 (IB4) (1:50, Sigma), and 
visualised with Extravidin FITC (1:200, Sigma). Macrophages were labelled 
with rabbit anti-IBA1 (1:1000, WAKO), and visualised with Alexa Fluor 488 
(1:1000, Stratech). As a negative control, antibody specificity was confirmed by 
the omission of primary antibody (data not shown). Coverslips were mounted 
onto glass slides using Vectashield mounting medium with DAPI (Vectorlabs) 
and visualised using a Zeiss Axioplan 2 fluorescent microscope. Culture purity 
of 5 separate cultures was assessed by taking 10x images of 3 random fields 
per slide. The number of IB4 / IBA1 positive cells was divided by the number of 
DAPI stained nuclei and multiplied by 100 to give a percent purity. 
 
2.4.   Western blot 
Cell stimulation: Harvested microglial cells, and primary macrophage cells 
were plated at a density of 1x106 cells per well in a 6 well plate and allowed 
time to "rest". Media were replaced with serum-free media for 3 hours before 
stimulation with LPS (1 μg/ml) or vehicle for 4 hours, followed by ATP (5mM) 
or vehicle for 15 minutes. Each experiment was carried out 3 times, using 3 
separate cultures. 
Media: Media were collected and stored at -80°C. Proteins were precipitated 
using trichloroacetic acid (TCA). Briefly samples were incubated with 1:5 TCA 
stock at 4°C for 10 minutes and then centrifuged at 100,000 g 4°C for 5 
minutes. Carefully supernatant was removed and remaining cell pellets were 
washed with acetone twice before being dried for 5-10 minutes at 95°C. Pellets 
were re-suspended first in 10 μl 0.2M NaOH, in order to aid re-suspension of 
the pellet, and then in 30 μl lysis buffer.   
Cells: Cells were lysed in 80 μl lysate buffer (20mM Tris, pH8, 137mM NaCl, 
1%NO-40, 1mM sodium orthovanadate, and protease inhibitor mixture (Pierce, 
containing 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride, aprotinin, 
bestatin, E-64, leupeptin, pepstatin, and EDTA)). Cells were scraped, and the 
lysates removed. Lysates were centrifuged at 100,000 g at 4°C for 15 minutes, 




Collected animal tissue: Tissues were homogenised in lysis buffer (as 
above), and rotated gently at 4°C for two hours. Samples were then 
centrifuged at 100,000 g for 15 minutes. The supernatant was stored at -80°C, 
while the pellet was discarded. Numbers of animals used differed between 
experiments. Refer to individual study results for this information. 
 
Protein concentration of all samples was determined using a BCA Protein 
Assay kit (Thermo Scientific). Cell and tissue lysates were normalised to 35 μg 
protein per sample. Although media sample protein concentrations were 
determined, they were not normalised owing to the assumption that LPS/ATP 
stimulated cells would have released more protein into the extracellular media 
than control-treated cells. Normalisation would have diluted any observed 
effect of protein secretion. Proteins (35 μg cell lysate, or 40 μl resuspended 
media protein solution [see Media, above] per well) were separated using 
SDS-PAGE (15% gel to visualise ASC, caspase-1, 10% to visualise NLRP3) 
and transferred to PVDF membranes (Millipore) at 100 V for 60 minutes. For 
ASC and Caspase-1 blots, PVDF membranes of 0.2 μm pore size were utilised 
(Millipore). Membranes were blocked in 10% skimmed milk in PBS-T for 45 
minutes before overnight incubation with primary antibody at 4°C. The 
membranes were then washed for 5 minutes, 6 times in PBS-T before 
incubation with species appropriate HRP-conjugated secondary antibody 
(1:10,000, Amersham) for 1 hour at room temperature. Membranes were 
visualised using ECL-prime reagent for 5 min (GE Healthcare) for detection by 
autoradiography.  
 
Membranes were stripped with a 50°C pre-heated β-mecaptoethanol-
containing buffer (0.7% β-mecaptoethanol, 20% 10% SDS, 6% 1M Tris-HCl pH 
6.7), incubated for 30 min at 50°C. Cells were then washed thoroughly first in 
dH2O, then several times in PBS-T, as above. Membranes were blocked in 
10% skimmed milk in PBS-T for 45 minutes, before incubation with primary 
antibody for 1 hour. The membrane was washed in PBS-T, as above, before 
incubation with species appropriate HRP-conjugated secondary antibody for 1 





Antibodies used: Rabbit anti-caspase-1 (1:400, Abcam, antibody recognises 
p20 subunit of active caspase-1, and p45 subunit of pro-caspase-1), rabbit 
anti-ASC (1:1000, Alexis Biochemicals), NLRP3 (0.25 μg/ml, Adipogen), 
mouse β-actin (1:15,000, Sigma), donkey anti-rabbit horseradish peroxidase 
(HRP)-conjugated antibody (1:20,000, GE Healthcare), donkey anti-mouse 
horseradish peroxidase (HRP)-conjugated antibody (1:20,000, GE 
Healthcare).  
 
Blots were analysed by determining mean intensity of each band using a fixed 
box size for all. The background intensity for each blot was then subtracted 
from all values obtained. All quantifications were then normalised against β-
actin loading control. All blots were then compared to the mean band intensity 
for control-treated samples or naive animals. Analysis was carried out using 
Quantity One 1-D Analysis Software version 4.6.9 (Biorad). 
 
2.5.   IL-1β ELISA 
Harvested microglial cells were plated on sterile glass coverslips at a density of 
5x104 cells per well in 24-well plates, and left overnight. Cells were washed in 
HBSS, and then media was replaced with serum-free media for 3 hours before 
stimulation with LPS (1 µg/ml) or vehicle for 4 hours, then ATP (5 mM) or 
vehicle for 15 minutes. Media were collected for ELISA analysis using 
Quanktikine IL-1β ELISA kit (R&D Systems). Kit-supplied standards were run 
in triplicate, and test samples in duplicate following the manufacturer 
instructions. Each experimental condition was performed in triplicate (i.e. 3 
wells for control, 3 wells for LPS, etc.). The optical density data for each 
triplicate were averaged. The experiment was performed on 3 separate 
occasions using 3 separate microglial cultures. Averaged triplicate data from 
each experimental set were combined and meaned to give an overall result. All 
samples were tested using the same ELISA kit to eliminate inter-experiment 
variability. Samples were read at 450 nm with wavelength correction at 540 
nm. 
 




Adult male Wistar rats (Harlan, UK) were used in accordance with UK Home 
Office regulations (Animals Scientific Procedures Act 1986). Animals were 
anaesthetised using a mixture of medetomidine hydrochloride (0.25 mg/kg) 
and ketamine (60 mg/kg) administered through a single intraperitoneal 
injection. The left L5 spinal nerve was exposed by removing  the relevant 
vertebral process, ligated with 6-0 silk suture for later identification, and 
transected distal to the suture. The muscle layer was sutured, and the wound 
closed with a Vicryl 3-0 suture. In animals undergoing “sham” surgery, the L5 
spinal nerve was exposed in the same way, but was not transected. The 
muscle layer was sutured and the wound closed in the same way as the other 
animals. No post-surgical analgesia was given in order to avoid potential 
modulation of the nociceptive and immune systems of the animals. The 
general health of the animals was monitored daily after the surgery.  
 
Animals were sacrificed by terminal anaesthesia and transcardially perfused 
with either 4% paraformaldehyde plus 1.5% picric acid for histology, or saline 
alone for Western blot analysis at defined survival times. Tissue used for 
histology: Lumbar spinal cords were excised and post-fixed overnight, dorsal 
root ganglia (DRG) were post-fixed for 3-4 hours. Tissue was cryoprotected in 
20% sucrose in 0.1M Phosphate Buffer (PB) for 4-7 days before OCT 
embedding. Tissue used for Western blot analysis: Lumbar spinal cords were 
excised and quadrisected. The ipsilateral dorsal horns were used for Western 
blot analysis. Lumbar spinal cords and DRG were snap-frozen in liquid 
nitrogen and stored at -80°C.  
 
2.7.   Behavioural testing 
Animals were tested in a temperature stable room during the light period of 
their day/night cycle, at the same time every day. Animals were placed in a 
polymethyl methacrylate box with a wire grid bottom and allowed to habituate 
for a period of 15-30 minutes before testing. Animals were trained once for 






Assessment of mechanical withdrawal thresholds: Mechanical withdrawal 
thresholds were assessed using calibrated von Frey hairs (Ugo Basile) 
according to the “up-down” method (Chaplan et al., 1994). Briefly, nylon 
filaments were applied to the plantar surface of the hindpaw until they just bent 
and were held in position for 5 seconds. A positive response was defined as 
rapid withdrawal of the paw not associated with other behaviours such as 
locomotion or grooming. In the event of a positive response, the next lower 
hair was applied until a change in response was observed. Conversely in the 
event of a negative response, the next higher hair was applied until a change 
in response was observed. Four subsequent hairs were then assessed using 
this up/down sequence. The 50% withdrawal threshold was then calculated 
using the method described by Dixon (Dixon, 1980).  
 
Cold testing: For measurement of cold hypersensitivity, a drop of acetone 
was applied to the plantar surface of the rat hindpaw. Evaporation of the 
acetone exerts a cooling effect to which naïve animals do not normally 
respond. However nerve injured animals respond by licking and shaking the 
paw. The time spent behaving in this manner was measured in the 2 minutes 
following acetone application. 3 tests were carried out, at least 10 minutes 
apart from each other, and an average response was recorded.  
 
2.8.   Histology 
Lumbar spinal cords were cryostat cut in 20 μm sections and thaw-mounted 
onto glass slides. When slides were fully dry (at least 1 hour after tissue 
mounting), they were stored in cryoprotectant (30% ethylene glycol, 30% 
glycerol, 40% PBS) at -20°C until required.  
 
Tyramide Signal Amplification: Slides were washed for 5 minutes, 6 times, in 
PBS to ensure all OCT and cryoprotectant was washed away from the 
sections. Sections were incubated for 30 minutes with 10% normal goat serum 
in PBS, 0.2% Triton X, 0.1% Azide, and 1% H2O2, to quench any peroxidases, 
followed by overnight incubation with primary antibody. The signal was then 




Elmer). Briefly, slides were incubated with species appropriate biotinylated 
antibody (1:400, Vectorlabs) for 1.5 hours. Slides were then washed for 5 
minutes, 3 times, in PBS. ABC solution (Vectorlabs ABC kit), made 30 minutes 
in advance, was applied to the sections for 30 minutes. Slides were then 
washed as before.  Biotinyl tyramide solution (1:50, TSA Biotin System, Perkin 
Elmer), was then applied for 10 minutes. Slides were washed as before. Finally 
sections were incubated with ExtrAvidin FITC (1:200, Sigma) for 2-3 hours. 
Slides were washed as before. Slides were then either mounted on coverslips, 
or subjected to a conventional staining protocol for co-staining purposes.  
 
Conventional immunohistochemistry: Slides were washed, as above. Sections 
were incubated for 30 minutes with 10% normal donkey serum in PBS, 0.2% 
Triton X, 0.1% Azide, followed by overnight incubation with primary antibody. 
The slides were washed, as before, and incubated in species appropriate 
secondary fluorescent antibody for 2-3 hours. Slides were washed and 
mounted on coverslips using Vectashield mounting medium with DAPI 
(Vectorlabs) and visualised using a Zeiss Axioplan 2 fluorescent microscope. 
Specificity of staining was determined by omission of the appropriate primary 
antibody as a negative control.  
 
Primary antibodies: The primary antibodies ASC and caspase-1 were 
visualised using tyramide amplification. Rabbit anti-ASC (1:2000, Alexis 
Biochemicals), rabbit anti-caspase-1 (1:500, Abcam), mouse anti-NeuN (1:100, 
Chemicon), rabbit anti-GFAP (1:1000, DAKO), rabbit anti-IBA1 (1:1000, 
WAKO). Secondary antibodies: anti-mouse or anti-rabbit Alexa Fluor 488 
(1:1000, Stratech), anti-mouse or anti-rabbit Alexa Fluor 546 (1:1000, 
Stratech), ExtrAvidin FITC (1:200, Sigma). 
 
Quantification:  
Cell counts / colocalisation: 3 100 μm2 boxes were drawn over the superficial 
L5 dorsal horn, ipsilateral and contralateral to the injury. Cells which were 
associated with a nuclear stain, within the confines of the box, were counted. 




taken. At least 3 sections per animal were analysed. All analysis was carried 
out blind to treatment. 
 
2.9.   qPCR 
This body of work was kindly carried out in collaboration with Dr. Ana Antunes-
Martins. 
RNA extraction: DRG and ipsilateral lumbar dorsal horn tissue samples were 
flash frozen in liquid nitrogen immediately after dissection. Total RNA was 
extracted using the miRNeasy mini kit (Qiagen), according to manufacturer’s 
instructions, including optional treatment with RNase-free DNase (Qiagen). 
RNA quantity and purity were measured with a NanoDrop spectrophotometer 
2000  (Thermo Scientific Inc.) and integrity was assessed using Agilent RNA 
6000 Pico chips (Agilent) on an  Agilent 2100 Expert Bioanalyzer.  
Quantitative real-time PCR: Total RNA was reverse transcribed into double 
stranded cDNA using random primers (Promega) and Superscript III Reverse 
Transcriptase (Invitrogen). cDNA QPCR  amplification was performed using 
the LC FS DNA MasterPLUS SG (Roche), with final primer concentrations of 1 
μM. Amplifications were performed in a Rotor Gene 6000 (Corbett Research)  
instrument, with the following  conditions: 10 min at 95°C and 40 cycles of 10 
sec at 95°C, 10 sec at 60°C, 20 sec at 72°C. Relative Quantification to the 
housekeeping gene GAPDH was performed by the Rotor Gene 6000 software 
(v1.7)  using the DeltaDelta Ct method. Primer pairs used were: 
   
Gene Direction Sequence (5’ > 3’) Efficiency 
Caspase-1 Forward CCGACAAGGTCCTGAGGGCAA 1.17 
(R2=0.99242) Reverse TCGCACAGGTCTCGTGCCTT 
NLRP3 Forward ACCCCAAGCCCTACTGTTCT 1.05 
(R2=0.99190) Reverse TCAGGTCACCAAGAGGGAAC 
 
2.10.   Statistical analysis 
All data are represented as mean ± SEM where appropriate. ELISA, Western 
blot, and histology data were analysed using one-way ANOVA followed by 




measures ANOVA followed by Dunnett’s post-test. Where data were not 
normally distributed, ANOVA tests were performed on ranked data. All analysis 






3.   Results 
 
3.1.   Primary cultures are >90% pure 
Primary rat microglial cultures were found to be, on average, 95.29±0.79% 
pure when assessed in five separate experiments. Primary rat peritoneal 
macrophage cultures were found to be, on average, 94.44±2.14% pure when 
assessed in three separate experiments. The number of IB4-(microglia) or 
IBA1-positive (macrophages) and negative cells were counted to assess the 
purity of the cultures. 3 random field images were taken of cells from at least 3 
mounted coverslips. Morphologically, microglia had long, thin processes with 
small cell bodies, indicating a “resting” phenotype. Macrophages similarly had 
small cell bodies, with some branching processes, though less than those 


































Figure 1.1: Primary cultured microglia and primary cultured peritoneal 
macrophages 
a: Representative image of rat primary cultured microglia. IB4 represented in the 
green channel, DAPI represented in the blue channel. Scale 50 μm. b: 
Representative image of rat primary cultured peritoneal macrophages. IBA1 
represented in the green channel, DAPI represented in the blue channel. Scale 50 
μm. c: Graph shows the average purity of 5 different microglial cultures. Data 
represented as mean ± SEM. d: Graph shows the average purity of 3 different 





3.2.   Microglia express the NLRP3 inflammasome  
Components of the NLRP3 inflammasome are known to be highly expressed 
in macrophages, and more recently have been shown to be present in 
microglia (Halle et al., 2008). Cultured rat peritoneal macrophages and 
postnatal microglia were used to confirm expression of NLRP3 inflammasome 
components and sensitivity of IL-1β release to caspase-1 inhibition in these 
cells. Consistent with previous reports (Qu et al., 2007) the component 
proteins of the NLRP3 inflammasome NLRP3, ASC, and caspase-1 were 
found to be expressed in rat peritoneal macrophages (Figure 1.2 a-c). Cells 
were primed with LPS (1 μg/ml) for 4 hours before being stimulated with ATP 
(5mM), a well-characterised activator of the NLRP3 inflammasome, for 15 
minutes. This protocol was chosen in line with that published by other groups 
using LPS/ATP stimulation of macrophages to study inflammasome activation 
(Sanz and Di Virgilio, 2000, Mariathasan et al., 2004, Qu et al., 2007). 
Immunoblot of cell lysates showed a significant increase in NLRP3 protein 
(7.62-fold ± 2.19, p<0.05 compared to unstimulated control), which was almost 
undetectable in unstimulated cells. NLRP3 protein was not detected in 
extracellular media from either control or stimulated cells. Immunoblot of 
extracellular media taken from stimulated cells showed significantly increased 
levels of ASC and the 20kDa active form of caspase-1 compared to 
unstimulated cells (9.12-fold ± 4.44, p<0.05, and 2.12-fold ± 0.22, p<0.01 
respectively).  
 
NLRP3 inflammasome components were also found to be present in postnatal 
cultured microglia (Figure 1.2 d-f). Similar to the data shown in macrophages, 
ATP stimulation of LPS-primed microglia led to a significant increase in NLRP3 
protein in cell lysates compared to unstimulated control cells (2.53-fold ± 0.48, 
p<0.05), and a small but significant decrease in ASC protein (0.70-fold ± 0.11, 
p<0.05), likely reflecting ejection of the protein with active caspase-1 and IL-
1β. Immunoblot of extracellular media showed a significant increase in ASC 
and the 20kDa active form of caspse-1 protein compared to that of 
unstimulated control cells (4.3-fold ± 0.92, p<0.01, 2.80 ± 0.65, p<0.05 
respectively). ATP stimulation of LPS-primed microglia resulted in IL-1β 




inflammasome activation pathway (Figure 1.2 g). To determine if this effect 
was caspase-1 dependent cells were pre-treated with 1- and 10 μM Ac-YVAD-
CMK, a cell-permeant peptide inhibitor of caspase-1, for 2 hours prior to ATP 
stimulation. YVAD dose-dependently decreased the amount of IL-1β released 
from stimulated cells (1007.12 ± 42.02 pg/ml, p<0.05, and 630.18 ± 54.81 


































Figure 1.2: The NLRP3 inflammasome is expressed, and can be activated, in 
primary peritoneal macrophages and primary microglia 
Western blot analysis shows primary peritoneal macrophages express inflammasome 
components NLRP3, ASC, and active caspase-1 p20 subunit under control, non-
stimulated conditions. ATP stimulation of LPS-primed cells alters expression of 
inflammasome components in cell lysates and extracellular media, quantified in c and 
d respectively. Representative blots shown in a. Primary microglia also express 
inflammasome components NLRP3, ASC, and active caspase-1 p20 subunit under 
control, non-stimulated conditions; representative blots shown in b. ATP stimulation of 
LPS-primed cells alters expression of inflammasome components in cell lysates and 
extracellular media, quantified in e and f respectively. g: ATP stimulation of LPS-
primed microglial cells leads to an increase in IL-1β released into the extracellular 
media, an effect dose-dependently reduced by caspase-1 inhibitor Ac-YVAD-CMK. 
Data represented as mean ± SEM. n=3-6 samples per group (a – f). Students t test, 
where *, ** p<0.05, 0.01 respectively when compared to unstimulated control cells. IL-
β ELISA (g): n=3 experiments. From each experiment 3 samples per condition were 
analysed, and averaged to give overall data for each experiment. Data represented as 
mean of the 3 experiments ± SEM. One-way ANOVA followed by Tukey’s post-test, 






3.3.   L5 spinal nerve transection causes behavioural hypersensitivity, 
spinal microgliosis, and macrophage infiltration of the DRG 
Baseline mechanical and cold responses in adult male rats were assessed 
prior to any surgery. Following L5 spinal nerve transection (SNT) injury the 
change in behavioural sensitivities were assessed intermittently over a two 
week period, to ensure that the animals developed neuropathic pain-like 
behaviours. L5 SNT caused a significant decrease in hindpaw 50% withdrawal 
threshold to von Frey hairs, observed from the first time-point assessed; 3 
days. This mechanical hypersensitivity lasted for the duration of the study, 14 
days, and was only observed in the hindpaw ipsilateral to the injury, whereas 
contralateral thresholds were unaffected (Figure 1.3 a). Prior to L5 SNT injury, 
rats showed little to no response to the application of acetone to the plantar 
surface of the hindpaw. From as early as 3 days post-surgery the response to 
acetone applied to the ipsilateral hindpaw (licking, biting, and flicking) was 
significantly elevated. The response was strongest at 6 – 8 days post-surgery, 
and reduced again 10 days post-surgery (Figure 1.3 b). 
 
Following L5 SNT injury a robust microgliosis was observed, visualised using 
IBA1, a marker for microglia and macrophages, immunohistochemistry. The 
number of IBA1-positive cells in the ipsilateral dorsal horn was significantly 
increased as early as 3 days post-surgery (4.90-fold increase ± 0.95 compared 
to contralateral dorsal horn), was similarly elevated 7 days post-surgery (4.72-
fold increase ± 0.95, compared to contralateral dorsal horn), and was still 
significantly increased 21 days post-surgery (3.05-fold ± 0.32, compared to 
contralateral dorsal horn), though numbers had begun to decrease from earlier 
timepoints. IBA1-positive cells were significantly increased when compared to 
both the contralateral dorsal horn, and also compared to the ipsilateral dorsal 
horn of 7-day sham animals. Interestingly, the number of IBA1-positive cells in 
the ipsilateral dorsal horn of sham animals was significantly greater than the 
number of IBA1-positive cells in the contralateral dorsal horn of the same 
animals (1.96-fold increase ± 0.45), though still significantly less than numbers 
seen in L5 SNT animals at all timepoints examined (Figure 1.4 a and b). In 
addition to the increased number of microglia, it was noted that the 




hypertrophied, and there were fewer processes extending from the cell body. 
The number of macrophages in the injured DRG was also examined following 
L5 SNT injury. The number of IBA1-positive cells was significantly higher than 
that in the contralateral L5 DRG, and in the L5 ipsilateral DRG of 7-day sham-
injured animals from 3 days post-surgery (1.11-fold increase ± 0.35, and 1.13-
fold increase ± 0.36, respectively. This number increased further 7- and 21 
days post-surgery (respectively, 1.56-fold increase ± 0.18 compared to 
contralateral, and 1.91-fold increase ± 0.65 compared to contralateral). As with 
microglia in the spinal cord, the cell bodies of the macrophages in the injured 
DRG appeared hypertrophied when compared to the contralateral DRG. Cells 
appeared to form in a circular shape, surrounding large circular profiles 
presumed to be neurons which would be consistent with previous reports (Hu 






Figure 1.3: L5 spinal nerve transection causes lasting behavioural 
hypersensitivity  
a: L5 SNT caused a significant decrease in hindpaw 50% withdrawal threshold to von 
Frey hairs, observed from the first time-point assessed, lasting up to two weeks. 
Contralateral hindpaw mechanical withdrawal thresholds were unaffected. b: Prior to 
injury, rats showed little to no response to the application of acetone to the plantar 
surface of the hindpaw. Following L5 SNT, duration of responses to acetone, licking, 
biting, and flicking of the hindpaw, were significantly elevated. Responses reduced 
and plateaued from 10 days post-surgery. Data represented as mean ± SEM, n=7 
animals. Two-way repeated measured ANOVA, followed by Dunnett’s post-test, 
where *, #, p<0.05 compared to baseline responses, same-day contralateral 
responses (a). One-way repeated measures ANOVA, followed by Dunnett’s post-test, 






Figure 1.4: L5 spinal nerve transection causes spinal microgliosis and 
macrophage infiltration of the injured DRG 
a: Lumbar spinal cord of an animal 7 days post-surgery, immunostained for microglia 
using IBA1 antibody. Scale 50 μm. b: The number of cells in the ipsilateral superficial 
dorsal horn significantly increased from 3 days post-surgery, remaining elevated 21 
days post-surgery. n=3-5 animals per timepoint, with at least 3 spinal cord sections 
analysed per animal. Analysis was carried out blind to timepoint. Two-way ANOVA 
with Dunnett’s post-test, where *,*** p<0.05, 0.001 respectively compared to same 
day contralateral superficial dorsal horn, where ## p<0.01 compared to 7-day sham 
ipsilateral dorsal horn. c and d: L5 contralateral and ipsilateral DRG respectively of an 
animal 7 days post-surgery, immunostained for macrophages using IBA1 antibody. 
Scale 20 μm. e: The number of cells in the ipsilateral L5 DRG significantly increased 
from 3 days post-surgery, remaining elevated 21 days post-surgery. n=3 animals per 
timepoint, with ≥3 DRG sections analysed per animal. Analysis was carried out blind 
to timepoint. Data represented as mean ± SEM. Two-way ANOVA on ranks (data 
were not normally distributed) with Dunnett’s post-test, where *, ***, p<0.05, 0.001 
respectively compared to 7-day sham ipsilateral L5 DRG, where ##, ###, p<0.01, 
0.001 respectively compared to same day contralateral L5 DRG, where † p<0.05 




3.4.   The NLRP3 inflammasome is dysregulated after L5 SNT 
Quantitative PCR and Western blot techniques were employed to determine if 
the expression of inflammasome components is altered in the ipsilateral 
lumbar dorsal horn and injured DRG following L5 SNT. At the mRNA level, 
NLRP3 expression increased significantly 7 days post-surgery in the ipsilateral 
lumbar dorsal horn compared to both naïve animals, and sham animals 7 days 
post-surgery (3.04-fold ± 0.41, p<0.001, and 2.89-fold ±0.39, p<0.001 
respectively), whereas expression of caspase-1 mRNA was significantly 
increased 3 days post-surgery in the ipsilateral lumbar dorsal horn (3.11-fold ± 
0.45, p<0.001, and 1.74-fold ± 0.25, p<0.05, compared to naïve and sham 
animals respectively) (Figure 1.5). Changes in expression of ASC mRNA were 
not tested owing to a lack of specificity of primers for this transcript. At the 
protein level, expression of ASC was significantly increased 7 days post-injury 
(1.61-fold ± 0.14, p<0.05 compared to naïve control) in the ipsilateral lumbar 
dorsal horn. Expression of the 20kDa subunit of active caspase-1 was also 
significantly increased 7 days post-injury (2.96-fold ± 0.59, p<005 compared to 
naïve control) in the ipsilateral lumbar dorsal horn (Figure 1.6).  
 
In the injured DRG, expression of NLRP3 mRNA was found to be significantly 
upregulated 3, 7, and 21 days post-surgery compared to naïve animals (4.99-
fold ± 1.20, 6.25-fold ± 1.21, 4.48-fold ± 0.57, respectively, p<0.05), while 
expression of caspase-1 mRNA was significantly upregulated 7 days post-
surgery (4.49-fold ± 0.95 compared to naïve animals, 3.24-fold ± 0.68 
compared to sham animals, p<0.05) (Figure 1.7). At the protein level, 
expression of the adaptor protein ASC within the L5 DRG significantly 
increased 7 and 21 days following nerve injury (4.06-fold ± 0.19, p<0.01, and 
3.66-fold ± 0.84, p<0.05 compared to naive control, respectively). A significant 
increase in the expression of the 20kDa active form of caspase-1 in the L5 
DRG was also observed 7 days post-injury (7.35-fold ± 1.92, p<0.05 compared 




























Figure 1.5: NLRP3 inflammasome components NLRP3 and caspase-1 mRNA is 
dysregulated in the ipsilateral lumbar dorsal horn after L5 SNT 
Ipsilateral lumbar dorsal horn expression of NLRP3 (a) and caspase-1 (b) mRNA 
increases significantly following L5 SNT, as assessed by quantitative real-time PCR. 
One-way ANOVA with Dunnett’s post-test, where ***,# p<0.001, 0.05 compared to 
naïve animals and sham animals respectively. n=4-8 animals per timepoint (1 






















Figure 1.6: NLRP3 inflammasome components ASC and caspase-1 protein 
expression is dysregulated in the ipsilateral lumbar dorsal horn after L5 SNT 
Ipsilateral lumbar dorsal horn expression of ASC (a) and caspase-1 (c) protein 
increases significantly following L5 SNT, quantified in b and d. One-way ANOVA with 
Dunnett’s post-test (ASC), and one-way ANOVA on ranks with Dunn’s post-test 
(caspase-1), where * p<0.05 compared to naïve animals. n=3-4 animals per timepoint 


















Figure 1.7: NLRP3 inflammasome components NLRP3 and caspase-1 mRNA is 
dysregulated in the ipsilateral L5 DRG after L5 SNT 
Ipsilateral lumbar L5 DRG expression of NLRP3 (a) and caspase-1 (b) mRNA 
increases significantly following L5 SNT, as assessed by quantitative real-time PCR. 
One-way ANOVA on ranks (NLRP3) with Dunn’s post-test, where *, # p<0.05 
compared to naïve animals and sham animals respectively. One-way ANOVA 
(caspase-1) with Dunnett’s post-test, where *, # p<0.05 compared to naïve animals 























Figure 1.8: NLRP3 inflammasome components ASC and caspase-1 protein 
expression is dysregulated in the ipsilateral L5 DRG after L5 SNT 
Ipsilateral L5 DRG expression of ASC (a) and caspase-1 (c) protein increases 
significantly following L5 SNT, quantified in b and d. One-way ANOVA with Dunnett’s 
post-test  where *,** p<0.05, 0.01 compared to naïve animals. n=3-4 animals per 






3.5.   Dysregulation of inflammasome components occurs within 
microglia and macrophages 
Immunohistochemical analysis revealed expression of ASC within the lumbar 
spinal cord. ASC positive cells were found to have a ramified morphology, 
typical of microglia. To further investigate the origin of ASC expression, lumbar 
spinal cord sections were co-stained with either IBA1 (to identify microglia), 
GFAP (to identify astrocytes) or NeuN (to label neurons). Little to no co-
localisation was observed with either GFAP or NeuN (<1%), whereas 
extensive co-localisation was observed with IBA1 (>97% ASC-positive cells 
expressing IBA1 at all timepoints examined (Figure 1.9). As discussed above, 
peripheral nerve injury leads to a marked increase in number and altered 
morphology (hypertrophy of the cell body and retraction of processes) of 
microglia in rodents; a process termed “microgliosis”. Following L5 SNT there 
was a marked increase in ASC immunoreactive profiles in superficial laminae 
of the ipsilateral dorsal horn, with a similar timecourse to that seen for IBA1-
positive cells (see Figure 1.4). These ASC immunoreactive cells had the 
characteristic morphology of “effector” microglia. Increased numbers of ASC 
immunoreactive microglia were also observed around the soma of motor 
neurons within the ventral horn of the spinal cord. 
 
Within the injured L5 DRG, ASC-positive cells were also found to co-localise 
extensively with IBA1 (<98% ASC-positive cells expressing IBA1 at all 
timepoints examined). As with IBA1 immunoreactive profiles, ASC-positive 
cells in the injured DRG took on a hypertrophied appearance compared to 
those seen in the contralateral DRG (Figure 1.10 a and b). Following L5 SNT 
there was a marked increase in ASC-positive cells, with a similar timecourse to 
that seen for IBA1-positive cells (Figure 1.10 c).  
 
Finally, Immunostaining of the lumbar spinal cord for caspase-1 revealed an 
increase in caspase- positive cells in the superficial laminae of the dorsal horn 
following nerve injury. Similar to ASC, extensive co-localisation was observed 
with IBA1 in the superficial laminae (>85% caspase-1-positive cells expressing 
IBA1 at all timepoints examined), with little to no co-localisation with GFAP or 




occasional neurons were weakly caspase-1 immunoreactive (Figure 1.11 a, 
and also refer to Appendix figure a.5). Similar to data obtained from IBA1 and 
ASC immunostaining, the number of caspase-1 immunoreactive profiles in the 
ipsilateral superficial lumbar dorsal horn increased significantly 3, 7, and 21 
days-post surgery compared to both 7-day sham animals and the contralateral 
dorsal horn (see Figure 1.11 c).  
 
These co-localisation studies suggest that the increased expression of the 
NLRP3 inflammasome components following L5 SNT is likely to be due to 
increased numbers of macrophages within the injured DRG and microglia 
































Figure 1.9: Inflammasome adaptor ASC is highly expressed in microglia in the 
spinal cord 
a: Immunohistochemical analysis reveals expression of ASC within the lumbar spinal 
cord. ASC positive cells were found to have a ramified morphology (inset), typical of 
microglia. b and c: Co-staining of lumbar spinal cord sections with IBA1 reveals a 
strong co-localisation, indicating this protein is expressed in microglia. ASC 
represented in the green channel, IBA1 represented in the red channel. Confocal 
microscopy reveals little to no co-localisation of ASC (green channel) with NeuN (red 
channel), d, or GFAP (red channel), e, but extensive co-localisation with IBA1 (red 
channel), f. Scale 20 μm. g: ASC shows >95% co-localisation with IBA1 at all 
timepoints examined. h: The number of ASC-positive cells within the ipsilateral lumbar 
dorsal horn significantly increases from 3 days post-surgery, in a manner similar to 
that observed for IBA1-positive cells (see Figure 1.4). n=3-5 animals per timepoint, 
with ≥3 spinal cord sections analysed per animal. Two-way ANOVA with Dunnett’s 
post-test, where *, ** p<0.05, 0.01 respectively compared to same day contralateral 
superficial dorsal horn, where ## p<0.01 compared to 7 day sham ipsilateral 
























Figure 1.10: Inflammasome adaptor protein ASC is highly expressed in 
macrophages in the DRG 
a: Immunohistochemical analysis reveals expression of ASC within the contralateral 
L5 DRG. Confocal microscopy reveals extensive co-localisation with IBA1. b: ASC is 
also extensively co-localised with IBA1 in the injured ipsilateral L5 DRG. Cells appear 
in a circular shape, surrounding circular profiles presumed to be neurons. ASC is 
represented in the green channel, and IBA1 is represented in the red channel. Scale 
20 μm. c: ASC shows >95% co-localisation with IBA1 at all timepoints examined. d: 
The number of ASC-positive cells in the ipsilateral injured L5 DRG significantly 
increases from 3 days post-surgery, in a manner similar to that observed for IBA1-
positive cells (see Figure 1.5). n=3-5 animals per timepoint, with ≥3 DRG sections 
analysed per animal. Two-way ANOVA with Dunnett’s post-test, where *** p<0.001 
compared to same day contralateral L5 DRG, where ### p<0.001 compared to 7 day 
sham ipsilateral L5 DRG, where † p<0.05 compared to 7 day sham contralateral L5 





























Figure 1.11: Caspase-1 is highly expressed in microglia in the spinal cord 
a: Immunohistochemical analysis reveals expression of caspase-1 within the lumbar 
spinal cord. b and c: Co-staining of lumbar spinal cord sections with IBA1 reveals a 
strong co-localisation, indicating this protein is expressed in microglia. Scale 100 μm. 
Confocal microscopy in the superficial dorsal horn reveals little to no co-localisation 
with NeuN, d, or GFAP, e, but extensive co-localisation with IBA1, f. Scale 20 μm. g: 
Caspase-1 shows high co-localisation with IBA1 at all timepoints examined. h: The 
number of Caspase-1-positive cells significantly increases from 3 days post-surgery, 
in a manner similar to that observed for IBA1-positive cells (see Figure 1.5). Data 
represented as mean ± SEM, n=3-5 animals per timepoint, with ≥3 spinal cord 
sections analysed per animal. Two-way ANOVA with Dunnett’s post-test, where *** 
p<0.001 compared to same day contralateral superficial dorsal horn, where # p<0.05 
compared to 7 day sham ipsilateral superficial dorsal horn. Caspase-1 antibody 




4.   Discussion 
 
Several studies have previously shown a role for IL-1β in pain states. For 
example injection of IL-1β into a variety of tissues elicits a potent hyperalgesic 
response while in various models of inflammatory and neuropathic pain IL-1β 
expression has been shown to increase in the injured nerve, DRG, and spinal 
cord (Ren and Torres, 2009). Release of IL-1β is a complex, multi-step 
process, requiring first assembly of the inflammasome in order to effect 
activation of caspase-1, the enzyme responsible for the cleavage of pro-IL-1β 
into the mature, secreted, cytokine. Uncontrolled and abnormal inflammasome 
activation, leading to aberrant release of IL-1β has been demonstrated in 
autoinflammatory diseases such as the CAPS syndromes in which there is a 
mutation in the cryopyrin gene. Symptoms of these disorders include rash, 
fever/chills, and joint and muscle pain (Petrilli and Martinon, 2007). Following 
peripheral nerve injury in rodents there is a robust microgliosis in the spinal 
cord, as well as infiltration of the DRG by macrophages, a key feature of which 
is the release of pro-inflammatory cytokines including TNF-α and IL-1β 
(McMahon and Malcangio, 2009, Calvo et al., 2012).  Thus we explored 
whether the inflammasome, responsible for regulating the cleavage and 
release of inflammatory cytokines IL-1β and IL-18, which in turn act to increase 
the transcription of other pro-inflammatory cytokines, plays a role in 
neuropathic pain.  
 
There are few publications in which the inflammasome has been investigated 
in microglia. In 2008, Halle and colleagues carried out work looking at the 
response of primary microglia to Amyloid β (Aβ) (Halle et al., 2008). It was 
shown that microglia release IL-1β in response to incubation with Aβ, resulting 
in frustrated phagocytosis and Cathepsin B release from ruptured lysosomes, 
a protease that has been implicated in NLRP3 inflammasome activation 
(Hornung et al., 2008). However, the publication did not directly show the 
presence of inflammasome components in this cell type. More recently work 
has been published which shows a reduction in S. aureus-induced  IL-1β, 
though interestingly not IL-18, release from primary microglia cultured from 




that microglia do express the NLRP3 inflammasome (Hanamsagar et al., 
2011). Early work by Kingham and colleagues had showed caspase-1 
activation in microglia activated with chromogranin A. Interestingly the 
apoptotic effects mediated by caspase-1 activation were found to not directly 
involve the production of IL-1β (Kingham et al., 1999, Kingham and Pocock, 
2000). 
 
Data presented here show that the NLRP3 inflammasome component proteins 
NLRP3, ASC, and caspase-1 are all expressed in primary cultured peritoneal 
macrophages, in line with previous reports, and also in primary cultured 
microglia, as determined by Western blot analysis. Cells were either primed 
with LPS for 4 hours, followed by a brief 15 minute stimulation with high 
concentration ATP, or treated with vehicle and so essentially unstimulated. This 
experimental paradigm was chosen in line with that published by other groups 
using LPS/ATP stimulation of macrophages to study inflammasome activation 
(Sanz and Di Virgilio, 2000, Mariathasan et al., 2004, Qu et al., 2007). It is 
known that inflammasome expression must be induced in vitro, and LPS 
stimulation is known to license NLRP3 upregulation via NF-κB activation 
(Bauernfeind et al., 2009). There are several known activators of the NLRP3 
inflammasome, as discussed in the General Introduction. The choice of ATP as 
an activator in these experiments was in line with previously published reports 
investigating inflammasome activation in macrophages which were used as a 
positive control in these experiments. Additionally it is thought that ATP 
released from damaged neurons contributes to microglial activation and 
subsequent development of behavioural hypersensitivity in animal models of 
peripheral nerve injury (Tsuda et al., 2003, Coull et al., 2005, Clark et al., 
2010b, Beggs et al., 2012, Trang et al., 2012). 
 
The overall pattern of inflammasome protein expression and release following 
stimulation was very similar in microglial cells to that seen in macrophages. In 
control, unstimulated, cells there was little to no expression of NLRP3. 
Expression of this protein was rapidly upregulated following LPS/ATP 
stimulation, however. It is widely reported that NLRP3 expression in 




al., 2003, Bauernfeind et al., 2009, Franchi et al., 2009), and this data is also 
consistent with the report that circulating macrophages from naïve animals 
have only a modest level of NLRP3 expression (Guarda et al., 2011).  This 
study shows that NLRP3 expression is similarly inducible in microglia, with little 
to no constitutive expression. The adaptor protein ASC was present in the cell 
lysates of unstimulated macrophages and microglia. Following cell stimulation, 
the amount of ASC detected in cell lysates decreased with a concomitant 
increase detected in the extracellular media. This is in agreement with 
published reports showing that, along with mature IL-1β and active caspase-1, 
ASC is quickly ejected from the cell following stimulation both in vitro and ex 
vivo (Mariathasan et al., 2004, Clark et al., 2006, Qu et al., 2007). That there 
was some ASC protein detected in the extracellular media of unstimulated cells 
was unexpected. This may reflect some constitutive release of the protein from 
cells, possibly as a regulatory mechanism aimed at controlling the amount of 
IL-1β activation or release. Alternatively this may reflect the fact that, by 
necessity for the purposes of gaining enough protein for detection, cells were 
densely plated. This may have resulted in a low level of activation. However, 
active caspase-1 was not detected in the extracellular media, arguing against 
this possibility.  
 
There was a small amount of active caspase-1 present in the lysates of 
unstimulated cells. This was significantly increased following LPS/ATP 
stimulation. At the same time, active caspase-1 was detected in the 
extracellular media of stimulated cells, whilst it was undetectable in the 
extracellular media of control, unstimulated, cells. ATP stimulation of LPS-
primed microglia resulted in IL-1β release into the extracellular media, an 
endpoint in the inflammasome activation pathway. Pre-treatment with the cell-
permeant inhibitor of the enzymatic activity of caspase-1, Ac-YVAD-CMK, 
dose-dependently decreased the amount of IL-1β released from stimulated 
cells. IL-1β release was not completely abolished. This may either be due to 
an insufficient concentration of inhibitor used, or alternatively may indicate that 
other, caspase-1-independent, pathways leading to IL-1β release may be 
present in these cells. It was previously known that brief stimulation of LPS-




2000, Clark et al., 2006, Calvo et al., 2010). This data indicates that this 
release is, at least in part, mediated by the activation of the NLRP3 
inflammasome and activation of caspase-1.  
 
It should be noted that while the release of ASC, caspase-1, and IL-1β is 
postulated to have come about as a result of inflammasome activation, the 
possibility that the presence of these proteins in the extracellular media 
occurred as a result of cell death cannot be excluded. Following cell 
stimulation, media were collected and immediately frozen. Any cells which had 
detached from the well’s surface, which may occur following cell death, would 
have remained in the media and ruptured upon freezing. This represents a flaw 
in the protocol. If the experiments were to be repeated in the future, the media 
should be centrifuged, and any debris discarded. This would remove the 
potential confounds of proteins released from ruptured cells, and increase 
certainty in the subsequent findings. 
 
L5 SNT is a commonly used animal model of neuropathic pain, which results in 
robust behavioural hypersensitivity as well as a robust microgliosis of the 
lumbar spinal cord and increased numbers of macrophage within the DRG. In 
this study, L5 SNT resulted in long-lasting mechanical hypersensitivity in rats 
as well as a hypersensitivity to cold stimulus, though this was not as long-
lasting. L5 SNT resulted in a microgliosis of the lumbar spinal cord, in a 
timecourse similar to that reported previously (Scholz et al., 2008), as well as 
increased numbers of macrophages within the DRG similar to published 
reports (Hu and McLachlan, 2002). It is not possible to tell from these 
experiments if these numbers represent migration of cells, proliferation, or 
both.  
 
Having established that the inflammasome is expressed in both macrophages 
and microglia in vitro, we next sought to determine if inflammasome expression 
was altered in an animal model of neuropathic pain, given the importance of 
macrophages and microglia in the development of pain-like behaviours in such 
models. Using a combination of qPCR and Western blot analysis it was 




all dysregulated in both the spinal cord and DRG following L5 SNT in rats. All 
proteins showed a similar pattern of dysregulation, with increases beginning 3 
days after injury, generally maximal after 7 days, but remaining elevated to 
some extent 21 days after injury. This data is confirmed in independent 
experiments carried out by Dr. Ana Antunes-Martins, using next generation 
genome sequencing techniques, which revealed a significant increase in 
NLRP3, Pycard (ASC), and caspase-1 cDNA in rat ipsilateral lumbar dorsal 
horns and L5 DRG 7 days after L5 SNT injury (see Appendix).  
 
Further investigation using immunohistochemical analysis revealed that ASC-
positive cells in the lumbar spinal cord had a ramified morphology, typical of 
that of microglia. Co-staining with IBA1 revealed that ASC was almost 
exclusively expressed by microglia in the spinal cord in both sham-operated 
animals as well as SNT-injured animals at all timepoints examined. ASC was 
not seen to be present in either astrocytes or neurons. This is in disagreement 
with a previous report stating that ASC was found to be present in astrocytes, 
oligodendrocytes, and neurons, as well as in microglia in the spinal cord (de 
Rivero Vaccari et al., 2008). The reason for this discrepancy is unclear; 
although the group did use a different antibody. The antibody used in this study 
is specific to ASC since ASC-positive staining disappears in tissues obtained 
from ASC-/- mice (see Chapter 3). Additionally it was reported that following 
spinal cord injury ASC was upregulated in motor neurons in the ventral horn of 
the spinal cord. This was not observed in this study; though the location and 
severity of injury differed between studies and differences in the changes in 
expression profiles of different cell types would be expected.  
 
In the present study ASC immunofluorescence appeared to be present 
throughout the cells, including in the smaller branched processes of cells in a 
more quiescent state, usually observed contralateral to the injury. This differs 
from reports of cellular distribution of ASC in vitro where activation of the 
inflammasome or pyroptosome results in ASC immunostaining taking on a 
speck-like appearance, from which it gains its name (Masumoto et al., 1999, 
Yu et al., 2006, Fernandes-Alnemri et al., 2007, Halle et al., 2008). Potentially 




following L5 SNT. Alternatively it could indicate that the protein behaves 
differently in artificial in vitro conditions. Indeed it has been suggested that the 
formation of these characteristic specks occurs as a result of forced 
overexpression of ASC in these cell systems (Bryan et al., 2009). 
Immunostaining for ASC was also carried out in the DRG. As in the spinal cord, 
there was extensive colocalisation with IBA1 (>95% at all time points 
examined), indicating it was present almost exclusively in macrophages in this 
tissue. 
 
Immunostaining for caspase-1 in the lumbar spinal cord also showed extensive 
co-localisation with microglia. However the staining differed from that of ASC in 
that caspase-1 staining was less extensively localised within the microglial 
processes. Additionally co-localisation was not as extensive as that of ASC. It 
is not possible to determine the state of activation of caspase-1 in microglia in 
this experiment as the antibody used detects both the p45 subunit of pro-
caspase-1 and the p20 subunit of the cleaved active caspase-1. In this study, 
caspase-1 staining appeared to be localised to the nucleus, and rarely 
visualised in microglial processes. This raises the possibility that the staining 
observed was non-specific and instead an artefact of overexposure. However 
examination of confocal microscopy images of caspase-1 and DAPI co-
localisation suggest this is not the case (refer to Appendix, figure a.5). 
 
That caspase-1 co-localised with microglial marker IBA1 in this study is in 
agreement with the observations of Kawasaki et al. who reported some, but 
not complete, co-localisation with microglial marker IBA1 in the lumbar dorsal 
horn of SNL-injured rats (Kawasaki et al., 2008a). However the group also 
reported no injury-induced change in the level of caspase-1 protein levels in 
the dorsal horn of SNL-injured rats at either 1- or 10- days post-injury, which is 
in disagreement with data presented here. A significant increase in active 
caspase-1 protein levels in the ipsilateral lumbar dorsal horn was observed 
only 7 days post-surgery in this study. Potentially this increase is transient, and 
protein levels may be reduced again to non-significant levels by 10 days post-
surgery. The group also reported no change in caspase-1 protein expression in 




significant change in active caspase-1 protein level in the injured DRG was not 
detected until 7 days after injury. Thus it is possible that the group did not 
detect a change owing to the early time point investigated.  
 
Data presented here show that, at least in the L5 SNT model of neuropathic 
pain, the inflammasome is dysregulated after peripheral nerve injury. Several 
lines of evidence indicate that this dysregulation occurs in macrophages within 
the DRG, and microglia in the spinal cord. Firstly the temporal pattern of 
dysregulation of both mRNA message and protein expression is similar to that 
of the macrophage infiltration observed in the DRG and microgliosis observed 
in the spinal cord in this study, and others. Data presented here show that the 
inflammasome components NLRP3, ASC, and caspase-1 are all expressed in 
vitro in primary macrophages and microglia. This was previously shown for 
macrophages (Sanz and Di Virgilio, 2000, Mariathasan et al., 2004, Qu et al., 
2007), and the presence of caspase-1 in microglia had been previously 
reported (Kingham et al., 1999, Kingham and Pocock, 2000).Finally ASC and 
caspase-1 immunopositive cells were found to co-localise extensively with 
microglial marker IBA1 within the spinal cord. The increase in inflammasome 
message and protein expression may reflect the infiltration of macrophages 
and microglia in the DRG and spinal cord respectively. However, given that 
stimulation of macrophages and microglia in vitro led to an increase in 
inflammasome component expression either in the cell lysates or within the cell 
media, it is also possible that within the macrophages and microglia 
themselves, likely in an “effector” state, there is also some increase in 
inflammasome expression contributing to the observed increases.  
 
Having established that L5 SNT leads to increases in inflammasome 
components, it will be of interest to determine if this contributes to the 
behavioural hypersensitivity associated with L5 SNT injury. Further 
experiments will focus on the effect of inhibition of the inflammasome at 
different levels of the pathway on both peripheral nerve injury-induced 
behavioural hypersensitivity as well as the associated microglial changes in 





Chapter 2: Inhibition of Caspase-1 Activity Attenuates Behavioural 




1.   Introduction 
 
In the previous chapter, it was shown that L5 SNT injury in rats causes 
dysregulation of the NLRP3 inflammasome, with ASC found to be expressed in 
both macrophages and microglia in the DRG and lumbar spinal cord 
respectively, and caspase-1 expressed in microglia in the spinal cord. 
However, it was unclear as to whether this change merely reflected a change 
in cell numbers, given that both macrophage and microglia cell numbers were 
shown to increase in the injured DRG and ipsilateral lumbar dorsal horn, or if 
inflammasome protein expression within these cells was concomitantly 
increased. Subsequent work aims to disrupt inflammasome signalling in order 
to investigate whether or not inflammasome assembly and activation plays a 
functional role in animal models of persistent pain, and associated microgliosis. 
 
Cleavage of pro-IL-1β into the mature cytokine is the endpoint of the 
inflammasome pathway. IL-1β is known to contribute to the generation of pain 
states in various animal models of pain, and injection of IL-1β into various 
tissues generates behavioural hypersensitivity in rodents (Ren and Torres, 
2009). In this chapter the focus is on the inhibition of caspase-1, upstream of 
IL-1β activation. Caspase-1, originally called interleukin converting enzyme, or 
ICE, was first described following attempts to purify the enzyme responsible for 
the cleavage of pro-IL-1β (Thornberry et al., 1992). Pro-capsase-1 is recruited 
to the inflammasome complex via an N-terminal CARD domain (Lamkanfi and 
Dixit, 2009). Pro-caspase-1 is an autolytic enzyme meaning that it is able to 
enzymatically cleave, and subsequently activate, other pro-caspase-1 
molecules when in close proximity following recruitment to the inflammasome 
complex. Cleavage of the larger 45kDa pro-caspase-1 molecule results in 




consists of two p10 and two 20 subunits (Boatright et al., 2003, Boatright and 
Salvesen, 2003, Martinon and Tschopp, 2004). 
 
Experiments presented in this chapter aimed to disrupt inflammasome 
signalling in order to investigate whether or not inflammasome assembly and 
activation plays a functional role in animal models of persistent pain, and 
associated microgliosis. Ac-YVAD-CMK is a cell-permeable irreversible 
peptide inhibitor of caspase-1 activity (Rabuffetti et al., 2000), and was used to 
determine if caspase-1 inhibition results in an alteration of behavioural 
hypersensitivity following L5 SNT, as an animal model of neuropathic pain, and 






2.   Methods 
 
2.1.   Animals and surgery 
Adult male Wistar rats (Harlan, UK) were used in accordance with UK Home 
Office regulations (Animals Scientific Procedures Act 1986).  
L5 SNT: Animals received L5 SNT injury using the same method as described 
in Chapter 1.   
Drugs and delivery: Ac-YVAD-CMK (Calbiochem) was administered as 20 
nmol dissolved in 20 μl 10% DMSO in sterile saline. Under isoflurane 
anaesthesia a 29G insulin syringe (Myjector U-100 Terumo) was inserted 
between the L5 and L6 vertebrae, where the spinal cord consists mainly of 
spinal roots. A volume of 20 μl was injected, after which the needle was slowly 
removed. The accuracy of each injection was ensured through the observation 
of an injection-induced tail-flick (Mestre et al., 1994). Ac-YVAD-CMK or vehicle 
were administered intrathecally immediately before L5 SNT surgery, and 
thereafter daily in the first study. In the second study Ac-YVAD-CMK or vehicle 
was administered 5, 6, 7, and 8 days after surgery. 
LPS-induced mechanical hypersensitivity: Under isoflurane anaesthesia 
rats were intrathecally injected into the rat lumbar region, between the L5 and 
L6 vertebrae using a 29 G 13mm needle, with LPS (2 μg dissolved in 10 μl of 
0.9% sterile saline) twice; the first dose, to prime the immune system, the 
second was administered 24 hours later, concomitant with either vehicle (10% 
DMSO in 0.9% sterile saline), or 20 nmol Ac-YVAD-CMK (Calbiochem). 
Mechanical withdrawal thresholds were assessed 30 minutes, 1 hour, and 3 
hours after the second injection of LPS. Animals were then sacrificed, and 
tissue collected.  
 
As described in Chapter 1, animals were either sacrificed by terminal 
anaesthetisation and transcardially perfused with either 4% paraformaldehyde 
plus 1.5% picric acid for histology, or saline alone for Western blot analysis. 
Tissue used for histology: Lumbar spinal cords were excised and post-fixed 
overnight, dorsal root ganglia (DRG) were post-fixed for 3-4 hours. Tissue was 
cryoprotected in 20% sucrose in 0.1M Phosphate Buffer (PB) for 4-7 days 




cords were excised and quadrisected. Lumbar spinal cords and DRG were 
snap-frozen in liquid nitrogen and stored at -80°C.  
 
2.2.   Behavioural testing 
Animals were tested in a temperature stable room during the light period of 
their day/night cycle, at the same time every day. Animals were placed in a 
polymethyl methacrylate box with a wire grid bottom and allowed to habituate 
for a period of 15-30 minutes before testing. Animals were trained once for 
each behavioural test, and then two baseline tests were performed on different 
days.  
Mechanical testing: Mechanical withdrawal thresholds were assessed using 
calibrated von Frey hairs (Ugo Basile) according to the “up-down” method 
(Chaplan et al., 1994), as described in Chapter 1. The 50% withdrawal 
threshold was then calculated using the method described by Dixon (Dixon, 
1980). 
Cold testing: For measurement of cold hypersensitivity, a drop of acetone 
was applied to the plantar surface of the rat hindpaw, as described in Chapter 
1. 3 tests were carried out, at least 10 minutes apart from each other, and an 
average response was recorded.  
All behavioural testing was carried out blind to treatment. 
 
2.3.    Western blot 
Tissues were homogenised in the same way as described in Chapter 1. 
Protein concentration of all samples was determined using a BCA Protein 
Assay kit (Thermo Scientific). Lysates were normalised to 3 5μg protein per 
sample. Proteins (35 μg lysate per well) were separated using SDS-PAGE 
(15% gel to visualise IL-1β) and transferred to 0.2 μm pore size PVDF 
membranes (Millipore). Membranes were blocked in 10% skimmed milk in 
PBS-T for 45 minutes before overnight incubation with primary antibody at 4°C 
as already described in Chapter 1. Species appropriate HRP-conjugated 
secondary antibody (1:10,000, Amersham) was applied the subsequent day for 
1 hour at room temperature. Membranes were visualised using ECL-prime 




visualisation of protein loading control, the membranes were stripped using a 
β-mecaptoethanol buffer  as described in Chapter 1, before incubation with 
primary antibody.  
 
Antibodies used: Rabbit anti-IL-1β (1:800, Millipore), mouse anti-β-actin 
(1:15,000, Sigma), donkey anti-rabbit horseradish peroxidase (HRP)-
conjugated antibody (1:20,000, GE Healthcare), donkey anti-mouse 
horseradish peroxidase (HRP)-conjugated antibody (1:20,000, GE 
Healthcare).  
 
Blots were analysed by determining mean intensity of each band using a fixed 
box size for all. The background intensity for each blot was then subtracted 
from all values obtained. All quantifications were then normalised against β-
actin loading control. All blots were then compared to the mean band intensity 
for control-treated samples or naive animals. Analysis was carried out using 
Quantity One 1-D Analysis Software version 4.6.9 (Biorad). 
 
2.4.   Histology 
Lumbar spinal cords were cryostat cut in 20 μm sections and thaw-mounted 
onto glass slides. When slides were fully dry (at least 1 hour after tissue 
mounting), they were stored in cryoprotectant (30% ethylene glycol, 30% 
glycerol, 40% PBS) at -20°C until required.  
 
Immunohistochemistry was carried out according to the methods described in 
Chapter 1. Primary antibodies used: Rabbit anti-GFAP (1:1000, DAKO), rabbit 
anti-IBA1 (1:1000, WAKO), rabbit anti-p-p38 (1.100, Cell Signalling). Tyramide 
signal amplification was used to visualise p-p38 (refer to Chapter 1 Methods, 
Section 2.8). Secondary antibodies: anti-mouse or anti-rabbit Alexa Fluor 488 
(1:1000, Stratech), anti-mouse or anti-rabbit Alexa Fluor 546 (1:1000, 
Stratech), ExtrAvidin FITC (1:200, Sigma). Specificity of staining was 
determined by omission of the appropriate primary antibody as a negative 




medium with DAPI (Vectorlabs) and visualised using a Zeiss Axioplan 2 
fluorescent microscope.  
 
Quantification:  
Cell counts / colocalisation: 3 100 μm2 boxes were drawn over the 
superficial L5 dorsal horn, ipsilateral and contralateral to the injury. Cells which 
were associated with a nuclear stain, within the confines of the box, were 
counted. Counting was performed manually. An average count from the 3 
boxes was taken. At least 3 sections per animal were analysed.  
GFAP intensity: All GFAP images had been taken on the same day, using the 
same exposure. As for the cell counts, 3 100 μm2 boxes were drawn over the 
superficial L5 dorsal horn, ipsilateral and contralateral to the injury. A 20 μm2 
box was drawn in the white matter, and was used to generate a background 
intensity value. The intensity of the 3 boxes, minus the background intensity 
value, was averaged. At least 3 sections per animal were analysed. All 
analysis was carried out blind to treatment. Analysis was carried out using 
AxioVision LE version 4 software. 
 
2.5.   Statistical analysis 
All data are represented as mean ± SEM where appropriate. Western blot, and 
histology data were analysed using one-way ANOVA followed by Dunnett's 
post-test. Behavioural data were analysed using two-way repeated measures 
ANOVA followed by Dunnett’s post-test. Where data were not normally 
distributed, ANOVA tests were performed on ranked data. All analysis was 






3.   Results 
 
3.1.   Pre-treatment with a caspase-1 inhibitor attenuates L5 SNT-induced 
behavioural hypersensitivity 
To investigate the role of the inflammasome in SNT-induced pain-like 
behaviours, animals received intrathecal Ac-YVAD-CMK (20 nmol), a cell-
permeant irreversible peptide inhibitor of caspase-1, or vehicle (10% DMSO) 
immediately before L5 SNT surgery, and thereafter daily injections to the end 
of the study. It was felt that this technique was sufficient for drug delivery to the 
lumbar dorsal horn since it has been shown that volumes as low as 5 µl 
injected intrathecally reach the L3-L4 regions of the spinal cord (Xu et al., 
2006). Rats were assessed for mechanical hypersensitivity 3, 5, and 7 days 
post-surgery. On days 5 and 7, rats treated with the caspase-1 inhibitor 
showed a significant increase in 50% paw withdrawal threshold compared to 
vehicle-treated animals (p<0.05 on both days) (Figure 2.1 a). Cold 
hypersensitivity was assessed 2, 4, and 6 days post-surgery. On days 4 and 6 
drug-treated animals had significantly decreased duration of responses to 
acetone compared to vehicle-treated animals (p<0.05, and p<0.001 
respectively) (Figure 2.1 b).  
 
Western blot of the injured DRG revealed a significant decrease in expression 
of both the pro-and mature form of IL-1β in YVAD-treated animals compared to 
vehicle (0.66-fold ± 0.14, p<0.05 and 0.37-fold ± 0.13, p<0.05, respectively) 
(Figure 1.2). Thus it is concluded that administration of the inhibitor indeed led 
to a reduction of caspase-1 enzymatic activity. It was not possible to visualise 
bands for IL-1β in the ipsilateral lumbar dorsal horn of either vehicle- or Ac-
YVAD-CMK-treated animals. It is speculated that too little of the protein is 
present in these tissues, and that a dilution effect occurred owing to the size of 





















Figure 2.1: Caspase-1 inhibition attenuates L5 SNT-induced behavioural 
hypersensitivity 
Daily intrathecal administration of 20 nmol Caspase-1 inhibitor Ac-YVAD-CMK 
attenuated L5 SNT-induced mechanical (a) and cold (b) hypersensitivity compared to 
vehicle-treated animals. Data represented as mean ± SEM, n=11-12 animals per 
group. Two-way repeated measures ANOVA, followed by Dunnett’s post-test, where 
*,*** p<0.05, 0.001 respectively, compared to vehicle-treated control responses on the 



















Figure 2.2: Caspase-1 inhibition reduces expression of IL-1β 
a: Western blot of the injured L5 DRG in rats 7 days after L5 SNT injury, with daily 
intrathecal injections of either vehicle (10% DMSO) or 20 nmol Ac-YVAD-CMK, a cell-
permeant inhibitor of caspase-1, with quantification in b. Daily treatment with 20 nmol 
Ac-YVAD-CMK led to a reduction of both the immature pro-IL-1β, and the mature 
active IL-1β compared to vehicle-treated animals. Data represented as mean ± SEM, 
n=4 animals per group (1 whole L5 DRG from each animal). One-way ANOVA, 





3.2.   Caspase-1 inhibition does not affect SNT-induced spinal 
microgliosis 
Immunostaining for IBA1 in the lumbar dorsal horn revealed no change in 
microglia numbers between the two groups, indicating that caspase-1 activity 
is not required for the development of microgliosis in the spinal cord. p38 is a 
MAP kinase, and phosphorylation of p38 is observed in microglia as they 
adopt an effector state following peripheral nerve injury. Its activation has been 
shown to be associated with peripheral nerve injury-induced behavioural 
hypersensitivity, and its inhibition has been shown to prevent the development 
of these behaviours. Immunostaining for phosphorylated p38 (p-p38) showed 
that microglial activation, according to this measure, was not altered by 
intrathecal pre-treatment with Ac-YVAD-CMK (Figure 2.3). Thus the 
attenuation of behavioural hypersensitivity observed in animals in which 
caspase-1 activity was inhibited is likely due to an effect downstream of the 
signalling processes leading to microglial activation.  
 
Following peripheral nerve injury there are also changes in astrocytes within 
the spinal cord, including cellular hypertrophy and altered protein expression 
including an increase in GFAP. This occurs later than the development of 
microgliosis, generally reported to be significant 7 days after injury, and is 
much longer lasting. Immunostaining for the astrocyte marker GFAP revealed 
a significant decrease in the intensity of immunoreactivity in the ipsilateral 
superficial dorsal horn of animals treated with the caspase-1 inhibitor 
compared to vehicle treated animals (GFAP intensity of YVAD-treated rats 






























Figure 2.3: Caspase-1 inhibition does not alter L5 SNT-induced microgliosis: 
a and d: Immunostaining for microglial marker IBA1 reveals no change in the number 
of microglia in the superficial dorsal horn of animals treated with caspase-1 inhibitor 
Ac-YVAD-CMK compared with vehicle-treated control animals. Quantified in g. b and 
e: Immunostaining for p-p38 shows no change in the number of p-p38 positive cells in 
the superficial dorsal horn of animals treated with caspase-1 inhibitor. c and f: 
merged images showing extensive co-localisation of IBA1 with p-p38. Scale bar 100 
μm. h: Quantification showing the number of IBA1-positive cells expressing p-p38. No 
difference was observed between Ac-YVAD-CMK-treated animals, and vehicle-
treated control animals. Data represented as mean ± SEM, n=3 animals per group, 







Figure 2.4: Caspase-1 inhibition reduces spinal cord astrocytosis after L5 SNT 
Immunostaining for GFAP showed a significantly greater intensity of staining in the 
ipsilateral superficial dorsal horn in vehicle-treated animals than that observed in 
YVAD-treated animals. GFAP intensity was significantly greater in the superficial 
ipsilateral dorsal horn than the superficial contralateral dorsal horn of vehicle-treated 
animals. The intensity of GFAP was not significantly different in the ipsilateral and 
contralateral dorsal horns in YVAD-treated animals (e).  Representative images, a 
and c, with higher-power confocal images, b and d. Scale bars: 100 μm, a and c, 20 
μm, b and d. Data represented as mean ± SEM, n=3 animals per group, with ≥3 
spinal cord sections analysed per animal. Two-way ANOVA with Dunnett’s post-test, 
where ***, ### p<0.001 compared to vehicle-treated control animals, and compared to 




3.3.   Caspase-1 inhibition attenuates established hypersensitivity 
We next asked whether caspase-1 inhibition could reverse or attenuate 
established pain-like behaviours. Animals received either vehicle (10% DMSO) 
or 20nmol Ac-YVAD-CMK intrathecally on days 5 to 8 post-surgery inclusive. 
Mechanical hypersensitivity was significantly attenuated in drug-treated 
animals on days 6 and 8 post-surgery (p<0.05), and cold hypersensitivity was 
significantly reduced on day 6 post-surgery (p<0.05). This effect was abolished 
on days 10 and 13 following cessation of treatment (Figure 2.5). No difference 
was observed in microglial number, co-localisation with p-p38, or GFAP 
immunoreactivity intensity, likely due to the fact that this was assessed 14 days 













Figure 2.5: Caspase-1 inhibition attenuates established L5 SNT-induced 
behavioural hypersensitivity  
Intrathecal administration of 20 nmol Caspase-1 inhibitor Ac-YVAD-CMK on days 5 to 
8 post-surgery inclusive attenuated L5 SNT-induced mechanical (a) and cold (b) 
hypersensitivity compared to vehicle-treated animals. Shaded area on graphs indicate 
drug treatment. Data represented as mean ± SEM, n=6-7 animals per group. Two-
way repeated measures ANOVA, followed by Dunnett’s post-test, where * p<0.05 
compared to vehicle-treated control responses on the same day. All behaviour was 







Figure 2.6: No change in microgliosis or astrocytosis in the superficial dorsal 
horns of animals 6 days after cessation of Ac-YVAD-CMK treatment 
a: Immunostaining for microglial marker IBA1 reveals no change in the number of 
microglia in the superficial dorsal horn of animals treated with caspase-1 inhibitor Ac-
YVAD-CMK compared to vehicle-treated control animals. b: No difference was 
observed in the amount of p-p38 co-localisation with IBA1 in superficial dorsal horns 
of drug-treated and vehicle-treated animals. c: No difference in GFAP 
immunoreactivity intensity was observed in the superficial dorsal horn of drug-treated 
animals and vehicle-treated animals. Data represented as mean ± SEM, n=3 animals 









3.4. Caspase-1 inhibition prevents LPS-induced mechanical 
hypersensitivity 
Intrathecal administration of LPS leads to hyperalgesia in the hind-paw (Cahill 
et al., 2003, Clark et al., 2006, Clark et al., 2010a). Rats were given a priming 
dose of LPS (2 μg in 10 μl 0.9% sterile saline), followed by a second 
intrathecal injection of LPS and either vehicle (10% DMSO in 0.9% sterile 
saline) or 20 nmol Ac-YVAD-CMK 24 hours later. Mechanical hypersensitivity 
was assessed 30 minutes, 1 hour, and 3 hours later. Following the final 
behavioural test animals were sacrificed and tissue collected. Vehicle-treated 
animals showed a significantly reduced mechanical withdrawal threshold from 
baseline at all time-points tested, whereas YVAD-treated animals did not 
develop a mechanical hypersensitivity compared to baseline levels at any time-
point tested. Mechanical withdrawal thresholds were significantly greater in 
YVAD versus vehicle-treated animals at all time-points tested after LPS 
administration (Figure 2.7).  
 
Immunohistochemical analysis revealed that although the total number of 
microglia in the superficial lumbar dorsal horn of YVAD-treated animals was 
not statistically different, there was a trend toward a decrease in number 
(average 4.4 ± 0.4 cells/100 μm2 compared to 3.3 ± 0.3 cells/100 μm2 in 
vehicle- and YVAD-treated animals respectively, p=0.09). The  number of 
microglia expressing p-p38, indicating a state of activation, was significantly 
reduced in the superficial dorsal horns of animals treated with the caspase-1 
inhibitor (85.9% ± 3.0 compared to 67.8% ± 4.3 IBA1-positive cells expressing 
p-p38 in vehicle- and YVAD-treated animals respectively, p<0.05) (Figure 2.8). 
No difference was detected in the intensity of GFAP immunoreactivity between 







Figure 2.7: Caspase-1 inhibition prevents LPS-induced mechanical 
hypersensitivity 
Intrathecal LPS produces a mechanical hyperalgesia of the hind-paw. Animals 
received a priming injection of LPS (2 μg in 10 μl 0.9% sterile saline), before receiving 
a second dose 24 hours later with a concomitant injection of either vehicle (10% 
DMSO in 0.9% sterile saline) or 20 nmol Ac-YVAD-CMK. Mechanical hypersensitivity 
was assessed 30 minutes, 1 hour, and 3 hours after the second LPS administration. 
Data represented as mean ± SEM, n=8 animals per group. Two-way repeated 
measures ANOVA, followed by Dunnett’s post-test, where *, ** p<0.05, 0.01 
compared to vehicle-treated animals’ responses at the same time-point, where 
##,###, p<0.01, 0.001 compared to baseline responses of the same treatment group. 



























Figure 2.8: Caspase-1 inhibition reduces microglial activation following 
intrathecal LPS 
Representative confocal microscope images of the superficial lumbar dorsal horns of 
vehicle- (a) and YVAD- (b) treated animals, IBA1 staining in the red channel, and p-
p38 staining represented in the green channel. Yellow arrow indicates example cells 
which are double-labelled, whereas red arrows indicate example IBA1-positive cells 
which do not express p-p38. Scale: 20 μm. c: The number of microglia in the lumbar 
dorsal horn did not differ significantly between treatment groups, whereas the number 
of p-p38 positive cells was significantly reduced in animals treated with 20 nmol Ac-
YVAD-CMK. d: The number of microglia expressing p-p38 was significantly reduced 
in YVAD-treated animals. Data represented as mean ± SEM, n=4 animals per group, 
with ≥3 spinal cord sections analysed per animal. Two-tailed t test, where * p<0.05 






Figure 2.9: No change in GFAP immunoreactivity in the superficial dorsal horns 
of YVAD-treated animals following intrathecal LPS treatment 
Immunostaining for GFAP, a marker of astrocytic activation, reveals no change in the 
superficial lumbar dorsal horn of animals treated with caspase-1 inhibitor Ac-YVAD-
CMK compared to vehicle-treated control animals, following intrathecal LPS 
treatment. Data represented as mean ± SEM, n=4 animals per group, with ≥3 spinal 





4.   Discussion 
 
There are several published reports showing that IL-1β can elicit behavioural 
hypersensitivity (Falchi et al., 2001, Sung et al., 2004, Sung et al., 2005, Wolf 
et al., 2006, Gabay et al., 2011), as well as enhance  AMPA- and NMDA-
mediated currents and suppressing GABA-mediated currents (Kawasaki et al., 
2008b). Moreover blockade of IL-1β has been shown to attenuate pain-like 
behaviours in both inflammatory and neuropathic animal models of pain 
(Watkins et al., 1994, Sung et al., 2005, Gabay et al., 2011). Thus, in this 
study, the actions of IL-1β were targeted upstream by inhibiting caspase-1 
action with the cell-permeable peptide inhibitor Ac-YVAD-CMK.  
 
In the present study, intrathecal pre-treatment and daily administration of 
YVAD-CMK decreased L5 SNT-induced mechanical and cold hypersensitivity. 
This appears to have been mediated, at least in part, by a reduction in IL-1β as 
the amount of both inactive pre-cursor and active IL-1β was significantly 
reduced in the injured DRG of YVAD-treated animals. This data is in 
disagreement with Kawasaki and colleagues who reported that inhibition of 
caspase-1 with YVAD-CMK did not affect L5 SNT-induced IL-1β cleavage 
(Kawasaki et al., 2008a). However the group investigated the contribution of 
caspase-1 to SNT-induced changes at a much earlier timepoint than those 
investigated in this study. As reported in Chapter 1, increases in caspase-1 
mRNA and protein expressions observed both in the ipsilateral lumbar dorsal 
horn and injured DRG did not become statistically significant until 7 days post-
injury, and were decreasing again by 21 days post-injury; Kawasaki et al. 
reported no upregulation in the dorsal horn at 1 or 10 days post-injury. 
Additionally, YVAD was administered acutely with changes in IL-1β expression 
investigated only 1 day post-injury whereas in the current study IL-1β 
suppression was investigated 7 days after injury, with daily administration of 
YVAD. It is possible that the effect of the drug requires several treatments, 
which would explain the discrepancy between the two reports. This idea is 
enforced by the observation that differences in the behaviour between vehicle- 





IL-1β released by microglia can activate glial IL-1R receptors in a positive 
feedback loop leading to the further activation of glia (Watkins and Maier, 
1999). Thus, following daily treatment of L5 SNT-injured rats with either vehicle 
or YVAD, the number and activation state of spinal cord microglia was 
investigated. YVAD-treated animals did not show any difference in microglial 
number, or in the number of microglia expressing p-p38, a commonly used 
marker of microglial activation (Ji and Suter, 2007), suggesting that caspase-1 
activity is likely to be a consequence, rather than cause, of SNT-induced 
microgliosis. Following peripheral nerve injury there are also changes in 
astrocytes within the spinal cord, including cellular hypertrophy and altered 
protein expression including an increase in GFAP. This occurs later than the 
development of microgliosis, generally reported to be significant 7 days after 
injury, and is much longer lasting (Colburn et al., 1999, Tanga et al., 2004, 
Tanga et al., 2006, Romero-Sandoval et al., 2008). Immunostaining for the 
astrocyte marker GFAP revealed a significant decrease in the intensity of 
immunoreactivity in the ipsilateral superficial dorsal horn of animals treated 
with the caspase-1 inhibitor compared to vehicle treated animals, suggesting a 
decrease in astrocytic activation. IL-1β secreted from microglia is able to act 
on IL-1R expressed on neighbouring astrocytes, bringing about their activation 
(Watkins and Maier, 2003, Vallejo et al., 2010). In addition to IL-1β cleavage, 
caspase-1 is able to cleave pro-IL-18 to the mature cytokine. A recent study 
showed that, following L5 SNT injury in rats, expression of IL-18 was 
significantly upregulated in microglia in the ipsilateral lumbar dorsal horn, while 
IL-18R expression was upregulated in astrocytes. IL-18 blockade attenuated 
injury-induced mechanical hypersensitivity, whereas intrathecal administration 
of IL-18 in rats caused mechanical hypersensitivity and astrocytic activation. 
Thus it is possible that, in addition to reducing IL-1β activation of astrocytes, 
YVAD administration also reduced IL-18 activation of astrocytes. Unlike 
microglial activation following peripheral nerve injury, which is acute, astrocytic 
activation in animal models of pain occurs several days after the insult, and is 
much longer lasting (Romero-Sandoval et al., 2008). In the present study, 
although YVAD was administered daily after the injury, drug-treated animals 
did not show a difference in behavioural hypersensitivity until several days 




this study was mediated by the prevention of IL-1β and IL-18-induced 
activation of astrocytes; a process that occurs several days after injury. This 
idea is supported by the finding that intrathecal YVAD treatment was also able 
to attenuate established hypersensitivity from 5 days post-injury. Astrocytosis 
was not investigated in these animals until several days after cessation of 
treatment, and so no difference in GFAP immunoreactivity was detected 
between vehicle- and YVAD-treated animals. It is also possible that IL-1β and 
IL-18 act on dorsal horn neurons, which also have been shown to express 
these receptors to alter synaptic function, and YVAD treatment reduces this 
effect.  
 
In the present study L5 SNT-induced hypersensitivity was not completely 
prevented, or reversed, by YVAD treatment. This could be due to an 
insufficient dose, though the amount of both inactive pre-cursor and active IL-
1β was significantly reduced in the injured DRG of YVAD-treated animals. 
Instead it is more likely that the behavioural data indicates that there are other 
mechanisms of importance contributing to L5 SNT-induced behavioural 
hypersensitivity. Blockade of IL-1 signalling has been shown to reduce, and 
even reverse, behavioural hypersensitivity in several animal models of pain 
(Maier et al., 1993, Safieh-Garabedian et al., 1995, Watkins et al., 1997, Wolf 
et al., 2006, Gabay et al., 2011, Nadeau et al., 2011). Caspase-1 has been 
known for several years to cleave inactive pro-IL-1β to the mature cytokine, 
although there are reports that pro-IL-1β can also undergo caspase-1-
independent cleavage (Pinteaux et al., 2007, Kawasaki et al., 2008a). 
Following L5 SNT it has been shown that IL-1β cleavage can occur through 
the action of matrix metalloproteases (MMP) MMP-9 and MMP-2 during early 
and later phases of neuropathic pain respectively (Kawasaki et al., 2008a). 
Thus, although IL-1β cleavage was reduced by YVAD treatment, it is likely that 
other mechanisms of IL-1β cleavage persisted contributing to the generation 
and maintenance of behavioural hypersensitivity.  
 
Caspase-1 inhibition has been previously investigated in inflammatory models, 
including the carrageenan model (Cunha et al., 2000) and hindpaw injection of 




caspase-1 inhibition was peripheral. In the present study we investigated the 
effect of caspase-1 inhibition on LPS-induced inflammation. This particular 
model of inflammation was chosen because the LPS is applied directly to the 
spinal cord to produce a sterile central inflammation, isolated from any 
peripheral immune response. Additionally it relates closely to the in vitro 
experiments carried out in Chapter 1. A priming dose of LPS was administered 
24 hours before the second dose, after which behavioural testing was carried 
out. LPS produced bilateral hindpaw mechanical hypersensitivity within 30 
minutes of administration in vehicle-treated rats. 1 hour after administration the 
hindpaw mechanical withdrawal threshold was decreased further. Concomitant 
treatment of Ac-YVAD-CMK with the LPS prevented this reduction in hindpaw 
withdrawal threshold. Immunohistochemical analysis revealed that although 
the number of microglial cells in the superficial lumbar dorsal horn of animals 
treated with the caspase-1 inhibitor was not significantly altered, the number of 
microglial cells expressing p-p38 was significantly reduced in YVAD-treated 
animals indicating that YVAD treatment led to a reduced microglial activation in 
response to LPS. No difference was observed in the intensity of GFAP 
immunoreactivity, though astrocytic activation would not be expected at such 
an early timepoint following the inflammatory stimulus, and has not been 
previously reported.  
 
Data presented here suggest that caspase-1 plays a role in the generation and 
maintenance of behavioural hypersensitivity in the L5 SNT model of 
neuropathic pain and also the central inflammatory model of LPS-induced 
hypersensitivity. However it has been shown that the relative contribution of 
caspase-1 to the development and maintenance of neuropathic pain differs 
between animals models such that the non-specific caspase-1 inhibitor Z-
VADFMK was maximally effective in ddC- (HIV therapy) model, marginally 
effective in vincristine-induced hyperalgesia model, but was ineffective in STZ-
induced model of neuropathic pain (Joseph and Levine, 2004). Subsequent 
work will examine other proteins of the inflammasome, and their role in 





Chapter 3: The Role of the Inflammasome Adaptor Protein ASC in 
Persistent Pain States 
 
 
1.   Introduction 
 
Data presented thus far show that caspase-1 signalling contributes to 
mechanical and cold hypersensitivity in the L5 SNT model of neuropathic pain, 
and to a greater extent following intrathecal LPS administration as a model of 
central inflammation. Several studies have shown a requirement for ASC in 
pro-caspase-1 activation. ASC is a 22kDa protein, consisting of two homotypic 
protein interaction domains; an amino-terminal PYRIN domain and a carboxy-
terminal CARD domain. Several lines of evidence suggest that this protein is 
necessary for NLRP3 inflammasome mediated secretion of IL-1β. 
Immunodepletion of ASC in THP-1 cell extracts has been shown to block 
caspase-1 activation, and subsequent IL-1β maturation following LPS 
stimulation (Martinon et al., 2002). Additionally LPS-primed macrophages from 
ASC-/- mice fail to activate caspase-1, and subsequently release IL-1β and IL-
18. However TNF-α and IL-6, also pro-inflammatory cytokines, were released 
from cells normally. In vivo experiments show that mice deficient in ASC do not 
demonstrate elevated serum IL-1β and IL-18 following systemic LPS challenge 
(Mariathasan et al., 2004, Yamamoto et al., 2004).  
 
Given that caspase-1 inhibition reduced behavioural hypersensitivity in a 
model of neuropathic pain and inflammation, we next explored the effect of 










2.   Methods 
 
2.1.   Animals and surgery 
Adult (250 – 300g) male Wistar rats (Harlan, UK), adult (10 – 12 weeks) male 
C57Bl/6 mice (Harlan, UK), and adult (10 – 12 weeks) male and female ASC-/- 
and wildtype littermates (sourced from Genentech), bred on a C57Bl/6 
background, were used in accordance with UK Home Office regulations 
(Animals Scientific Procedures Act 1986).  
 
Genotyping: A tissue sample of mouse pups (postnatal days 10 – 14) was 
obtained by ear punch (Harvard Apparatus, UK), which was also used for 
identification purposes. The tissue incubated with 30 μl lysis buffer (consisting 
of 67 mM Tris (Sigma), 16 mM (NH4)2SO4 (Sigma), 6.7 mM MgCl2 (Sigma), 
0.2%w/v β-mercaptoethanol (Sigma), 0.4 mg/ml Proteinase K (VWR)) at 55°C 
for 1 hour, followed by 10 minutes at 95°C. Samples were briefly vortexed, 
then centrifuged, with the resultant supernatant containing the DNA used for 
PCR. Genotype was determined by a polymerase chain reaction (PCR). The 
master mix solution consisted of 1.5 mM MgCl2 (Promega), 20% v/v 5x 
Reaction Buffer (Promega) 0.2mM dNTP (Promega), 50 units/ml Taq DNA 
polymerase (Promega), 0.1 μM primers x 3 (Sigma), 0.5 μl DNA sample.  
Primer sequences:  
sm99-gASC (forward): CTA GTT TGC TGG GGA AAG AAC 
sm105-cASC (reverse): CTA  AGC ACA GTC ATT GTG AGC TCC 
sm141-NEOseq6 ASC (forward): AAG ACA ATA GCA GGC ATG CTG G  
Each reaction consisted of 0.5 μl DNA, and 24.5 μl master mix. The PCR 
reaction was performed in TC412 Flexigene thermal cycle (Techne, UK). The 
conditions for the PCR reaction were as follows: denaturation at 94°C for 4 
minutes, followed by 30 cycles of denaturation at 94°C for 1 minute, annealing 
at 62°C for 30 seconds, and polymerisation at 72°C for 1 minute. This was 
followed by a final extension step at 72°C for 10 minutes. The expected size of 
the products were 450bp for wildtype, 260bp for knockout, and 450 and 260bp 
for heterozygotes.  
Visualisation: To visualise the PCR products, gel electrophoresis of the 




ethidium bromide (Sigma) for visualisation. Gels were viewed using 
GeneGenius system (Syngene), and imaged using GeneSnap (Syngene).  
 
L5 SNT: Rats received L5 SNT injury using the same method as described in 
Chapter 1.   
Partial sciatic nerve ligation: Under isoflurane anaesthesia, the left sciatic 
nerve was exposed at mid-thigh level. A 5-0 silk suture was used to tightly 
ligate approximately a third to half of the nerve. The wound was closed using 
two wound clips. No post-surgical analgesia was given in order to avoid 
potential modulation of the nociceptive and immune system of the animals. 
The general health of the animals was monitored daily after the surgery. 
 
Drugs and delivery: CRID3 (CP-456,773) (Pfizer, Ltd., UK) was administered 
as 25 nmol dissolved in 20 μl 10% DMSO in sterile saline. Under isoflurane 
anaesthesia a 26G insulin syringe (Myjector U-100 Terumo) was inserted 
between the L5 and L6 vertebrae, where the spinal cord consists mainly of 
spinal roots. A volume of 20 μl was injected, after which the needle was slowly 
removed. The accuracy of each injection was ensured through the observation 
of an injection-induced tail-flick (Mestre et al., 1994). 
 
As described in Chapter 1, animals were either sacrificed by terminal 
anaesthetisia and transcardially perfused with either 4% paraformaldehyde 
plus 1.5% picric acid for histology, or saline alone for Western blot analysis. 
Tissue used for histology: Lumbar spinal cords were excised and post-fixed 
overnight, dorsal root ganglia (DRG) were post-fixed for 3-4 hours. Tissue was 
cryoprotected in 20% sucrose in 0.1 M Phosphate Buffer (PB) for 4-7 days 
before OCT embedding. Tissue used for Western blot analysis: Lumbar spinal 
cords were excised and quadrisected. Lumbar spinal cords and DRG were 
snap-frozen in liquid nitrogen and stored at -80°C.  
 
2.2.   Behavioural testing 
Animals were tested in a temperature stable room during the light period of 
their day/night cycle, at the same time every day. Animals were placed in a 




for a period of 15-30 minutes before testing. Animals were trained once for 
each behavioural test, and then two baseline tests were performed on different 
days.  
Assessment of mechanical withdrawal thresholds: Mechanical withdrawal 
thresholds were assessed using calibrated von Frey hairs (Ugo Basile) 
according to the “up-down” method (Chaplan et al., 1994), as described in 
Chapter 1. The 50% withdrawal threshold was then calculated using the 
method described by Dixon (Dixon, 1980). 
Assessment of cold hypersensitivity – acetone test: For measurement of 
cold hypersensitivity, a drop of acetone was applied to the plantar surface of 
the rat hindpaw, as described in Chapter 1. 3 tests were carried out, at least 10 
minutes apart from each other, and an average response was recorded.  
Assessment of heat thresholds - Hargreaves test: The noxious heat 
threshold of the hind paw was determined using Hargreaves Plantar Test 
(Hargreaves et al., 1988). Animals were placed in acrylic cubicles (8 x 5 x 10 
cm) atop a uniform glass surface, and allowed to habituate before testing. An 
infrared light source was directed to the plantar surface of the hind paw, and 
the latency to withdraw was recorded. To prevent tissue injury, the maximum 
stimulus duration was 20 seconds. Three responses were recorded for each 
hind paw, and an average response for each taken.  
Hot / cold plate test: Response to continued noxious thermal stimulation of 
the paws was assessed using an Incremental Hot / Cold Plate (IITC Life 
Sciences, Woodland Hills, CA, USA), set at 4, 50, and 52 ± 0.1°C, with latency 
to lick or flinch the hindpaws recorded. To avoid tissue injury animals were 
removed after 20 seconds if no response was observed. Three responses 
were recorded, and an average response taken.  
Locomotor Function: Locomotor function was assessed using an 
accelerating RotaRod (Ugo Baile), set to accelerate from 2 to 40 rpm over a 
period of 560 seconds. Latency to fall was recorded. Three responses were 
recorded, and an average response taken. 
 






2.3.   Western blot 
Tissues were homogenised in the same way as described in Chapter 1. 
Protein concentration of all samples was determined using a BCA Protein 
Assay kit (Thermo Scientific). Lysates were normalised to 35 μg protein per 
sample. Proteins (35 μg lysate per well) were separated using SDS-PAGE  
and transferred to 0.2 μm pore size PVDF membranes (Millipore). Membranes 
were blocked in 10% skimmed milk in PBS-T for 45 minutes before overnight 
incubation with primary antibody at 4°C as already described in Chapter 1. 
Species appropriate HRP-conjugated secondary antibody (1:10,000, 
Amersham) was applied the subsequent day for 1 hour at room temperature. 
Membranes were visualised using ECL-prime reagent for 5 min (GE 
Healthcare) before detection by autoradiography. For visualisation of protein 
loading control, the membranes were stripped using a β-mecaptoethanol buffer 
as described in Chapter 1, before incubation with primary antibody.  
 
Antibodies used: Rabbit anti-ASC (1:1000, Alexis Biochemicals), mouse anti-β-
actin (1:15,000, Sigma), donkey anti-rabbit horseradish peroxidase (HRP)-
conjugated antibody (1:20,000, GE Healthcare), donkey anti-mouse 
horseradish peroxidase (HRP)-conjugated antibody (1:20,000, GE 
Healthcare).  
 
Blots were analysed by determining mean intensity of each band using a fixed 
box size for all. The background intensity for each blot was then subtracted 
from all values obtained. All quantifications were then normalised against β-
actin loading control. All blots were then compared to the mean band intensity 
for control-treated samples or naive animals. Analysis was carried out using 
Quantity One 1-D Analysis Software version 4.6.9 (Biorad). 
 
2.4.   Histology 
Lumbar spinal cords were cryostat cut in 20 μm sections and thaw-mounted 
onto glass slides. When slides were fully dry (at least 1 hour after tissue 
mounting), they were stored in cryoprotectant (30% ethylene glycol, 30% 





Immunohistochemistry was carried out according to the methods described in 
Chapter 1. Primary antibodies used: Rabbit anti-GFAP (1:1000, DAKO), rabbit 
anti-IBA1 (1:1000, WAKO), rabbit anti-p-p38 (1.100, Cell Signalling). Tyramide 
signal amplification was used to visualise p-p38. Secondary antibodies: anti-
mouse or anti-rabbit Alexa Fluor 488 (1:1000, Stratech), anti-mouse or anti-
rabbit Alexa Fluor 546 (1:1000, Stratech), ExtrAvidin FITC (1:200, Sigma). 
Specificity of staining was determined by omission of the appropriate primary 
antibody as a negative control. Slides were mounted on coverslips using 
Vectashield mounting medium with DAPI (Vectorlabs) and visualised using a 
Zeiss Axioplan 2 fluorescent microscope.  
 
Quantification:  
Cell counts / colocalisation: 3 100 μm2 boxes were drawn over the 
superficial L5 dorsal horn, ipsilateral and contralateral to the injury. Cells which 
were associated with a nuclear stain, within the confines of the box, were 
counted. An average count from the 3 boxes was taken. At least 3 sections per 
animal were analysed. Counts were performed manually. Analysis was carried 
out blind to treatment group / genotype. 
GFAP intensity: All GFAP images had been taken on the same day, using the 
same exposure. As for the cell counts, 3 100 μm2 boxes were drawn over the 
superficial L5 dorsal horn, ipsilateral and contralateral to the injury. A 20 μm2 
box was drawn in the white matter, and was used to generate a background 
intensity value. The intensity of the 3 boxes, minus the background intensity 
value, was averaged. At least 3 sections per animal were analysed. All 
analysis was carried out blind to genotype. Analysis was carried out using 
AxioVision LE version 4 software. 
 
2.5.   Statistical analysis 
All data are represented as mean ± SEM where appropriate. Western blot, and 
histology data were analysed using one-way ANOVA followed by Dunnett's 
post-test. Behavioural data were analysed using two-way repeated measures 
ANOVA followed by Dunnett’s post-test. Where data were not normally 
distributed, ANOVA tests were performed on ranked data. All analysis was 




3.   Results 
 
3.1.   ASC inhibition attenuates established L5 SNT-induced behavioural 
hypersensitivity 
To investigate the role of the inflammasome upstream of caspase-1 activation, 
we investigated the effect of inhibition of the adaptor protein ASC. The 
Cytokine Release Inhibitory Drug (CRID), CRID3 has recently been shown to 
inhibit IL-1β maturation and release by targeting ASC oligomerisation (Coll and 
O'Neill, 2011). Animals received either vehicle (10% DMSO) or 25 nmol CRID3 
intrathecally on days 5 to 8 post-surgery inclusive. There was a small but 
significant reduction in mechanical hypersensitivity drug-treated animals on 
days 7 and 8 post-surgery (p<0.05). This effect was abolished on days 9, 10, 
and 13 following cessation of treatment. However no difference in cold 






Figure 3.1: ASC inhibition attenuates established L5 SNT-induced mechanical 
but not cold hypersensitivity 
Intrathecal administration of 25 nmol CRID3 on days 5 to 8 post-surgery inclusive 
attenuated L5 SNT-induced mechanical (a) but not cold (b) hypersensitivity compared 
to vehicle-treated animals. Shaded area on graphs indicate drug treatment. Data 
represented as mean ± SEM, n=7-8 animals per group. Two-way repeated measures 
ANOVA, followed by Dunnett’s post-test, where * p<0.05 compared to vehicle-treated 




3.2.   Acute responses to noxious stimuli of ASC-/- mice are comparable 
to those of wildtype littermates 
The role of the adaptor protein ASC in animal models of pain was investigated 
further using a strain of ASC-/- mice. The generation of these mice has been 
described previously, and is illustrated in Figure 3.2 (Mariathasan et al., 2004). 
Immunohistochemical analysis shows that ASC-/- mice express microglial 
marker IBA1 normally, however ASC was not detected (Figure 3.3 a). Western 









Figure 3.2: Targeted disruption of the murine ASC gene 
a: Schematic demonstrating the targeted disruption of the murine ASC gene. Exons 
(closed black boxes) encoding the ASC gene were replaced with a neomycin 
resistance cassette. X up- and downstream of this cassette indicate homology arms. 
TK indicates a thymidine kinase negative selection marker, outside the region of 
sequence similarity between the wildtype allele and targeting vector. Adapted from 
(Mariathasan et al., 2004). b: Representative agarose gel of PCR products from 
genotyping, with wildtype mice yielding a 450bp product, knockout mice yielding a 





The effect of ASC gene deletion on sensory processing pathways has not 
previously been investigated. Thus the behaviour of ASC-/- mice and wildtype 
littermates was assessed in a range of tests to determine if there was any 
difference in acute pain processing in response to peripherally-applied 
mechanical and thermal stimuli. No significant difference was observed 
between ASC-/- mice and wildtype littermates in withdrawal latency to noxious 
thermal stimuli in the hot / cold plate test at any of the temperatures tested; 4, 
50, and 52°C. In line with these findings, no difference was observed in 
withdrawal latency to a gradual radiant heating of the plantar surface in the 
Hargreaves test. ASC-/- mice also exhibited equivalent withdrawal thresholds 
to von Frey mechanical stimuli. No deficit in motor function was observed, as 






Figure 3.3: ASC -/- mice are deficient in ASC protein expression 
a: ASC-/- mice express microglial marker IBA1in the spinal cord normally, but do not 
express ASC. Scale 200 μm. b: Western blot analysis of spinal cord lysates confirms 










Figure 3.4: ASC-/- mice display normal responses to acute thermal and 
mechanical noxious stimuli 
The withdrawal thresholds of naïve ASC-/- and ASC+/+ mice were assessed in the 
hot / cold plate test (a), the Hargreaves test (b), and the von Frey test (c). Motor 
function was assessed using the RotaRod test (d). Data represented as mean ± SEM, 




3.3.   Partial sciatic nerve ligation causes behavioural hypersensitivity 
and spinal microgliosis in mice 
Baseline mechanical responses in adult male C57Bl/6 mice were assessed 
prior to any surgery. The diagram in Figure 3.5 demonstrates the injury. 
Following partial sciatic nerve ligation (PSNL) the change in behavioural 
sensitivities were assessed intermittently over a ten-day period, to ensure that 
the animals developed neuropathic pain-like behaviours. PSNL caused a 
significant decrease in hindpaw 50% withdrawal threshold to von Frey hairs, 
observed from the first time-point assessed; 3 days. This mechanical 
hypersensitivity lasted for the duration of the study and was only observed in 
the hindpaw ipsilateral to the injury, whereas contralateral thresholds were 








Figure 3.5: Partial sciatic nerve ligation causes lasting hindpaw mechanical 
hypersensitivity 
a: The sciatic nerve is exposed at mid-thigh level. A 5-0 silk suture is used to tightly 
ligate ⅓ to ½ to of the nerve. Diagram adapted from (Shields et al., 2003). b: PSNL 
caused a significant decrease in hindpaw 50% withdrawal threshold to von Frey hairs 
using the Up-Down method in the ipsilateral hindpaw, observed from the first time-
point assessed, lasting up to ten days. Contralateral hindpaw withdrawal thresholds 
were unaffected. Data represented as mean ± SEM, n=8 mice. Two-way repeated 
measured ANOVA, followed by Dunnett’s post-test, where *, **, *** p<0.05, 0.01, 




10 days after PSNL a robust microgliosis was observed using 
immunohistochemical techniques, visualised using the microglial marker IBA1. 
The number of IBA1-positive cells in the ipsilateral dorsal horn was significantly 
increased compared to the contralateral dorsal horn (4.18-fold increase ± 0.74 
compared to contralateral dorsal horn). As observed in the rat after L5 SNT 
injury, the number of ASC-positive cells was significantly increased in the 
ipsilateral superficial lumbar dorsal horn compared to the contralateral dorsal 
horn (4.39-fold increase ± 0.84 compared to contralateral dorsal horn). Again, 
as observed in the rat, there was extensive co-localisation of ASC with 





Figure 3.6: Partial sciatic nerve ligation causes spinal microgliosis in the mouse 
Lumbar spinal cord of an animal 10 days post-surgery, immunostained for ASC (a), 
and microglia (b) using IBA1 antibody. Merged image shown in c. Scale 200 μm. d: 
The number of ASC-positive and IBA1-positive cells in the ipsilateral superficial dorsal 
horn was significantly greater than that observed in the contralateral dorsal horn, 10 
days post-surgery. e: Co-localisation of ASC- and IBA1-positive cells is 100%. Data 
represented as mean ± SEM, n=4 animals, with ≥3 spinal cord sections analysed per 





3.4.   Partial sciatic nerve ligation causes comparable behavioural 
hypersensitivity and immunohistochemical marker changes in ASC-/- 
mice and wildtype littermates 
Baseline mechanical responses in adult ASC-/- and ASC+/+ mice were 
assessed prior to surgery. PSNL caused a significant and lasting decrease in 
ipsilateral hindpaw 50% withdrawal threshold to von Frey hairs. Additionally 
there was a significant decrease in withdrawal latency of the hindpaw in the 
Hargreaves test. No difference was detected in the responses of knockout and 
wildtype animals, however (Figure 3.7). 14 days after injury a significant 
increase in the number of microglia in the superficial ipsilateral lumbar dorsal 
horn was observed, compared to the uninjured contralateral side. This 
increase was observed in both ASC-/- and wildtype littermates, with no 
difference between the two. Additionally there was no difference observed in 
the level of activation of microglia between the two genotypes, as assessed by 
co-localisation with p-p38. As well as an ipsilateral increase in microglial 
number, there was an increase in astrocyte activation as assessed by a 
significant increase in the intensity of GFAP immunofluorescence. No 
































Figure 3.7: Partial sciatic nerve ligation causes comparable behavioural 
hypersensitivity in ASC-/- mice and wildtype littermates 
a: PSNL caused mechanical hypersensitivity in the ipsilateral hindpaw in both ASC-/- 
mice and wildtype littermates, with no discernible difference between the two 
genotypes. b: PSNL caused a decrease in withdrawal latencies of the ipsilateral 
hindpaw to a radiant heat stimulus in the Hargreaves plantar test. There was no 
discernible difference in the withdrawal latencies of ASC-/- and wildtype littermate 
mice at any timepoint tested. Data expressed as mean ± SEM, n=11-14 mice per 






Figure 3.8: No difference in the level of microgliosis or astrocytosis in the 
superficial dorsal horns of ASC-/- mice and wildtype littermates following partial 
sciatic nerve ligation 
a: Immunostaining for microglial marker IBA1 reveals a significant increase in the 
number of microglia in the superficial ipsilateral lumbar dorsal horn of both ASC-/-  
and wildtype littermates compared to the contralateral side. No significant difference 
between the two phenotypes was observed. b: No difference was observed in the 
amount of p-p38 co-localisation with IBA1 in superficial dorsal horns of ASC-/- mice 
compared to wildtype littermates. c: Immunostaining for astrocyte marker GFAP 
reveals a significant increase in immunofluorescence in the superficial ipsilateral 
lumbar dorsal horn compared to the contralateral side in both ASC-/- and wildtype 
littermate mice. No significant difference between the two phenotypes was observed. 
Data represented as mean ± SEM, n=4 animals per group with ≥3 spinal cord 






3.5.  ASC deficiency attenuates LPS-induced hindpaw mechanical 
hypersensitivity 
Intrathecal administration of LPS leads to hyperalgesia in the hind-paw (Cahill 
et al., 2003, Clark et al., 2006, Clark et al., 2010a). Mice were given a priming 
dose of LPS (2 μg in 5 μl 0.9% sterile saline), followed by a second intrathecal 
injection of the same dose of LPS 24 hours later. Mechanical hypersensitivity 
was assessed 1- and 3 hours later. Following the final behavioural test animals 
were sacrificed and tissue collected. ASC-/- and wildtype mice showed a 
significantly reduced mechanical withdrawal threshold from baseline 3 hours 
after LPS administration. Wildtype mice also showed a trend for reduced 
mechanical withdrawal threshold 1 hour after LPS administration, although this 
was not statistically significant (p=0.063). Wildtype mice exhibited a 
significantly lower mechanical withdrawal threshold than ASC-/- mice 3 hours 
after LPS administration (p=0.017), and showed a trend for a lower mechanical 
withdrawal threshold 1 hour after LPS administration (p=0.059) (Figure 3.9).  
 
Immunohistochemical analysis revealed no difference in the total number of 
microglia in the superficial lumbar dorsal horn of ASC-/- mice and wildtype 
littermates (average 2.4 ± 0.1 cells/100 μm2 and 2.4 ± 0.5 cells/100 μm2 in 
wildtype and ASC-/- animals respectively). The number of microglia expressing 
p-p38, indicating a state of activation, showed a trend for reduction in the 
superficial dorsal horns of ASC-/- mice (73.1% ± 8.6 compared to 50.0% ± 5.7 
IBA1-positive cells expressing p-p38 in wildtype and ASC-/- mice respectively, 
p<0.067) (Figure 3.10). No difference was detected in the intensity of GFAP 







Figure 3.9: ASC deficiency results in an attenuated hindpaw mechanical 
hypersensitivity following intrathecal LPS administration 
Intrathecal LPS produces a mechanical hyperalgesia of the hindpaw. Animals 
received a priming injection of LPS (2 μg in 5 μl 0.9% sterile saline), before receiving 
a second dose 24 hours later. Mechanical hypersensitivity was assessed 1- and 3 
hours after the second LPS administration. Data represented as mean ± SEM, n=8-10 
mice per group. Two-way repeated measures ANOVA, followed by Dunnett’s post-test, 
where *, p<0.05 compared to wildtype animals’ responses at the same time-point, 
where #, p<0.05 compared to baseline responses of the same genotype. All behaviour 

























Figure 3.10: ASC-/- mice show a trend for reduced microglial activation 
following intrathecal LPS 
a: Representative images of the superficial lumbar dorsal horns of wildtype and ASC-
/- mice, IBA1 staining in the red channel, and p-p38 staining represented in the green 
channel. Scale: 100 μm. b: The number of microglia in the lumbar dorsal horn did not 
differ significantly between genotypes. The number of p-p38 positive cells showed a 
trend for reduction in ASC-/- mice, but was not significantly different (p=0.068). c: The 
number of microglia expressing p-p38 showed a trend for reduction in ASC-/- mice, 
but was not significantly different (p=0.067).  Data represented as mean ± SEM, n=3-4 





3.6.  ASC-/- mice develop comparable hypersensitivity to wildtype 
littermates in response to intraplantar CFA injection 
Although ASC deficiency did not affect PSNL-induced hypersensitivity, a 
model of neuropathic pain, ASC-/- mice did show an attenuated mechanical 
hypersensitivity following intrathecal LPS administration, a model of central 
inflammatory pain. Thus it was hypothesised that the role of ASC signalling 
may be of greater importance in inflammatory pain. To test this hypothesis, the 
response of ASC-/- mice to intraplantar administration of Complete Freud’s 
Adjuvant (CFA), a model of persistent peripheral inflammatory pain, was 
assessed. Following CFA administration, both ASC-/- mice and wildtype 
littermates developed a significant and lasting mechanical hypersensitivity of 
the ipsilateral hindpaw. There was no discernible difference between 
genotypes (Figure 3.11 a). Ipsilateral hindpaw withdrawal latencies to radiant 
heat stimulus in the Hargreaves plantar test significantly decreased at all 
timepoints assessed up to, and including, 10 days after CFA administration. 
Withdrawal latencies began to increase 10 days after CFA administration back 
toward baseline levels, and were not significantly different from baseline 
values 14 days after administration. There was no discernible difference in the 
withdrawal latencies of ASC-/- mice and wildtype littermate mice at any 
timepoint tested (Figure 3.11 b). Owing to the well-characterised role of ASC in 
innate immune responses and inflammation, paw thickness was also 
assessed. Both ASC-/- mice and wildtype littermates had significant paw 
swelling at all timepoints assessed. However, ASC-/- mice showed an overall 
trend for reduced paw thickness following intraplantar CFA administration 
compared to wildtype littermates (p=0.051) (Figure 3.11 c).  
 
Immunohistochemical analysis revealed no difference in the total number of 
microglia in the superficial ipsilateral or contralateral dorsal horns of ASC-/- 
mice compared to wildtype littermates. Additionally no difference in microglial 
number was observed between superficial ipsilateral and contralateral lumbar 
dorsal horns. An overall difference was observed in the proportion of microglia 
co-expressing activation marker p-p38 between the ipsilateral and contralateral 
sides, though no difference between genotype was detected. No difference 




contralateral lumbar dorsal horns of either ASC-/- mice or wildtype littermates. 
Additionally no difference in GFAP immunoreactivity was observed between 





Figure 3.11: Intraplantar CFA leads to comparable behavioural hypersensitivity 
in ASC-/- mice and wildtype littermates 
a: Intraplantar CFA caused lasting mechanical hypersensitivity in the ipsilateral 
hindpaw in both ASC-/- mice and wildtype littermates, with no discernible difference 
between the two genotypes. b: Intraplantar CFA caused a decrease in withdrawal 
latencies of the ipsilateral hindpaw to a radiant heat stimulus in the Hargreaves 
plantar test for 7 days after administration, after which time withdrawal latencies 
began to increase returning to close to baseline values 14 days after administration. 
There was no discernible difference in the withdrawal latencies of ASC-/- and wildtype 
littermate mice at any timepoint tested. c: Intraplantar CFA caused a significant 
increase in paw thickness at all timepoints. ASC-/- mice showed an overall trend for 
reduced paw thickness compared to wildtype littermates (p=0.051), with a significantly 
reduced paw thickness 10 days after CFA administration. Data expressed as mean ± 









Figure 3.12: No difference in the level of microgliosis or astrocytosis in the 
superficial dorsal horns of ASC-/- mice following intraplantar CFA 
administration 
a: Immunostaining for microglial marker IBA1 reveals no significant difference in the 
number of microglia in the superficial ipsilateral and contralateral lumbar dorsal horns 
in either ASC-/- mice or wildtype littermates. Additionally no significant difference was 
observed between genotypes. b: An overall difference was observed in the amount of 
p-p38 co-localisation with IBA1 in superficial ipsilateral and contralateral dorsal horns 
(p=0.037), with no significant difference observed between genotypes, c: 
Immunostaining for astrocyte marker GFAP reveals no significant difference in 
immunofluorescence in the superficial ipsilateral lumbar dorsal horn compared to the 
contralateral side in either ASC-/- or wildtype littermates. No significant difference 
between the two genotypes was observed. Data represented as mean ± SEM, n=3-4 
animals per group, with ≥3 spinal cord sections per animal analysed. Two-way 





4.   Discussion 
 
Data presented in Chapter 2 has suggested that caspase-1 activation 
contributes to the behavioural hypersensitivity observed following L5 SNT 
injury in rats, due to its activation of the pro-inflammatory cytokine IL-1β and 
possibly also IL18. Additionally caspase-1 activity appears to play a  role in the 
behavioural hypersensitivity observed following the intrathecal administration 
of LPS, an inflammatory stimulus. Thus subsequent work has focused on 
determining if the inflammasome, upstream of caspase-1 activation, plays a 
role in animal models of pain. This chapter has focused on the potential role of 
the adaptor protein ASC in nociceptive signalling.  
 
4.1.   The role of ASC in animal models of neuropathic pain 
In the previous chapter, spinal inhibition of caspase-1 activity attenuated L5 
SNT-induced hypersensitivity. This effect was not observed immediately, but 
instead several days after injury whether the drug was administered daily from 
the day of injury, or after behavioural hypersensitivity was established. 
Recently it has been shown that the cytokine release inhibitory drug CRID3 
prevents IL-1β release by preventing the oligomerisation of the inflammasome 
adaptor protein ASC (Coll and O'Neill, 2011). Because caspase-1 inhibition did 
not affect behavioural hypersensitivity until later timepoints, possibly due to 
prevention of astrocytic activation, it was decided to test the effect of ASC 
inhibition on established hypersensitivity in the L5 SNT model in rats. CRID3-
treated animals showed a small but significant attenuation of mechanical 
hypersensitivity, though no change was observed in cold hypersensitivity. 
Given the small difference observed in mechanical hypersensitivity, this is 
perhaps unsurprising as the acetone test produces more variable data. It is 
possible that the dose tested was not high enough to inhibit ASC 
oligomerisation. The dose chosen was equivalent to the most effective dose 
shown to inhibit IL-1β release from macrophages in vitro (Coll and O'Neill, 
2011). Pharmacokinetic data on the drug was not available, thus it is unknown 
how quickly the drug was broken down. Also, YVAD-CMK is known to be cell-




permeant. Another limitation of this study was the solubility of the compound. 
Owing to the route of administration the drug needed to be dissolved in 
relatively small volumes. Thus it was decided not to test a higher dose.  
 
To gain a better understanding of the role ASC in nociceptive signalling we 
made use of a line of ASC-/- mice. These mice were fist described by 
Mariathasan et al. who showed ASC to be essential for the ATP-stimulated IL-
1β release from LPS-primed macrophages (Mariathasan et al., 2004). ASC-/- 
mice have since been studied extensively, with the focus mainly on its role in 
innate immunity. However this is the first time these mice have been employed 
in the study of nociception. Data presented here indicate that acute nociceptive 
signalling is unaltered in ASC-/- mice, as indicated by comparable responses 
to hot and cold plate tests, radiant heat stimulus (Hargreaves test), and to 
punctate mechanical stimuli (von Frey test). Locomotor function is also 
unaffected by gene deletion, as assessed by the RotaRod test.  
 
The effect of ASC gene deletion on behavioural hypersensitivity in an animal 
model of neuropathic pain was assessed first. In previous studies, using rats, 
the L5 SNT model was employed. However this injury is technically more 
challenging to carry out in mice, and so the PSNL model was used. Preliminary 
experiments showed that PSNL injury in mice caused mechanical 
hypersensitivity and microgliosis similar to that observed in SNT-injured rats. 
PSNL injury in ASC-/- mice caused a comparable mechanical and thermal 
hypersensitivity to that observed in wildtype littermates. Immunohistochemical 
analysis showed a comparable microgliosis and astrocytosis between 
genotypes, which is perhaps unsurprising given the lack of behavioural 
difference. If ASC oligomerisation is directly upstream and obligatory for 
caspase-1 activation, then this data is at variance with that of the previous 
chapter where caspase-1 inhibition attenuated hypersensitivity in the L5 SNT 
model of neuropathic pain. This difference could be, at least in part, due to a 
species difference. This idea is possibly supported by the finding that CRID3 
attenuated mechanical hypersensitivity in the rat after L5 SNT, although the 
effect was small. There are several factors which may contribute to this 




4.1.1.   Differences in animal models of neuropathic pain 
Another fundamental difference between these studies is the model used. 
Behavioural differences in animal models of neuropathic pain induced by 
peripheral nerve injury have been previously compared (Kim et al., 1997, 
Dowdall et al., 2005), with the conclusion that, although each model produced 
behavioural hypersensitivity in a range of different tests, there were differences 
in the magnitude and timecourse of hypersensitivity across several sensory 
modalities. In addition to differences in behavioural outcomes, there has been 
some attempt to look at differences in molecular changes in these models (Lee 
et al., 1998, Scholz et al., 2008, Casals-Diaz et al., 2009, Maratou et al., 2009, 
Noma et al., 2011). For example extensive sympathetic sprouting in the injured 
DRG of SNT-injured rats was observed 1 week after injury, and gradually 
declined over several weeks. However no sympathetic sprouting was detected 
in the DRGs of animals following PSNL or CCI injury until 20 weeks after injury. 
Moreover the extent of sprouting was considerably less than that observed in 
SNT-injured rats (Lee et al., 1998). Differences have also been detected in 
spinal cord plasticity following CCI, SNI, and crush injuries as assessed by the 
extent of changes in the pattern of SP- and IB4-immunoreactivity in the spinal 
cord dorsal horn (Casals-Diaz et al., 2009). Changes in gene expression 
following L5 SNT injury have also recently been explored, and compared to a 
HIV-associated model of neuropathic pain, which does not involve peripheral 
nerve injury. The study showed that although there was some convergence in 
gene changes detected between the two models, ultimately there were many 
more genes which were dysregulated which differed between the two models 
(Maratou et al., 2009). Thus it is clear that although there are several nerve-
injury induced models of pain resulting in pain-related hypersensitivity, there 
may be underlying differences in the pathophysiology between models. This is 
not to say that there are not commonalities between models, however. Scholz 
et al. looked at potential differences in the timecourse and extent of 
microgliosis in CCI, SNI, and SNT models of neuropathic pain in rats. The 
group reported a similar extent of microgliosis across a similar timecourse in all 
models tested (Scholz et al., 2008). Data presented in previous chapters 
indicate that the inflammasome is expressed in microglia, and so it might be 




similar. However it is important to consider that microglial changes in animal 
models of pain occur as a result of neuronal-glial crosstalk. Thus differences in 
neuronal changes across models could, potentially, lead to differences in the 
degree of microglial activation and intracellular signalling.  
 
Another consideration in the apparent conflicting results of these studies is that 
CRID3, which was only minimally effective, might not have been acting solely 
at the level of ASC oligomerisation and may have been efficacious via some 
unknown, off-target, effect. Additionally it is possible that the antinociceptive 
effect of Ac-YVAD-CMK may have been due not only to caspase-1 inhibition, 
but also some off-target effect of other pro-inflammatory caspases. It has been 
shown that Ac-YVAD-CMK can inhibit caspase-4 and caspase-5, though with a 
considerably higher Ki (Rabuffetti et al., 2000).  
 
4.1.2.   Redundancy in inflammasome interactions 
A further consideration is the possibility of compensation of the adaptor protein 
ASC in ASC-/- mice. ASC participates in the assembly of the inflammasome 
complex via homotypic protein-protein interactions. There are several other 
proteins already identified which possess the PYRIN domain. Many of these 
have been identified as endogenous inhibitors of inflammasome assembly, for 
example POP1, POP2, and PYNOD (Wang et al., 2004a, Stehlik and 
Dorfleutner, 2007). However there are also PYRIN domain-possessing proteins 
which have been suggested to act as adaptors for inflammasome complexes. 
The first description of an inflammasome complex, the NLRP1 inflammasome, 
described two adaptors; ASC and Cardinal (Martinon et al., 2002). Cardinal 
has been shown to interact with the NLRP3 inflammasome in macrophages 
from patients with Muckle-Wells syndrome (Agostini et al., 2004). However it is 
thought that Cardinal is not expressed in the mouse genome, so a role for 
Cardinal in this instance is ruled out (Lamkanfi et al., 2007, Martinon and 
Tschopp, 2007). It has been suggested that the murine NLRP1 protein, which 
contains a FIIND (function to find) domain, a CARD domain, but lacks a PYRIN 
domain, may serve a similar function to human Cardinal, owing to their 




signalling, not requiring an adaptor protein, may activate caspase-1 as well as, 
or in compensation for, ASC-induced caspase-1 activation. The NLRC4 
(previously named IPAF) inflammasome protein also contains a CARD domain 
meaning it is also capable of activating capsase-1 directly, although by some 
unknown mechanism, interaction with ASC (NLRC4 does not contain a PYRIN 
domain) enhances its caspase-1 activating function (Mariathasan et al., 2004). 
Thus it is possible that another inflammasome complex, which does not require 
an adaptor protein, is either responsible for caspase-1 activation in animal 
models of neuropathic pain, or alternatively may be activated in the case of 
ASC-/- mice in a compensatory manner. 
 
RIP2 (receptor-interacting protein 2, also known as CARDIAK and RICK) is a 
recently described caspase-1-activating protein. It is a serine/threonine kinase 
with a CARD domain and has been shown to interact with several CARD-
containing proteins including caspase-1, leading to its activation. RIP2 
activation occurs downstream of TLR2, 3, and 4 receptor signalling (Kobayashi 
et al., 2002). When first identified RIP2 was shown to interact directly with the 
CARD domain of caspase-1, as well as with the TNF receptor adaptor 
molecules TRAF-1 and TRAF-2. Furthermore overexpression of RIP2 induced 
activation of NFκB and JNK (Thome et al., 1998). However data from 
Kobayashi et al. suggests that RIP2 is not critically involved in TNF-receptor 
signalling since TNF-α stimulation of RIP2-null embryonic fibroblasts leads to 
IL-6 production normally. In the same report the authors found that RIP2-null 
mice showed deficits in IL-1β and IL-18 signalling, both of which share 
similarities with TLR signalling pathways (Kobayashi et al., 2002). Thus it is 
possible that RIP2-mediated caspase-1 activation, and not activation via the 
inflammasome complex, contributes to behavioural hypersensitivity in animal 
models of neuropathic pain. This might explain why caspase-1 inhibition 
attenuated behavioural hypersensitivity in L5 SNT-injured rats, but ASC 
deficiency did not affect PSNL injury-induced behavioural hypersensitivity.  
 
4.2.   The role of ASC in a model of central inflammatory pain 




assessed. This experimental paradigm was initially chosen as a model for 
inflammation for several reasons. Firstly it is a model of central inflammation, 
without any complicating contributory factors from the periphery. Secondly, it 
relates closely to the in vitro experiments carried out in Chapter 1. ASC-/- mice 
showed an attenuated mechanical hypersensitivity in response to LPS 
compared to wildtype littermates. Immunohistochemical analysis showed a 
trend toward reduced microglial activation, as indicated by reduced 
colocalisation with activation marker p-p38. This was not statistically 
significant, and greater insight would have been provided with a greater n 
number for immunohistochemical analysis. Caspase-1 inhibition similarly led to 
an attenuation of LPS-induced hindpaw sensitivity and also a reduction in 
microglial activation. It is therefore possible that the attenuation of mechanical 
hypersensitivity in ASC-/- mice was also mediated by a reduction in microglial 
activation. LPS is a commonly used priming stimulus in investigations of 
inflammasome activation and signalling in vitro, and stimulation has been 
shown to lead to dose-dependent increases in Nlrp3 mRNA (O'Connor et al., 
2003, Kahlenberg et al., 2005, Bauernfeind et al., 2009). In this model a 
priming LPS stimulus is used, which potentially results in the upregulation of 
NLRP3. Subsequent activation of the NLRP3 protein would result in 
inflammasome assembly, which would require an adaptor protein. However, 3 
hours after LPS administration, although significantly attenuated compared to 
wildtype littermates, ASC-/- mice displayed significant mechanical 
hypersensitivity compared to baseline responses. Thus although ASC 
contributes to LPS-induced hypersensitivity it is not indispensable for this 
process.  
 
LPS administration to ex vivo dorsal horn slices has been shown to lead to the 
release of caspase-1 and ASC, as well as IL-1β (Clark et al., 2006). This, in 
line with in vitro data, suggests that the inflammasome is activated following 
intrathecal LPS. Data in Chapter 1 suggest the inflammasome is expressed in 
microglia, also known to express TLR4 receptors, the receptor through which 
LPS acts, and the activation of which has been shown to contribute to 
behavioural hypersensitivity in animal models of neuropathic pain (Tanga et al., 




the inflammasome, contributes to LPS-induced hypersensitivity, but not 
exclusively. It has been shown that microglia from NLRP3-/- and ASC-/- mice 
stimulated with intact S. aureus secrete significantly reduced levels of IL-1β. 
However, the response is not completely ablated. Thus there are other, 
independent, cellular mechanisms capable of bringing about IL-1β maturation 
and release in response to this inflammatory stimulus. Interestingly IL-18 
maturation and release was unaffected in response to this stimulus suggesting 
that, under certain conditions, IL-1β and IL-18 maturation and release are 
differentially regulated (Hanamsagar et al., 2011). Thus it is possible that the 
mechanical hypersensitivity of ASC-/- mice following intrathecal LPS 
administration seen in this study was due to some residual IL-1β release, or IL-
18, by some other ASC-independent mechanism. Intrathecal administration of 
IL-18 has been shown to elicit mechanical hypersensitivity in rats (Miyoshi et 
al., 2008). Differences in mature IL-18 expression in spinal cord lysates was 
investigated, but this proved to be technically challenging and it was not 
possible to detect expression of the mature cytokine in either genotype. RIP2 
has been shown to be upregulated in macrophages following LPS stimulation. 
Although RIP2 is known to be activated downstream of TLR4 signalling, and to 
interact with caspase-1, macrophages from RIP2-/- mice did not show a deficit 
in IL-1β production when stimulated with LPS. The authors suggested that this 
could mean that RIP2 is not involved in caspase-1 activation downstream of 
TLRs, or alternatively RIP2-mediated caspase-1 activation is not the dominant 
means of activation in this situation and is a redundant mechanism  
(Kobayashi et al., 2002). Potentially RIP2-mediated capsase-1 activation is 
responsible for the mechanical hypersensitivity observed in ASC-/- mice in this 
study. This could explain why rats treated with caspase-1 inhibitor Ac-YVAD-
CMK did not display mechanical hypersensitivity following intrathecal LPS 
administration. 
 
Alternatively the residual mechanical hypersensitivity of ASC-/- mice following 
intrathecal LPS administration may be due to separate signalling mechanisms, 
independent of IL-1β and IL-18. Clark et al. have shown that the protease 
Cathepsin S is released from activated microglia in the dorsal horn following 




neuronal membrane-bound fractalkine which acts on glial CX3CR1 receptors, 
leading to further glial activation (Clark et al., 2009). Additionally intrathecal 
LPS administration has been shown to increase expression of TNF-α in 
microglia (Shen et al., 2009). These factors, and others, could be responsible 
for nociceptive signalling following intrathecal LPS administration.  
 
4.3.   The role of ASC in a model of peripheral inflammatory pain 
That ASC-/- mice showed a difference in behaviour following intrathecal LPS 
administration, but not after PSNL injury, led to the hypothesis that ASC, and 
perhaps inflammasome signalling, may have a greater contribution to 
inflammatory pain mechanisms than neuropathic pain. To test this, ASC-/- 
mice, and wildtype littermates, were given intraplantar CFA, a well-documented 
model of persistent peripheral inflammatory pain, and subsequent behaviour 
was assessed. The level of inflammation of the injected hindpaw of ASC-/- 
mice, as assessed by paw thickness measurements, was found to be overall 
significantly less than that of wildtype littermates. The inflammasome is known 
to be important in the innate immune response, so it is perhaps not surprising 
that the level of peripheral inflammation is reduced in ASC-/- mice. However, 
despite a reduced level of inflammation of the hindpaw, mechanical and 
thermal hypersensitivity of ASC-/- mice did not differ from that of wildtype 
littermates, suggesting that inflammasome signalling does not contribute to 
CFA-induced hypersensitivity. In a study investigating inflammasome 
responses to adjuvants commonly used in vaccines it was found that LPS-
primed macrophages from wildtype, NLRP3-/-, and ASC-/- mice showed 
comparable IL-1β release when stimulated with CFA (Eisenbarth et al., 2008). 
However this was just one cell type, in an in vitro assay. CFA is known to elicit 
an inflammatory reaction which sensitises peripheral nociceptors and leads to 
central sensitisation (Okun et al., 2011). Thus although it is thought that CFA 
does not directly activate the inflammasome in the periphery, the experimental 
question in this study was whether or not ASC-deficiency affected the 
development of behavioural hypersensitivity, driven by inflammation-mediated 
peripheral and central sensitisation. In the present study it was shown that 




 There is conflicting data on the role of spinal glia in the CFA model of 
inflammatory pain. In one report spinal microgliosis and astrocytosis were 
reported in the rat following hindpaw administration of CFA, although whether 
this was uni- or bilateral is unclear (Raghavendra et al., 2004). In the present 
study no difference was detected in microglial number in the superficial lumbar 
dorsal horn between the ipsilateral and contralateral sides. A better 
understanding of these data would have been obtained if the study had 
included sham-injected mice; if a bilateral change in microglial number had 
occurred this would have been detected. Using microglial morphology as a 
marker of activation, Lin et al. reported no change in spinal microglial 
activation following intraplantar CFA administration, and no change in 
microglial number (Lin et al., 2007). Another group, however, reported limited 
change in microglial number, with some change in morphology (Lee et al., 
2010b). Subjectively, in this study, it was felt that microglia in the ipsilateral 
superficial dorsal horn had larger soma. However this was not quantified. 
Instead the level of microglial activation was assessed by the extent of 
colocalisation with activation marker p-p38. An overall statistical difference was 
detected in the level of p-p38 colocalisation with IBA1 between the ipsilateral 
and contralateral superficial lumbar dorsal horns. No difference was detected 
between genotypes, perhaps unsurprisingly given that no behavioural 
difference was observed. Additionally no difference in GFAP immunoreactivity 
was observed.  
 
4.4.   Conclusions 
Data presented in this chapter indicate that ASC plays an important role in 
LPS-induced hypersensitivity. This is in line with in vitro data presented in 
Chapter 1, as well as various published reports, where it was shown that ATP-
stimulation of LPS-primed primary microglia and macrophages led to caspase-
1 activation and IL-1β release. Published data indicates that this is 
inflammasome-dependent since genetic ablation of NLRP3 and ASC leads to 
either a substantial reduction or abolition of IL-1β release in response to LPS 




2004, Sutterwala et al., 2006, Halle et al., 2008, Hanamsagar et al., 2011). 
ASC does not appear to have a more general role in inflammatory pain, 
however, as assessed by the lack of behavioural differences in ASC-/- mice 
and wildtype littermates in the CFA model of inflammatory pain. However, it 
was hypothesised that the inflammasome played a role in nociceptive 
signalling through IL-1β, and possibly IL-18, release from microglia and 
macrophages. In the present study, although there was a small difference in 
ipsilateral spinal microglial activation, there was no change in the number of 
microglia ipsilaterally. Differences in macrophage activation were not 
investigated. Thus this may not have been an ideal model of inflammation to 
investigate the role of the inflammasome. Following PSNL an ipsilateral spinal 
microgliosis was observed. However ASC-/- mice showed comparable 
behavioural hypersensitivity to wildtype littermates. This may reflect a 
compensation of other inflammasome proteins not requiring an adaptor 
protein, for example NLRP1 or NLRC4, or this may reflect compensation of 
another, as yet unidentified, adaptor protein. Alternatively this may be due to 
an inflammasome-independent activation of caspase-1 for example by RIP2. 
In conclusion ASC contributes to LPS-induced inflammatory pain, but does not 
contribute to CFA-induced inflammatory pain or PSNL injury-induced 









Chapter 4: The Central Inflammasome Scaffold Protein NLRP3 Does Not 
Contribute to Behavioural Hypersensitivity in an Animal Model of 
Neuropathic and Central Inflammatory Pain 
 
 
1.   Introduction 
 
Data presented thus far shows that caspase-1 signalling contributes to 
mechanical and cold hypersensitivity in the L5 SNT model of neuropathic pain, 
and following intrathecal LPS administration as a model of central 
inflammation. The activation of caspase-1 in neuropathic pain appears to be 
inflammasome-independent since ASC-/- mice develop mechanical and 
thermal hypersensitivity normally in the PSNL injury model of neuropathic pain. 
However ASC-/- mice did show a significantly attenuated hindpaw mechanical 
hypersensitivity following intrathecal LPS administration. The current chapter 
explores the role of NLRP3 in animal models of pain by looking at the effect of 
genetic ablation of NLRP3 expression.  
 
The NLRP3 inflammasome has been extensively studied in the field of 
immunology, specifically exploring its role in innate immunity. Several 
pathogens, including malarial hemozoin, muramyl dipeptide, 
lipopolysaccharide, sendai virus, and influenza virus have been shown to elicit 
an inflammatory response via the activation of the NLRP3 inflammasome 
(Mariathasan et al., 2006, Martinon et al., 2007, Dostert et al., 2009). 
Additionally the NLRP3 inflammasome has been shown to be activated by a 
variety of endogenous factors indicating stress or injury, often referred to as 
danger-associated molecular patterns (DAMPs). These include ATP, uric acid, 
and β-amyloid (Mariathasan et al., 2006, Martinon et al., 2006, Ogura et al., 
2006, Halle et al., 2008, Gasse et al., 2009). In this respect NLRP3 is unique 
among the inflammasomes; the range of activators of other inflammasome 
complexes is more limited, and generally limited to exogenous, pathogenic, 





There are now several published reports indicating a role for NLRP3 in a range 
of pathological conditions including type 2 diabetes, atherosclerosis. 
Alzheimer’s disease, and obesity (Halle et al., 2008, Zhou et al., 2010, 
Leemans et al., 2011, Collino et al., 2012). Given an already established role 
of IL-1β and IL-18 in several animal models of pain (Wolf et al., 2006, Miyoshi 
et al., 2008, Li et al., 2009, Ren and Torres, 2009), as well as data presented 
in Chapter 2 indicating a role for caspase-1 in nociceptive signalling, the role of 
NLRP3, and by implication the NLRP3 inflammasome, was assessed in an 
animal model of neuropathic and central inflammatory pain. Although 
inferences about the role of the inflammasome in nociceptive signalling can be 
drawn from studies presented in Chapter 3, looking at the effect of inhibition 
and deletion of the adaptor protein ASC, investigating the effect of NLRP3 
deletion provides a more complete understanding of the role of the 
inflammasome in nociception. In particular it is important to investigate all 
levels of the inflammasome pathway since ASC has, in some experimental 
paradigms, been shown to act independently of the inflammasome (Ippagunta 
et al., 2010, Shaw et al., 2010, Ellebedy et al., 2011), although there are 




2.   Methods 
 
2.1.   Animals and surgery 
Adult (10 – 12 weeks) male and female NLRP3-/- (sourced from Genentech), 
bred on a C57Bl/6 background,  and age- and sex-matched C57Bl/6 mice 
(Harlan, UK) were used in accordance with UK Home Office regulations 
(Animals Scientific Procedures Act 1986).  
 
Genotyping: A tissue sample of mouse pups (p10 – p14) was obtained by ear 
punch (Harvard Apparatus, UK), which was also used for identification 
purposes. The tissue incubated with 30 μl lysis buffer (consisting of 67mM Tris 
(Sigma), 16mM (NH4)2SO4 (Sigma), 6.7mM MgCl2 (Sigma), 0.2%w/v β-
mercaptoethanol (Sigma), 0.4 mg/ml Proteinase K (VWR)) at 55°C for 1 hour, 
followed by 10 minutes at 95°C. Samples were briefly vortexed, then 
centrifuged, with the resultant supernatant containing the DNA used for PCR. 
Genotype was determined by a polymerase chain reaction (PCR). The master 
mix solution consisted of 1.5 mM MgCl2 (Promega), 20% v/v 5x Reaction 
Buffer (Promega) 0.2 mM dNTP (Promega), 50 units/ml Taq DNA polymerase 
(Promega), 0.1 μM primers x 3 (Sigma), 0.5 μl DNA sample.  
Primer sequences:  
Cryopyrin-F (forward): CCA GCC AGA GTG GAG TGA GTA AAC 
Cryopyrin-R (reverse): CAG TCA CCT GCG AGTGAG TGA AGA C  
Cryopyrin-Neo (forward): CCG GTG GAT GTG GAA TGT GTG C 
Each reaction consisted of 0.5 μl DNA, and 24.5 μl master mix. The PCR 
reaction was performed in TC412 Flexigene thermal cycle (Techne, UK). The 
conditions for the PCR reaction were as follows: denaturation at 94°C for 4 
minutes, followed by 30 cycles of denaturation at 94°C for 1 minute, annealing 
at 62°C for 30 seconds, and polymerisation at 72°C for 1 minute. This was 
followed by a final extension step at 72°C for 10 minutes. The expected size of 
the products were 665bp for wildtype, 318bp for knockout, and 665 and 318bp 
for heterozygotes.  
Visualisation: To visualise the PCR products, gel electrophoresis of the 




ethidium bromide (Sigma) for visualisation. Gels were viewed using 
GeneGenius system (Syngene), and imaged using GeneSnap (Syngene).  
 
Partial sciatic nerve ligation: Under isoflurane anaesthesia, mice the left 
sciatic nerve was exposed at mid-thigh level. A 5-0 silk suture was used to 
tightly ligate approximately a third to half of the nerve. The wound was closed 
using two wound clips. No post-surgical analgesia was given in order to avoid 
potential modulation of the nociceptive and immune system of the animals. 
The general health of the animals was monitored daily after the surgery. 
 
Drugs and delivery: LPS was administered as 2 μg dissolved in 5 μl sterile 
saline. Awake mice were lightly restrained and a 10 μl Hamilton syringe was 
inserted between the L5 and L6 vertebrae, where the spinal cord consists 
mainly of spinal roots. The accuracy of placement was ensured through the 
observation of a tail flick. The needle was slowly withdrawn to ensure no loss 
of drug. Injections were kindly carried out by Mr. Clive Gentry.  
 
As described in Chapter 3, animals were either sacrificed by terminal 
anaesthesia and transcardially perfused with either 4% paraformaldehyde plus 
1.5% picric acid for histology, or saline alone for Western blot analysis. Tissue 
used for histology: Lumbar spinal cords were excised and post-fixed overnight. 
Tissue was cryoprotected in 20% sucrose in 0.1M Phosphate Buffer (PB) for 4-
7 days before OCT embedding. Tissue used for Western blot analysis: Lumbar 
spinal cords were snap-frozen in liquid nitrogen and stored at -80°C.  
 
2.2.   Behavioural testing 
Animals were tested in a temperature stable room during the light period of 
their day/night cycle, at the same time every day. Animals were placed in a 
polymethyl methacrylate box with a wire grid bottom and allowed to habituate 
for a period of 15-30 minutes before testing. Animals were trained once for 





Assessment of mechanical withdrawal thresholds: Mechanical withdrawal 
thresholds were assessed using calibrated von Frey hairs (Ugo Basile) 
according to the “up-down” method (Chaplan et al., 1994), as described in 
Chapter 1. The 50% withdrawal threshold was then calculated using the 
method described by Dixon (Dixon, 1980). 
Assessment of cold hypersensitivity – acetone test: For measurement of 
cold hypersensitivity, a drop of acetone was applied to the plantar surface of 
the rat hindpaw, as described in Chapter 1. 3 tests were carried out, at least 10 
minutes apart from each other, and an average response was recorded.  
Assessment of heat thresholds - Hargreaves test: The noxious heat 
threshold of the hind paw was determined using Hargreaves Plantar Test 
(Hargreaves et al., 1988). Animals were placed in acrylic cubicles (8 x 5 x 10 
cm) atop a uniform glass surface, and allowed to habituate before testing. An 
infrared light source was directed to the plantar surface of the hind paw, and 
the latency to withdraw was recorded. To prevent tissue injury, the maximum 
stimulus duration was 20 seconds. Three responses were recorded for each 
hind paw, and an average response for each taken.  
Hot / cold plate test: Response to continued noxious thermal stimulation of 
the paws was assessed using an Incremental Hot / Cold Plate (IITC Life 
Sciences, Woodland Hills, CA, USA), set at 4, 50, and 52 ± 0.1°C, with latency 
to lick or flinch the hindpaws recorded. To avoid tissue injury animals were 
removed after 20 seconds if no response was observed. Three responses 
were recorded, and an average response taken.  
Locomotor function: Locomotor function was assessed using an accelerating 
RotaRod (Ugo Baile), set to accelerate from 2 to 40 rpm over a period of 560 
seconds. Latency to fall was recorded. Three responses were recorded, and 
an average response taken. 
 
All behavioural testing was carried out blind to treatment, or genotype. 
 
2.3.   Western blot 
Tissues were homogenised in the same way as described in Chapter 1. 




Assay kit (Thermo Scientific). Lysates were normalised to 35 μg protein per 
sample. Proteins (35 μg lysate per well) were separated using SDS-PAGE  
and transferred to 0.2 μm pore size PVDF membranes (Millipore). Membranes 
were blocked in 10% skimmed milk in PBS-T for 45 minutes before overnight 
incubation with primary antibody at 4°C as already described in Chapter 1. 
Species appropriate HRP-conjugated secondary antibody (1:10,000, 
Amersham) was applied the subsequent day for 1 hour at room temperature. 
Membranes were visualised using ECL-prime reagent for 5 min (GE 
Healthcare) before detection by autoradiography. For visualisation of protein 
loading control, the membranes were stripped using a β-mecaptoethanol buffer 
as described in Chapter 1, before incubation with primary antibody.  
 
Antibodies used: mouse anti-β-actin (1:15,000, Sigma), donkey anti-mousse 
horseradish peroxidase (HRP)-conjugated antibody (1:20,000, GE 
Healthcare).  
 
Blots were analysed by determining mean intensity of each band using a fixed 
box size for all. The background intensity for each blot was then subtracted 
from all values obtained. All quantifications were then normalised against β-
actin loading control. All blots were then compared to the mean band intensity 
for control-treated samples or naive animals. Analysis was carried out using 
Quantity One 1-D Analysis Software version 4.6.9 (Biorad). 
 
2.4.   Histology 
Lumbar spinal cords were cryostat cut in 20 μm sections and thaw-mounted 
onto glass slides. When slides were fully dry (at least 1 hour after tissue 
mounting), they were stored in cryoprotectant (30% ethylene glycol, 30% 
glycerol, 40% PBS) at -20°C until required.  
 
Immunohistochemistry was carried out according to the methods described in 
Chapter 1. Primary antibodies used: Rabbit anti-GFAP (1:1000, DAKO), rabbit 
anti-IBA1 (1:1000, WAKO), rabbit anti-p-p38 (1.100, Cell Signalling). Tyramide 




mouse or anti-rabbit Alexa Fluor 488 (1:1000, Stratech), anti-mouse or anti-
rabbit Alexa Fluor 546 (1:1000, Stratech), ExtrAvidin FITC (1:200, Sigma). 
Specificity of staining was determine by omission of the appropriate primary 
antibody as a negative control. Slides were mounted on coverslips using 
Vectashield mounting medium with DAPI (Vectorlabs) and visualised using a 
Zeiss Axioplan 2 fluorescent microscope.  
 
Quantification:  
Cell counts / colocalisation: 3 100 μm2 boxes were drawn over the 
superficial L5 dorsal horn, ipsilateral and contralateral to the injury. Cells which 
were associated with a nuclear stain, within the confines of the box, were 
counted. An average count from the 3 boxes was taken. At least 3 sections per 
animal were analysed. Counts were performed manually. Analysis was carried 
out blind to treatment group / genotype. 
GFAP intensity: All GFAP images had been taken on the same day, using the 
same exposure. As for the cell counts, 3 100 μm2 boxes were drawn over the 
superficial L5 dorsal horn, ipsilateral and contralateral to the injury. A 20 μm2 
box was drawn in the white matter, and was used to generate a background 
intensity value. The intensity of the 3 boxes, minus the background intensity 
value, was averaged. At least 3 sections per animal were analysed. Analysis 
was carried out using AxioVision LE version 4 software. 
 
2.5.   Statistical analysis 
All data are represented as mean ± SEM where appropriate. Western blot and 
histology data were analysed using one-way ANOVA followed by Dunnett's 
post-test. Behavioural data were analysed using two-way repeated measures 
ANOVA followed by Dunnett’s post-test. Where data were not normally 
distributed, ANOVA tests were performed on ranked data. All analysis was 






3.   Results 
 
3.1.   Assessment of acute nociceptive behaviour in NLRP3-/- mice 
The role of the central scaffold inflammasome protein NLRP3 in animal models 
of pain was investigated using a strain of mice deficient in NLRP3 expression. 
The generation of these mice has been described previously, and is illustrated 
in Figure 4.1. Owing to initial breeding difficulties, along with time constraints, 
all experiments carried out with NLRP3-/- mice used age- and sex-matched 
C57Bl/6 mice as wildtype controls (termed “wildtype” in figure legends) as 
opposed to wildtype littermates. Western blot of spinal cord lysates from 
NLRP3-/- mice and C57Bl/6 mice generated several bands. Despite this, a 
difference was detected between the two genotypes with a band of 
approximately 50kDa in size produced by C57Bl/6 spinal cord lysates, absent 
from blot of NLRP3-/- spinal cord lysates. Additionally a band of approximately 
25kDa in size was detected in NLRP3-/- spinal cord lysates, which was absent 
from spinal cord lysates from C57Bl/6 mice. This may be a truncated, non-
functional, form of the NLRP3 protein, since exons 4 and 5 of the NLRP3 gene 
remain (Mariathasan et al., 2006). However it should be noted that the band 
detected in the spinal cord lysates of C57Bl/6 mice is smaller than that which 
would be expected, of around 70 - 80kDa dependent on the number of LRR 
regions (see Chapter 1, (Kummer et al., 2007)).  
 
The effect of NLRP3 gene deletion on sensory processing pathways has not 
previously been investigated. Thus the behaviour of NLRP3-/- mice and 
C57Bl/6 wildtype mice was assessed in a range of tests to determine if there 
was any difference in acute pain processing in response to peripherally-
applied mechanical and thermal stimuli. NLRP3-/- mice showed a significantly 
increased withdrawal latency in the coldplate test, set at 4°, and in the hotplate 
test set at 50°C, but not 52°C.  However, no difference was observed between 
NLRP3-/- mice and C57Bl/6 mice in withdrawal latency to a gradual radiant 
heating of the plantar surface in the Hargreaves test. NLRP3-/- mice also 




deficit in motor function was observed, as assessed by the RotaRod test 





Figure 4.1: Targeted disruption of the murine NLRP3 gene 
a: Schematic demonstrating the targeted disruption of the murine NLRP3 gene. Exons 
(closed black boxes) 1, 2, and 3 encompassing a 5’ untranslated region (5’ UTR), start 
codon, and the PYRIN domain of the protein were replaced with a neomycin 
resistance cassette. Exons 4 and 5 remain. X up- and downstream of this cassette 
indicate homology arms. TK indicates a thymidine kinase negative selection marker, 
outside the region of sequence similarity between the wildtype allele and targeting 
vector. Diagram adapted from (Mariathasan et al., 2006). b: Representative agarose 
gel of PCR products from genotyping, with wildtype mice yielding a 665bp product, 
and NLRP3-/- mice yielding a 318bp product. c: Western blot for NLRP3 of spinal 
cord lysates from C57Bl/6 mice and NLRP3-/- mice yields several bands. Arrows 
indicates a band of approximately 50kDa present in C57Bl/6 mice spinal cord lysates, 
absent from spinal cord lysates of NLRP3-/- mice, and a band of approximately 25kDa 
present in NLRP3-/- mice spinal cord lysates, but absent from C57Bl/6 mice spinal 





Figure 4.2: NLRP3-/- mice do not display normal responses to acute thermal and 
mechanical noxious stimuli 
The withdrawal thresholds of naïve NLRP3-/- and C57Bl/6  mice were assessed in the 
hot / cold plate test (a), the Hargreaves test (b), and the von Frey test (c). Motor 
function was assessed using the RotaRod test (d). Data represented as mean ± SEM, 
n=16 mice per group. Students t test. Where *, p<0.05 compared to C57Bl/6 mice. All 





3.2.  Partial sciatic nerve ligation causes comparable behavioural 
hypersensitivity and histochemical changes in NLRP3-/- mice and 
C57Bl/6 mice 
Baseline mechanical responses in adult NLRP3-/- and C57Bl/6 mice were 
assessed prior to surgery. PSNL caused a significant and lasting decrease in 
ipsilateral hindpaw 50% withdrawal threshold to von Frey hairs. Additionally 
there was a significant decrease in withdrawal latency of the hindpaw in the 
Hargreaves test. No overall difference was detected in the responses of 
knockout and wildtype animals (p=0.07), although NLRP3-/- mice had a 
significantly increased withdrawal latency compared to C57Bl/6 mice on day 
14, potentially indicating an earlier resolution in thermal hypersensitivity in 
these animals (Figure 4.3). 14 days after injury a significant increase in the 
number of microglia in the superficial ipsilateral lumbar dorsal horn was 
observed, compared to the uninjured contralateral side. This increase was 
observed in both NLRP3-/- and C57Bl/6 mice, with no difference between the 
two. Additionally there was no difference observed in the level of activation of 
microglia between the two genotypes, as assessed by co-localisation with p-
p38. As well as an ipsilateral increase in microglial number, there was an 
increase in astrocyte activation as assessed by a significant increase in the 
intensity of GFAP immunofluorescence. No difference was observed between 

























Figure 4.3: Partial sciatic nerve ligation causes comparable behavioural 
hypersensitivity in NLRP3-/- mice and C57Bl/6 mice 
a: PSNL caused mechanical hypersensitivity in the ipsilateral hindpaw in both NLRP3-
/- mice and C57Bl/6 mice, with no discernible difference between the two genotypes. 
b: PSNL caused a decrease in withdrawal latencies of the ipsilateral hindpaw to a 
radiant heat stimulus in the Hargreaves plantar test. There was no overall difference 
in the withdrawal latencies of NLRP3-/- and C57Bl/6 mice (p=0.07), although 
withdrawal latencies of NLRP3-/- mice were significantly increased compared to those 
of C57Bl/6 mice at day 14. Data expressed as mean ± SEM, n=8 mice per group. 
Two-way repeated measures ANOVA, with Dunnett’s post-test. *, p<0.05 compared to 






Figure 4.4: No difference in the level of microgliosis or astrocytosis in the 
superficial dorsal horns of NLRP3-/- mice and C57Bl/6 mice following partial 
sciatic nerve ligation 
a: Immunostaining for microglial marker IBA1 reveals a significant increase in the 
number of microglia in the superficial ipsilateral lumbar dorsal horn of both NLRP3 
knockout and C57Bl/6 mice compared to the contralateral side. No significant 
difference between the two genotypes was observed. b: No difference was observed 
in the amount of p-p38 co-localisation with IBA1 in superficial dorsal horns of NLRP3-
/- mice compared to C57Bl/6 mice. c: Immunostaining for astrocyte marker GFAP 
reveals a significant increase in immunofluorescence in the superficial ipsilateral 
lumbar dorsal horn compared to the contralateral side in both NLRP3-/- and C57Bl/6 
mice. No significant difference between the two genotypes was observed. Data 
represented as mean ± SEM, n=3-4 animals per group, with ≥3 spinal cord sections 
analysed per animal. Two-way repeated measures ANOVA with Dunnett’s post-test. 




3.3.   LPS-induced hindpaw mechanical hypersensitivity is comparable in 
NLRP3-/- mice and C57Bl/6 mice  
Intrathecal administration of LPS leads to hyperalgesia in the hind-paw (Cahill 
et al., 2003, Clark et al., 2006, Clark et al., 2010a). Mice were given a priming 
dose of LPS (2 μg in 5 μl 0.9% sterile saline), followed by a second intrathecal 
injection of LPS 24 hours later. Mechanical hypersensitivity was assessed 1- 
and 3 hours later. Following the final behavioural test animals were sacrificed 
and tissue collected. NLRP3-/- and C57Bl/6 mice showed a significantly 
reduced mechanical withdrawal threshold from baseline 3 hours after LPS 
administration. However, there was no difference in NLRP3-/- responses and 
C57Bl/6 responses at any timepoint (Figure 4.5). Immunohistochemical 
analysis revealed no difference in the total number of microglia in the 
superficial lumbar dorsal horn of NLRP3-/- mice and C57Bl/6 mice (average 
2.4 ± 0.3 cells/100 μm2 and 2.5 ± 025 cells/100 μm2 in C57Bl/6 and NLRP3-/- 
animals respectively). The number of microglia expressing p-p38, indicating a 
state of activation, was not different between the two genotypes (77.0% ± 10.0 
compared to 87.8% ± 3.8 IBA1-positive cells expressing p-p38 in C57Bl/6 and 
NLRP3-/- mice respectively) (Figure 4.6). No difference was detected in the 










Figure 4.5: No difference in hindpaw mechanical hypersensitivity following 
intrathecal LPS administration in NLRP3-/- mice compared to C57Bl/6 mice 
Intrathecal LPS produces a mechanical hyperalgesia of the hindpaw. Animals 
received a priming injection of LPS (2 μg in 5 μl 0.9% sterile saline), before receiving 
a second dose 24 hours. Mechanical hypersensitivity was assessed 1- and 3 hours 
after the second LPS administration. Data represented as mean ± SEM, n=8 mice per 
group. Two-way repeated measures ANOVA, followed by Dunnett’s post-test, where 

























Figure 4.6: No difference in microglial number or activation in NLRP3-/- mice 
compared to C57Bl/6 mice following intrathecal LPS 
a: The number of IBA1+ and p-p38+ cells in the lumbar dorsal horn did not differ 
significantly between genotypes. b: The proportion of microglia expressing p-p38 was 
not different between genotypes. Data represented as mean ± SEM, n=4 mice per 





4.   Discussion 
 
Data presented thus far has suggested that caspase-1 activation contributes to 
the behavioural hypersensitivity in an animal model of neuropathic pain, 
independent of the inflammasome. In this chapter NLRP3-/- mice have been 
used to further clarify this assertion.  
 
Before determining the role of NLRP3 in a model of chronic pain, it was 
necessary to first determine how, if at all, NLRP3-deficiency affects acute 
nociceptive signalling. No difference was detected in 50% withdrawal 
thresholds to punctate mechanical stimuli (von Frey hairs), or in withdrawal 
latencies to a gradual radiant heating of the plantar surface in the Hargreaves 
test. However, in the cold- and hotplate test, NLRP3-/- mice showed a 
significantly increased withdrawal latency at 4°C and 50°C, but not 52°C. This 
data suggests that NLRP3-deficiency confers a reduced sensitivity to acute 
noxious thermal stimuli. This is unlikely to be due to a general motor deficit 
since NLRP3-/- mice had comparable fall latencies in the Rotarod test to 
C57Bl/6 mice. This result was perhaps surprising given that mice deficient in 
the inflammasome adaptor protein ASC did not show any differences in 
withdrawal latencies in the cold- and hotplate tests (see Chapter 3). This 
indicates that this aspect of NLRP3 function is independent of the adaptor 
protein ASC. Mutations in the gene encoding the NLRP3 protein have been 
shown to be the underlying cause of a family of syndromes known as 
Cryopyrin-Associated Periodic Syndromes (CAPS), characterised by recurrent 
episodes of symptoms including rash, joint and muscle pain, headaches, 
fatigue, and fever (Hawkins et al., 2004, Stych and Dobrovolny, 2008). These 
symptoms are thought to be due to uncontrolled, excessive, inflammasome 
activation, leading to inappropriate IL-1β release (Agostini et al., 2004). There 
are three described CAPS syndromes; familial cold autoinflammatory 
syndrome (FACS), Muckle-Wells syndrome, and chronic infantile neurological 
articular syndrome (CINCA) with increasing severity respectively. Patients with 
FACS have a distinct trigger for their episodes, namely a cooling of the 
temperature such as air conditioning, exposure to colder temperatures e.g. 




2004, Shinkai et al., 2008). However there is reported overlap of symptoms 
among the syndromes, and cold can also be a trigger for episodes in Muckle-
Wells syndrome and CINCA. Interestingly some patients with NLRP3 
mutations also report heat as a trigger factor (Cuisset et al., 2011). Thus it is of 
interest that mice lacking the NLRP3 protein show altered responses in the 
cold- and hotplate tests. Investigation into the effect of temperature on the 
activation of NLRP3 and the mechanism behind cold-induced episodes in 
patients with NLRP3 mutations has not been reported in the literature 
however.  
 
In the PSNL model of neuropathic pain no difference was observed in 
mechanical hypersensitivity and no overall difference in thermal 
hypersensitivity was observed, although there was a trend for reduced 
hypersensitivity further indicating a difference in thermal sensitivity in animals 
lacking the NLRP3 protein. In line with literature reports a significant 
microgliosis and astrocytosis of the ipsilateral lumbar dorsal horn was 
observed. No difference in the level of gliosis was observed between 
genotypes however, as might be expected given the lack of behavioural 
difference. 
 
The response of NLRP3-/- mice to LPS-induced hypersensitivity was also 
assessed. In the previous chapter it was shown that, although ASC-/- mice did 
not show any behavioural differences compared to wildtype littermates in the 
PSNL model of neuropathic pain, ASC-deficiency conferred some protection 
against LPS-induced hindpaw mechanical hypersensitivity. ASC is known to 
associate with NLRP3, following NLRP3 oligomerisation, serving as an adaptor 
within the inflammasome for pro-caspase-1 recruitment (Martinon et al., 2002, 
Duncan et al., 2007). Thus it might be expected that NLRP3-deficiency would 
similarly confer protection from LPS-induced hypersensitivity. However 
NLRP3-/- mice showed comparable hindpaw hypersensitivity following 
intrathecal LPS administration to C57Bl/6 mice. This finding is unexpected 
since ATP stimulation of LPS-primed macrophages and microglia from NLRP3-
/- mice leads to a highly blunted release of IL-1β (Mariathasan et al., 2006, 




dorsal horn slices results in the release of IL-1β, active caspase-1, and the 
inflammasome adaptor protein ASC, suggesting an activation of the 
inflammasome (Clark et al., 2006). However the sensitivity of NLRP3-/- mice to 
high doses of LPS leading to endotoxic shock was comparable to wildtype 
littermates, whereas ASC-/- mice had a significantly higher survival rate 
compared to wildtype littermates (Sutterwala et al., 2006). NLRP3-/- mice 
given a lower dose of LPS showed a delay in mortality, and a greater overall 
survival rate than wildtype littermates suggesting that NLRP3-deficiency 
confers a degree of protection against LPS-induced mortality to a point. 
Interestingly, as with ASC-/- mice in the same study, NLRP3-/- mice treated 
with systemic LPS had significantly reduced serum concentrations of IL-1β and 
IL-18. That this was not sufficient to confer protection against endotoxic shock 
suggests that other inflammatory mediators are released in response to LPS 
administration, contributing to LPS-induced lethality. Taken together these 
findings suggest that although NLRP3 is important for LPS-induced IL-1β 
release, the effects of LPS application are likely mediated by other, NLRP3-
independent, mechanisms. That ASC-deficiency confers greater protection 
against the effects of LPS, both systemic and intrathecal, suggests a 
divergence in function of NLRP3 and ASC. There are several emerging reports 
of ASC acting independently of the inflammasome (Kolly et al., 2009, 
Ippagunta et al., 2010, Shaw et al., 2010, Ellebedy et al., 2011, Taxman et al., 
2011). Potentially, in addition to a role in inflammasome-mediated cytokine 
release, ASC acts independently of NLRP3 in response to intrathecal LPS 
administration mediating, in part, LPS-induced hypersensitivity.  
 
It is worth noting that exons 4 and 5 of the NLRP3 gene are not deleted in the 
NLRP3-/- mouse. Although several bands are visualised when blotting for 
NLRP3, one band was consistently present in NLRP3-/- spinal cord lysates 
which was absent from that of C57Bl/6 spinal cord lysates. This may be a 
truncated form of the protein. If a truncated form of the protein is translated, it 
is possible that some activity remains.  
 
Another important consideration is that, in this study, the mechanical 




magnitude than that observed in the previous chapter by ASC wildtype mice. 
This provided a smaller window to observe differences between the two 
genotypes. Additionally it brings into question the validity of the findings. 
Confidence in these findings would be increased if the replicate study 
produced the same findings. Although intrathecal administration of LPS 
appeared to result in a lesser hypersensitivity in C57Bl/6 mice in this study 
than that observed in ASC wildtype mice in the study described in the previous 
chapter, immunohistochemical changes appeared similar. Direct comparison of 
the number of IBA1+ and p-p38+ cells in the superficial dorsal horn of NLRP3-
/- knockout mice was comparable to that observed in C57Bl/6 mice. 
Additionally there was no difference observed in the proportion of activated 
microglia, as indicated by co-localisation of IBA1 with p-p38, between the two 
genotypes.  
 
Data presented in this chapter indicate that NLRP3, and by implication the 
NLRP3 inflammasome, does not contribute to behavioural hypersensitivity 
following peripheral nerve injury as an animal model of neuropathic pain. 
Moreover NLRP3 does not appear to contribute to hypersensitivity in an animal 
model of central inflammatory pain. However this is not an ideal model of 
inflammatory pain since it is an acute model, aimed solely at looking at spinal 
inflammatory processes. Although the aim of this study was to look at the 
central role of the inflammasome, specifically in glia, it would be of interest to 
investigate more clinically relevant models of inflammation. Patients with CAPS 
present with arthropathies, including arthritis. Further investigations of the role 
of NLRP3 in nociception should perhaps be directed at animal models of 
arthritic inflammatory pain. Emerging reports suggest that ASC contributes to 
the pathology of rheumatoid arthritis in an inflammasome-independent 
manner, although nociceptive outcomes were not assessed in these studies 
(Kolly et al., 2009, Ippagunta et al., 2010). However there are other reports in 
which NLRP3 function is implicated in the pathology of rheumatoid arthritis 
(Rosengren et al., 2005), and also crystal arthritis and Lyme arthritis (Jin et al., 





Of particular interest, data presented in this chapter indicate that, while NLRP3 
appears not to play a role in chronic nociceptive signalling, NLRP3 may play a 
role in acute nociceptive signalling in response to noxious thermal stimuli.  It is 
known that CAPS patients, in particular FCAS patients, report temperature 
change as a trigger for inflammatory episodes. Most frequently this trigger is 
cold, or cooling, stimuli. However, heat has also been reported as a trigger. 
These findings potentially indicate a temperature-sensitive regulation of 
NLRP3 signalling. Despite well-documented patient reports of temperature 
triggers of inflammatory episodes, the underlying molecular mechanism for this 
phenomenon is unknown, and as yet there are no reports in the literature 









1.   Aims and summary of findings 
Immune cell infiltration contributes to the generation and maintenance of 
behavioural hypersensitivity in animal models of neuropathic and inflammatory 
pain (Marchand et al., 2005, Calvo et al., 2012). The immune response 
consists of resident and infiltrating cells which release a variety of inflammatory 
mediators (Medzhitov, 2008) many of which are capable of eliciting a painful 
response via direct or indirect actions on the sensory pathway. Among these 
mediators are the pro-inflammatory cytokines IL-1β, and also IL-18, both of 
which are known to be algesic when injected into a variety of tissues (Fukuoka 
et al., 1994, Cunha et al., 2000). Additionally in animal models of neuropathic 
and inflammatory pain the expression of IL-1β message or protein has been 
shown to increase at various levels of the sensory pathway (Cunha et al., 
2000, Milligan et al., 2001, Okamoto et al., 2001, Samad et al., 2001, Lee et 
al., 2004, Uceyler and Sommer, 2008). Understanding the mechanisms which 
lead to the maturation and release of these cytokines may provide further 
opportunity for therapeutic targets, as well as increasing our understanding of 
those signalling mechanisms contributing to pathologic pain states.  
 
In recent years the mechanisms behind the regulation of IL-1β, and also IL-18, 
maturation and release have been elucidated. The first description of the 
inflammasome was in 2002 when Martinon and colleagues first demonstrated 
the existence of a multiprotein platform, the NLRP1 inflammasome, for the 
regulation of IL-1β release (Martinon et al., 2002). Since this time several other 
proteins have been proposed to form the central scaffold of inflammasomes 
including NLRP3, NLRC4, and AIM2. The NLRP3 inflammasome is perhaps 
the best studied and characterised. Compared to other inflammasome scaffold 
proteins, the NLRP3 inflammasome has a relatively restricted expression 
profile, found principally in granulocytes and monocytes and mainly in tissues 
highly populated in immune cells (Anderson et al., 2004, Kummer et al., 2007, 
Guarda et al., 2011). It is particularly interesting owing to the large range of 
activators so far described which, as well as PAMPs, include several DAMPs 
such as ATP, amyloid-β, and uric acid (Martinon et al., 2009). In recent years a 
role for the NLRP3 inflammasome has been described in several pathologic 




and obesity (Leemans et al., 2011). For these reasons it was considered that 
the NLRP3 inflammasome may also play a role in chronic pain, known to have 
a key inflammatory component (Samad et al., 2002, Marchand et al., 2005, 
Austin and Moalem-Taylor, 2010, Calvo et al., 2012).  
 
There are several lines of evidence which might indicate a role of the 
inflammasome in both neuropathic and inflammatory pain states. Microglia and 
macrophages have been strongly implicated as having a role in the 
development of pain-like behaviours (Liu et al., 2000a, Hu and McLachlan, 
2002, Hu et al., 2007, Fu et al., 2009, Xie et al., 2009, Ulmann et al., 2010, 
Clark et al., 2012). The NLRP3 inflammasome is expressed within 
macrophages (Petrilli et al., 2007b, Guarda et al., 2011) and microglia (Halle et 
al., 2008). IL-1β, as well as activated caspase-1 and ASC, have been shown to 
be released from LPS-stimulated microglia in ex-vivo dorsal horn slices (Clark 
et al., 2006). P2X7 receptor activation has been shown to cause 
inflammasome activation in primed cells, and P2X7 receptor signalling in 
microglia, as well as other cell types, plays a role in pain signalling (Chessell et 
al., 2005, Honore et al., 2009, Clark et al., 2010a). Increases in intracellular 
and extracellular calcium have been shown to activate the NLRP3 
inflammasome through the calcium-sensing receptor GPRC6A (Lee et al., 
2012, Rossol et al., 2012). TLR4 signalling has been shown to play a role in 
the initiation of neuropathic-pain like behaviours in mice (Tanga et al., 2005). 
TLR signalling converges to activate transcription factor NFκB which, in some 
cellular contexts at least, upregulates pro-IL-1β and NLRP3 expression 
(Bauernfeind et al., 2009, Berger et al., 2011). Finally it has been shown that, 
in several animal models of pain, ROS production, a putative trigger of NLRP3 
inflammasome activation, contributes to behavioural hypersensitivity (Wang et 
al., 2004b, Berger et al., 2011, Salvemini et al., 2011). Thus the aim of the 
research presented in this thesis was to investigate a possible role for the 








The main findings of this thesis are: 
 
• The NLRP3 inflammasome is expressed in macrophages and microglia 
• Inflammasome component proteins NLRP3, ASC, and active caspase-1 
are dysregulated in the L5 SNT model of neuropathic pain in the rat in 
the injured DRG and ipsilateral lumbar dorsal horn at the mRNA 
(NLRP3, caspase-1), and protein (ASC, active caspase-1) level 
• Caspase-1 inhibition attenuates behavioural hypersensitivity in the L5 
SNT model of neuropathic pain, and reduces the activation of 
inflammatory cells, astrocytes 
• This is likely to be inflammasome-independent since ASC-/- and 
NLRP3-/- mice develop behavioural hypersensitivity in response to 
partial sciatic nerve ligation injury, in the Seltzer model of neuropathic 
pain, normally 
• In the LPS-induced model of central inflammation caspase-1 inhibition 
prevent behavioural hypersensitivity and the activation of inflammatory 
cells, microglia 
• This is likely to be ASC-dependent since ASC-/- mice show attenuated 
behavioural hypersensitivity in response to LPS 
• However both are likely to be independent of NLRP3 activation since 
LPS-induced behavioural hypersensitivity is unaffected in NLRP3-/- 
mice 
• Despite an indication of a role for ASC signalling in a CNS inflammatory 




For many years the behavioural hypersensitivity observed following peripheral 
nerve injury in animal models of neuropathic pain was considered to be a 
result of dramatically altered protein expression within the neurons leading to 
heightened neuronal excitability. However in recent years it has become widely 
accepted that, even in models of neuropathic pain, there is a key role for the 
immune system in the initiation and maintenance of pathological pain states. 




while centrally microglia migrate and proliferate in the spinal cord at the level of 
the injury. Evidence suggests these events occur early on, contributing to the 
initiation of pain states (Tanga et al., 2004, Scholz et al., 2008). It is currently 
unclear which signalling mechanisms within these cells contribute to 
behavioural hypersensitivity. In Chapter 1 it was shown that the inflammasome 
is dysregulated in the injured DRG and ipsilateral lumbar dorsal horn of rats 
following L5 SNT injury. Further investigation showed that both macrophages 
and microglia express the inflammasome, and in vitro stimulation of these cell 
types led to NLRP3 upregulation and release of ASC and activated caspase-1 
in the extracellular media. However, it was unclear whether the dsyregulation 
of the inflammasome following L5 SNT was due to an upregulation of the 
inflammasome within macrophages and microglia, or merely a reflection of the 
increased number of macrophages and microglia following injury..  
 
 
2.   Differential mechanisms of caspase-1 activation in neuropathic and 
inflammatory pain? 
In animal models of both neuropathic and central inflammatory pain caspase-1 
inhibition attenuated behavioural hypersensitivity, and reduced the extent of 
associated histochemical changes with these models. In both cases caspase-1 
activation appears to be independent of NLRP3 since NLRP3-/- mice 
developed behavioural hypersensitivity normally following peripheral nerve 
injury and intrathecal LPS administration. Interestingly ASC-/- mice developed 
behavioural hypersensitivity normally following peripheral nerve injury, but not 
following intrathecal LPS administration demonstrating the activation of 
different signalling pathways in neuropathic and central inflammatory pain. This 
is not a simple distinction however since ASC-/- mice developed behavioural 
sensitivity normally following the peripheral administration of an inflammatory 
stimulus, CFA. 
 
LPS-induced behavioural hypersensitivity has been shown to be dependent on 
P2X7 receptor activation, since P2X7-/- mice do not develop behavioural 




was shown that ex vivo dorsal horn slices from these animals showed 
increased extracellular ATP following LPS administration, comparable to 
wildtype animals, but showed significantly reduced IL-1β release. This data is 
consistent with a role for P2X7 receptor activation in the assembly of the 
NLRP3 inflammasome, thought to be due to the P2X7-mediated K+ efflux 
(Kahlenberg and Dubyak, 2004, Kahlenberg et al., 2005, Qu et al., 2007). Data 
presented in this thesis show that, in vitro, ATP stimulation of LPS-primed 
microglia leads to the upregulation of NLRP3 protein expression, and an 
increase in extracellular ASC and active caspase-1. In line with this, following 
LPS stimulation of ex vivo rat dorsal horn slices, it has been shown that, along 
with IL-1β, ASC and caspase-1 are secreted (Clark et al., 2006). It is 
postulated that the release of these proteins allows for the further extracellular 
maturation of IL-1β. It is reasonable, therefore, to hypothesise a role of the 
inflammasome in LPS-induced behavioural hypersensitivity.  
 
In the LPS-induced hypersensitivity model of central inflammatory pain ASC-/- 
mice showed reduced behavioural hypersensitivity, and a trend towards 
reduced histochemical changes in the lumbar spinal cord associated with the 
model. This conferred protection was likely independent of NLRP3, however, 
since NLRP3-/- mice developed LPS-induced behavioural hypersensitivity 
normally. ASC was initially characterised as an adaptor protein for the 
inflammasome (Martinon et al., 2002, Srinivasula et al., 2002). However 
emerging reports suggest that ASC has several intracellular functions 
independent of the inflammasome, including a role in pyroptosis, T cell priming 
in collagen- and antigen-induced arthritis, experimental autoimmune 
encephalomyelitis, and activation of intracellular MAPK pathways (Kolly et al., 
2009, Ippagunta et al., 2010, Shaw et al., 2010, Ellebedy et al., 2011, Taxman 
et al., 2011). Intrathecal injection of LPS leads to the direct stimulation of 
microglia via TLR4 receptor activation, a consequence of which is the 
disinhibiton of NF-κB (Bauernfeind et al., 2009). It has been shown that NF-κB 
activation is a necessary “licensing” step for inflammasome activation 
(Bauernfeind et al., 2009). Interestingly LPS-priming has also been shown to 
be a necessary step in the formation of pyroptosomes, which are able to form 




it has been postulated that, at least in some situations, NLRP3 may act as a 
catalyst or enhancer of ASC oligomerisation (Fernandes-Alnemri et al., 2007). 
Since NLRP3-/- mice develop behavioural hypersensitivity to intrathecal LPS 
normally, whereas ASC-/- mice are protected, it is possible that ASC 
oligomerisation is sufficient for caspase-1 activation leading to IL-1β 
maturation and release in this model. Alternatively there may be redundancy at 
the level of the scaffold protein, but not at the level of the adaptor protein. In 
addition to IL-1β release, LPS application to spinal microglia in vitro, results in 
the release of nociceptive mediators PGE2 and NO, in a p38 MAPK-dependent 
manner (Matsui et al., 2010). Additionally in vivo data has shown that 
intrathecal LPS administration leads to the upregulation of TNF-α and TNF-R 
in microglia (Shen et al., 2009). In vitro it has been shown that microglial 
release of TNF-α following LPS stimulation occurs downstream of P2X7 
receptor activation (Suzuki et al., 2004). Both TNF-α and IL-1β have been 
shown to be capable of priming the inflammasome in a manner similar to LPS, 
possibly representing a positive feedback loop enhancing the release of IL-1β 
(Franchi et al., 2009).  
 
Since ASC-/- mice showed reduced sensitivity in the LPS-induced model of 
inflammatory pain, it was postulated that ASC may play a role in inflammatory 
pain. However ASC-/- mice did not show any difference in behavioural 
hypersensitivity compared to wildtype mice following intraplantar administration 
of CFA. Owing to time and resource restrictions, the role of other 
inflammasome components in this model of inflammatory pain was not tested. 
However it has been shown that IL-1αβ -/- mice show a reduction in 
behavioural hypersensitivity following CFA administration, possibly indicating a 
role of IL-1β maturation and release in this model (Honore et al., 2006, Honore 
et al., 2009). However data presented in this thesis indicate an inflammasome-
independent role.  
 
Finally an ASC- and NLRP3-independent mechanism of caspase-1 activation 
is apparent following peripheral nerve injury as an animal model of neuropathic 
pain. That ASC does not contribute to behavioural hypersensitivity in all animal 




published looking at differences in animal models of neuropathic and 
inflammatory pain. While there are some changes in common, such as an 
increased production of cytokines, the other changes are not (Honore et al., 
2000, Yajima et al., 2003, Zhao et al., 2006, Abrahamsen et al., 2008). For 
example mice lacking sodium channel Nav1.8 expression in sensory neurons 
show a reduction in behavioural hypersensitivity in response to inflammatory 
stimuli, but not following peripheral nerve injury (Abrahamsen et al., 2008). 
Similarly selective knockout of BDNF expression from sensory neurons results 
in a reduction in behavioural hypersensitivity to inflammatory stimuli, but not 
following peripheral nerve injury (Zhao et al., 2006). These findings reflect the 
different pathophysiological mechanisms underlying inflammatory and 
neuropathic pain.  
 
3.   Redundancy and the innate immune response 
The innate immune system can be considered as an organism’s first line of 
defence against invading microorganisms and pathogens. It is an ancient, 
evolutionarily-conserved series of host mechanisms which allow detection and 
defence in a non-specific manner (Medzhitov and Janeway, 2000, Janeway 
and Medzhitov, 2002). A major aspect of the innate immune system is the 
recognition of pathogen-associated molecular patterns, PAMPs. These are 
conserved molecular patterns not expressed by the host, but commonly 
expressed by invading microorganisms such as peptidoglycan or 
lipopolysaccharide (LPS). The host is able to recognise multiple PAMPs, and 
via multiple mechanisms, generating redundancy in the system which confers 
a greater level of host protection.  
 
Data presented in this thesis demonstrates a role for caspase-1 in animal 
models of neuropathic and central inflammatory pain. However this appears to 
be inflammasome-independent in the case of neuropathic pain, and NLRP3-
independent in the case of central inflammatory pain. When using transgenic 
mice, the possibility of some level of compensation should always be 
considered. In the case of the inflammasome and innate immunity, some level 




immunity. Indeed it has been shown that caspase-1, IL-1β, and IL-18 knockout 
mice are more susceptible to infection by Salmonella typhimurium with a 
reduced survival time, whereas mice deficient in NLRP3, NLRC4, and ASC are 
not (Lara-Tejero et al., 2006, Raupach et al., 2006). Similar results were 
obtained by Broz et al. who showed redundancy in NLR activation and, to a 
lesser extent, ASC in response to S. typhimurium (Broz et al., 2010). 
Additionally a level of redundancy in inflammasome activation has been 
demonstrated following infection with Listeria monocytogenes (Kim et al., 
2010b, Wu et al., 2010). Thus, as far as pathogen recognition is concerned, 
there is a level of redundancy among the inflammasomes. There is scope for 
such redundancy to occur not only at the level of the scaffold protein, but also, 
to some extent, at the level of the adaptor protein.  
 
The NLR family is characterised by a tripartite structure, consisting of an N-
terminal protein-protein interaction domain (a CARD domain, a PYRIN domain, 
acidic transactivating domain, or a baculovirus inhibitor repeat (BIR)), a central 
nucleotide-binding oligomerisation domain (NOD), and a C-terminal LRR 
domain. In humans there are 22 members of the NLR family, and in mice there 
are at least 33 NLR genes (Chen et al., 2009). Thus it is perhaps not surprising 
to find redundancy in this system. NLRP1-14 all contain a PYRIN domain, 
while several proteins of this family contain a CARD domain, including CIITA, 
NOD1, NOD2, NLRC4, NLRC5, and NLRP1, all of which could potentially 
interact with caspase-1 (Chen et al., 2009, Schroder and Tschopp, 2010). 
However this argument does not take into account the expression patterns of 
these proteins, or particular physiological conditions normally required for their 
activation. Expression of a PYRIN or CARD domain is not necessarily 
sufficient for protein-protein interactions. Bruey and colleagues have shown 
that NLRP2 is able to bind to the PYRIN domain of NLRP1 but not the full-
length NLRP1 suggesting that PYRIN domains may be in some way masked, 
limiting interactions (Bruey et al., 2004). 
 
NLRP2, expression of which is inducible following LPS stimulation of 
macrophages, has been shown to associate with the adaptor protein ASC and 




et al., 2004). NLRP12 has also been shown to associate with the adaptor 
protein ASC and enhance the activation of pro-caspase-1 and subsequent 
maturation and release of IL-1β (Wang et al., 2002). NLRP1 and NLRC4, also 
able to form functional IL-1β processing inflammasomes, possess a CARD 
domain and are therefore able to interact directly with caspase-1. Whereas 
NLRP2 and NLRP12, like NLRP3, are able to enhance caspase-1-mediated 
processing of IL-1β in response to LPS, NLRP1 and NLRC4 do not appear to 
assemble following LPS stimulation (Mariathasan et al., 2004, Faustin et al., 
2007). In fact NLRP1 and NLRC4 appear to have a more restricted range of 
activators, limited to PAMPs, compared to NLRP3 (Martinon et al., 2007, 
Martinon et al., 2009). Little is known about the physiological agonists of 
NLRP2 and NLRP12 inflammasomes, however. Evidence suggests a role for 
TLR4 activation in microglia, the receptor at which LPS exerts its effects, in 
neuropathic pain (Tanga et al., 2005, Bettoni et al., 2008, Cao et al., 2009). 
Thus inflammasomes which assemble in response to LPS stimulation may 
perhaps be considered as candidates for alternative mechanisms of caspase-1 
activation. 
 
Activation of Nod1, an intracellular pattern recognition receptor (PRR), leads to 
its oligomerisation and subsequent recruitment of its CARD-containing adaptor 
protein RIP2. RIP2 then oligomerises and interacts with the IKK complex, 
ultimately leading to the release and nuclear translocation of NF-κB (Inohara et 
al., 2000). Nod1 has been shown to enhance LPS-induced IL-1β release via its 
interaction with pro-caspase-1, apparently independent of TLR4 activation. 
Indeed Nod1 is activated by the presence of breakdown products of 
peptidoglycans, including LPS (Yoo et al., 2002, Khare et al., 2010, Kavathas 
et al., 2012). Consequently Nod1 is unlikely to play a role in animal models of 
neuropathic pain. The adaptor protein RIP2 has also been shown to directly 
interact with pro-caspase-1, an association that is enhanced following LPS 
stimulation (Thome et al., 1998, Humke et al., 2000, Zhang et al., 2003). In 
addition to its ability to associate with Nod1, RIP2 has also been suggested to 
act downstream of TNF receptor activation via an association with the adaptor 
proteins TRAF1 and TRAF2 (Thome et al., 1998). Increased TNF-α expression 




inflammatory and neuropathic pain (Kiguchi et al., 2008, Shen et al., 2009, 
Leung and Cahill, 2010, Zhang et al., 2011). Thus RIP2 represents a possible 
alternative pathway for the activation of caspase-1. 
 
In an independent study, carried out by Dr. Ana Antunes-Martins, next 
generation RNA sequencing techniques were employed to examine changes in 
gene expression in the ipsilateral lumbar dorsal horn and L5 DRG of rats 
following L5 SNT injury. Data from this study demonstrated that the genes 
encoding CARD-containing proteins NLRP1 and NLRC4 were significantly 
upregulated in the ipsilateral lumbar dorsal horn of rats 7 days after SNT injury. 
The genes encoding NLRP1, NLRC4, and Nod1 were similarly upregulated in 
the L5 DRG 7 days after injury, lending support to the idea of redundancy in 
the activation of caspase-1. Interestingly the genes encoding CARD-containing 
proteins NLRP12 and RIP2 were shown not to be dysregulated following L5 
SNT injury, and so it is perhaps less likely that these proteins were 
compensating for the loss of ASC or NLRP3 following PSNL injury, 
 
IL-1β has far-reaching physiological effects and subsequently its maturation 
and release is under tight control, as discussed in the Introduction. Perhaps 
unsurprisingly, then, there are alternative mechanisms of IL-β maturation and 
release. Leptin is a small peptide hormone, mainly secreted by adipose tissue. 
Leptin has been implicated in the inflammatory process through its actions at 
the Ob receptor (ObR) expressed on cells of the innate and adaptive immune 
response including T and B cells, macrophages, and haemopoietic cells 
(Matarese et al., 2005, Bernotiene et al., 2006). Leptin-stimulated 
macrophages and monocytes have been shown to up-regulate phagocytic 
function and pro-inflammatory cytokine secretion (Gainsford et al., 1996). More 
recently leptin-induced mature IL-1β secretion from microglia was shown to be 
via a caspase-1-independent mechanism (Pinteaux et al., 2007). Interestingly 
a role for leptin in animal models of neuropathic pain has been suggested. 
Following partial sciatic nerve ligation leptin has been shown to increase in 
adipocytes in the proximity of the injured nerve. Mice deficient in the ObR 
failed to develop peripheral nerve injury-induced behavioural hypersensitivity, a 




treated macrophages to the injured nerve (Maeda et al., 2009). Following 
peripheral nerve injury expression of the ObR has been shown to be 
significantly upregulated in the ipsilateral lumbar dorsal horn. Spinal 
administration of a leptin antagonist has been shown to both prevent and 
reverse peripheral nerve injury-induced behavioural hypersensitivity, while 
intrathecal administration of leptin to naïve rats induced behavioural 
hypersensitivity (Lim et al., 2009).  
 
Matrix metalloproteases (MMPs) are extracellular proteases which participate 
in tissue remodelling via the breakdown of extracellular matrix proteins. MMPs 
play a key role in the inflammatory response. Following peripheral nerve injur 
TNF-α and IL-1β secreted by Schwann cells and resident mast cells induces 
the production of MMP-9 in Schwann cells, which degrades myelin basic 
protein (MBP) and promotes macrophage recruitment (Chattopadhyay et al., 
2007, Kobayashi et al., 2008a). MMPs are also able to cleave chemokines and 
cytokines, including IL-1β (Schonbeck et al., 1998, Parks et al., 2004). 
Following peripheral nerve injury, IL-1β cleavage has been shown to occur 
through the actions of MMP-9 and MMP-2 in the early and later phases of the 
model, respectively (Kawasaki et al., 2008a). In addition to leptin and MMPs, 
chymase and elastase, both mast cell and neutrophil-derived proteases, have 
been implicated in IL-1β maturation and release in an animal model of arthritis 
(Guma et al., 2009). 
 
As well as the need for redundancy in sensor proteins and cytokine maturation 
mechanisms, there is also redundancy in the mediators of the inflammatory 
response, many of which have effects in common. Although much evidence 
points to an algesic role of IL-1β as a result of an inflammatory response, in 
neuropathic and inflammatory pain states, it is only one of several pro-
inflammatory cytokines shown to play a key role in the inflammatory response. 
The prototypical pro-inflammatory cytokines TNF-α and IL-6 are also widely 
reported to contribute to pain-like behaviours in animal models of inflammatory 
and neuropathic pain (Cui et al., 2000, Ozaktay et al., 2006, Schoeniger-
Skinner et al., 2007, Kawasaki et al., 2008b, Kiguchi et al., 2008, Shen et al., 




IL-β, and IL-6 are all able to sensitise sensory neurons either by increasing 
excitatory synaptic transmission or by decreasing inhibitory synaptic 
transmission of sensory neurons (Ozaktay et al., 2006, Kawasaki et al., 
2008b). Interestingly the pro-nociceptive actions of these cytokines appears to 
be synergistic. Combinatorial treatment aimed at reducing both IL-1R and 
TNF-R signalling was found to be more efficacious at reducing peripheral 
nerve injury-induced hypersensitivity than either treatment administered alone 
(Schafers et al., 2001, Sweitzer et al., 2001). Additionally IL-1R and TNF-R 
signalling converges at the level of TAK1, an activating kinase for the IKK 
complex, ultimately leading to the ubiquitination and degradation of IκB 
allowing NF-κB to translocate to the nucleus (Holtmann et al., 2001). 
Consequently reduction of IL-1β maturation and release alone may not be 
sufficient for reduction of peripheral nerve injury-induced hypersensitivity.  
 
Blockade of IL-1β signalling in neuropathic pain has been shown to be only 
mildly efficacious, or ineffective. In line with the concept of redundancy in the 
inflammatory response, combination treatment with a therapy which inhibits 
TNF-α actions results in synergistic reductions in peripheral nerve injury-
induced hypersensitivity (Schafers et al., 2001, Sweitzer et al., 2001). It is 
postulated that joint reduction of these cytokines reduces the subsequent 
upregulation of IL-6, downstream of both signalling pathways. Potentially 
attempts at reducing IL-1β signalling through the knockout of inflammasome 
component proteins are not sufficient to alter behavioural hypersensitivity 
owing to the compensatory actions of TNF-α. The differing relative 
contributions of these cytokines, and indeed other mechanisms, may be 
reflected in the differing responses of ASC-/- mice in the different animal 
models of pain. Caspase-1 inhibition led to a partial reversal of mechanical 
hypersensitivity following L5 SNT injury. However ASC-/- mice developed 
behavioural hypersensitivity normally following Seltzer injury. This discrepancy 
may lie in a developmental compensation. Indeed treatment with CRID3, an 
inhibitor of ASC oligomerisation, led to a small but significant reversal of SNT-






4.   Future directions 
There currently exist few pharmacological options for the inhibition of the 
inflammasome. This is due, in part, to the nature of assembly and activation 
via homotypic protein-protein interactions. Inhibition of these interactions is 
unlikely to be specific to the inflammasome and could disrupt several 
intracellular signalling pathways. The sulfonylurea anti-diabetic drug glyburide 
has been shown to inhibit the inflammasome, via an action that is independent 
of its actions on ATP-sensitive potassium channels (Lamkanfi et al., 2009). The 
anti-inflammatory compounds parthenolide and Bay11-7082 also inhibit 
inflammasome activation independently of their effects on NF-κB inhibition 
(Juliana et al., 2010). Although these actions appear to be inflammasome-
specific, these compounds have other actions which are unrelated to the 
inflammasome, and so are not a suitable option for treatment. Indeed the 
treatment for CAPS patients is not targeted at the inflammasome, but rather 
the downstream effect of excessive activation; IL-1β release. Anakinra, 
rilonacept, and canakinumab, recombinant IL-1Ra, soluble IL-1R, and an 
antibody against IL-1β respectively, are all highly effective therapies in CAPS 
(Dinarello, 2011). Interestingly anakinra has proved to be an effective drug in 
rheumatoid arthritis both in terms of disease-state and pain (Mertens and 
Singh, 2009). Although administration of IL-1Ra in rodents following peripheral 
nerve injury has been shown to reduce behavioural hypersensitivity, 
administration in combination with a treatment for blocking the actions of TNF-
α has been shown to be more efficacious (Schafers et al., 2001, Sweitzer et 
al., 2001, Winkelstein et al., 2001). There are no reports on the effect of either 
IL-1Ra or a combinatorial therapy in humans for neuropathic pain however. 
Therapy directed towards reducing the level of pro-inflammatory cytokines may 
be of some benefit. However therapy directed at inhibiting pathways upstream 
of cytokine production and release may not be. Data presented in this thesis 
point towards a complex system of redundancy within the innate immune 
system, and so it is preferable to target the final common output. Further the 
innate immune response is a critical first-line defence against invading 
microorganisms, with the inflammasome seemingly playing a key role. As 
such, pharmacological inhibition of such a system may be more harmful than 












Figure a.1: Inflammasome component genes NLRP3, Pycard (ASC), and 
caspase-1 are dysregulated in the ipsilateral lumbar dorsal horn after L5 SNT 
RNA-sequencing of ipsilateral lumbar dorsal horns of rats following L5 SNT injury 
reveals a significant increase in gene expression of inflammasome components 
NLRP3 (a) Pycard (ASC) (b), and caspase-1 (c). One-way ANOVA with Dunnett’s 










Figure a.2: Inflammasome component genes NLRP3, Pycard (ASC), and 
caspase-1 are dysregulated in the L5 DRG after L5 SNT 
RNA-sequencing of injured L5 DRG of rats following L5 SNT injury reveals a 
significant increase in gene expression of inflammasome components NLRP3 (a) 
Pycard (ASC) (b), and caspase-1 (c). One-way ANOVA with Dunnett’s post-test, 







Figure a.3: CARD domain-containing proteins NLRP1, NLRP12, NLRC4, Nod1, 
and RIP2 genes are dysregulated in the ipsilateral lumbar dorsal horn after L5 
SNT 
RNA-sequencing of ipsilateral lumbar dorsal horns of rats following L5 SNT injury 
reveals a significant increase in gene expression of CARD domain-containing proteins 
NLRP1a (a), NLRP12 (b), NLRC4 (c), Nod1 (d), and RIP2 (e). One-way ANOVA with 
Dunnett’s post-test, where *,**,*** p<0.05, 0.01, 0.001 respectively, compared to naïve 








Figure a.4: CARD domain-containing proteins NLRP1, NLRP12, NLRC4, Nod1, 
and RIP2 genes are dysregulated in L5 DRG after L5 SNT 
RNA-sequencing of injured L5 DRG of rats following L5 SNT injury reveals a 
significant increase in gene expression of CARD domain-containing proteins NLRP1a 
(a), NLRP12 (b), NLRC4 (c), Nod1 (d), and RIP2 (e). One-way ANOVA with Dunnett’s 




















Figure a.5: Caspase-1 immunohistochemistry within the rat spinal cord 
a – d: Representative image of caspase-1 immunostaining within the ipsilateral dorsal horn of a rat 7 days after L5 SNT. e – h: Representative 
image of caspase-1 immunostaining within the ipsilateral ventral horn of a rat 7 days after L5 SNT. Co-localisation of caspase-1 with nuclear 
marker DAPI can be seen in panels c and g. Caspase-1 is represented in the green channel, DAPI is represented in the blue channel, and IBA1 is 
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